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Abstract 
Aims 
To evaluate the in vitro potential of umbilical cord(UC)-derived cells as an allogeneic cell 
source that could be used ‘off-the-shelf’ in orthopaedics for bone and cartilage 
regeneration. The study also assesses the in-vivo efficacy of cell therapy in orthopaedics 
for the formation of de novo bone, cartilage and integration of both.  
Methods 
 In vitro potential of cells isolated from the four structural layers of the umbilical cord 
were characterised according to the criteria of the International Society for Cellular 
Therapy (ISCT). The differentiation potentials of these cell preparations, particularly 
for bone and cartilage formation, were also evaluated to ascertain their efficacy as 
potential cell sources for orthopaedic regenerative medicine. 
 Efficacy of autologous bone marrow-derived mesenchymal stromal cells (BMSC) for 
new bone formation in vivo for patients with lower limb long bone nonunions were 
assessed with a self-controlled randomised trial.  
 Efficacy and structural outcome of simultaneous autologous bone plug graft to 
restore subchondral bone with Autologous Chondrocyte Implantation (ACI) were 
evaluated to identify the quality and integration of the repair cartilage with the 
subchondral bone, described as the ‘Osplug’ technique.  
 Efficacy of concurrent realignment with ACI in patients with underlying chondral 
defects and idiopathic varus or valgus malalignments of the knee joint were studied 
to ascertain the outcome of simultaneous correction of the mechanical axis in 
patients receiving biological repair of the cartilage. 
Results 
 Potential of UC-derived cells in bone and cartilage formation: Cell preparations from 
four structural regions of umbilical cord were isolated via an in vitro explant culture 
technique. Osteogenic differentiation in these cell preparations correlated with a 
significant rise in alkaline phosphatase activity in the culture medium of the 
differentiated cells, in comparison to their respective controls. Following 
chondrogenic differentiation, a considerable variation in metachromasia was noted 
with toluidine blue staining, although type II collagen immunostaining was 
 xx 
 
predominantly absent except in one sample of cells from Wharton’s Jelly. Cells from 
all the four layers of UC also expressed surface markers according to the ISCT criteria 
for Mesenchymal Stem Cells (MSC). However, it did not conform to the 
recommended standards quantitatively on fluorometric analysis. 
 New bone formation in nonunion: There was absence of significant increase in new 
bone formation on the side of BMSC insertion in cases with nonunion of fracture. 
Four predictors of successful fracture union in this study were shorter in-vitro cell 
doubling times of patient’s BMSC, the absence of diabetes, younger age and fewer 
operative procedures to treat the nonunion before the trial intervention. 
 Bone and cartilage healing in osteochondral defects: Significant improvement in 
clinical and functional outcome was found at mid-term follow-up after concurrent 
bone graft and ACI to restore subchondral bone and cartilage. Integration of the 
grafted bone had a direct correlation with the clinical outcome in these patients. 
 Cartilage repair with realignment: Simultaneous ACI with correction of malalignment 
led to significant improvement in clinical outcome, particularly in patients with varus 
deformity. Patients with valgus deformity were noted to fail relatively early with 
poor outcome. 
Conclusion 
The current thesis extends from exploring the in vitro potential of UC to the clinical 
application of autologous chondrocytes and BMSC for cartilage and bone regeneration. UC-
derived cells were noted to have properties akin to MSC with trilineage differentiation 
capacity. However, regeneration of new bone with BMSC in nonunions remains challenging. 
Nonetheless,significant clinical improvement was noted in patients receiving ACI with 
underlying malalignment and subchondral bone defect when treated with concurrent 
realignment and bone graft respectively. Further work on the immunomodulatory effect of 
UC-derived cells in addition to longer-term follow-up of the patients receiving cell-based 
therapy is required to consolidate our understanding of future cell therapy in orthopaedics. 
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Chapter 1: Introduction 
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1.1 Background 
Arthritis and trauma have been identified as emerging challenges for the current and future 
generations of musculoskeletal health care providers (Speerin et al., 2014). Both these 
conditions are predicted to create significant social and financial liabilities over the coming 
years (Busija et al., 2013, Tecic et al., 2013). Conventional orthopaedic surgical procedures 
currently dominate the choice of treatment for both these conditions. 
A total of 620,400 primary hip replacements and 676,082 primary knee replacements were 
carried out predominantly for osteoarthritis (OA) in England and Wales during 2003-2013, 
with approximately 15,000 in each group being revised at least once within this period (NJR, 
2014). The median age of patients for a cemented total knee replacement is 70 years. The 
median age of patients receiving a partial knee replacement, however, is 7-11 years younger 
than those receiving total knee replacements, and there has been an increasing 
requirement for revision surgeries among this group (NJR, 2014). The survivorship of 
primary hip and knee replacements additionally showed a steady decline among young 
patients, representing the high physical demands of such patients (NJR, 2014). Moreover, 
the financial implications of revision knee replacements can vary from £9,655 to £30,111 
within the National Health Service in the UK  (Kallala et al., 2015). 
The incidence of nonunions following a new fracture has been reported to range from 
0.02%-10% (Court-Brown et al., 2010, Mills and Simpson, 2013). Such nonunions of lower 
limb fractures have been observed in 6.7 per 100,000 people with an estimated cost of 
£7500 to £85,000 per person to the NHS, excluding morbidity and loss of earnings (Mills and 
Simpson, 2013). 
 3 
 
While early arthritis from cartilage defects and fractures continue to evolve as a significant 
economic and social burden, complementary treatment options need to be developed to 
curtail the complications and address the above conditions from a biological perspective. 
Treating fractures and focal cartilage defects with pertinent cells to regenerate bone and 
repair cartilage, respectively, can evolve as a useful alternative. Such a cell-based therapy 
for treatment of cartilage defects can potentially prolong the survival of the natural joint 
reducing the risk of primary joint replacement surgeries and also of revision surgeries. 
Similarly, regenerating bone with appropriate cells can potentially promote bone healing in 
fracture nonunions by forming new bones.  
In the present work, the prospect of cells derived from the human umbilical cord for the 
generation of cartilage and bone has been assessed in vitro to identify the allogeneic 
potential of these cells for ‘off-the-shelf’ use in bone and cartilage repair. The work also 
evaluates the outcome of clinical applications of autologous cell therapy in the regeneration 
of bone in fracture nonunions and repair of cartilage for focal cartilage defects.  
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1.2 Scope of umbilical cord-derived cells in bone and cartilage regeneration in 
orthopaedics 
1.2.1 Overview  
In 1966 Freidenstein et al. demonstrated progenitor cells with fibroblastoid morphology 
from bone marrow with the capacity of osteogenic differentiation (Freidenstein et al., 
1966). In 1991, Caplan defined them as mesenchymal stem cells (MSCs) because of their 
mesodermal location and multi-lineage differentiation potential triggered by environmental 
cues and their genetic potential (Caplan, 1991). In the same year,  fibroblast-like cells from 
Wharton’s Jelly (WJ) of the umbilical cord (UC) were also isolated (McElreavey et al., 1991). 
In 1999 Pittenger et al. performed monolayer culture of undifferentiated bone marrow 
derived cells and induced in vitro tri-lineage mesodermal differentiation (bone, fat & 
cartilage) of these particular cells  (Pittenger et al., 1999). These cells had a uniform absence 
of haematopoietic surface antigen but the presence of SH2, SH3, CD24, CD70, CD90, CD106, 
CD120, CD120a and  CD124 surface antigens  (Pittenger et al., 1999). Subsequently, three 
position statements have been published by the  International Society for Cellular Therapy 
(ISCT), proposing criteria for defining MSCs irrespective of their isolation and culture 
expansion strategy  (Pittenger et al., 1999, Dominici et al., 2006, Krampera et al., 2013, 
Horwitz et al., 2005).  
1.2.2 Definition of Mesenchymal Stem Cell 
The initial definition of MSC was laid by Pittenger et al. based on cells isolated from bone 
marrow and cultured in monolayer with trilineage differentiation capacity at a controlled in 
vitro condition. Additionally, these cells from bone marrow had a stable phenotype with 
retention of their characteristics inclusive of their differentiation potential following in vitro 
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expansion (Pittenger et al., 1999). Horwitz et al.(2005) proposed a formal approach to 
classifying MSC by advocating the use of the term ‘Mesenchymal Stem Cell (MSC)’ for long-
term self-renewing cells with in vivo differentiation capacity to multiple cell types. The 
unfractionated fibroblastoid and plastic adherent cells originating from supporting 
mesodermal stromal tissue regardless of the source (e.g., bone marrow, umbilical cord 
blood) may contain a subset of the MSC. However, often this cell population are 
heterogeneous and should be identified as multipotent ‘Mesenchymal Stromal Cells ’ until 
their particular biologic potential is demonstrated  (Horwitz et al., 2005). A further 
structured and objective approach was laid by Dominici et al. (2006) clearly defining MSC 
with three criteria- 
 Plastic adherence at the culture 
 Specific surface phenotype 
      ≥ 95%  positive expression of CD105, CD73 and CD90 
 ≤ 2% negative expression of CD45, CD34, CD14(or CD11b), CD79α(CD19) and 
HLA-DR 
 In vitro differentiation to osteoblasts, adipocytes and chondroblasts (demonstrated 
in vitro cell culture)  (Dominici et al., 2006).  
However, the definition by Dominici et al. had very little focus on immunological 
properties of these cells. A recent working proposal by ISCT has highlighted the 
importance of specific areas including immunological properties of these cells while 
defining the characteristics of MSCs (Krampera et al., 2013). The following areas 
highlighted by Krampera et al. (2013) will allow methodological standardisation and 
improve comparability of results amongst different published reports: 
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 MSC are specific to tissues from which they are isolated and their distinct 
embryological origin, which also predicts the pool of endogenous progenitors. 
 Functional assay of both resting and primed MSC to demonstrate the immune 
regulatory properties is clinically more pertinent, regardless of the species or tissue 
source. 
 Variables of cell culture influencing the immune properties of the cells, e.g., cell 
density at passage, culture medium, growth factors, population doublings (along 
with number of passages) should be accounted before generalisability of the 
features present in these cells 
 Properties of MSC drawn from animal models should be cautiously interpreted 
because of the distinct mechanistic pathways between species for, e.g.,- the 
activation of indoleamine dioxide (IDO) pathway in humans in contrast to inducible 
Nitric Oxide Synthase (iNOS) pathway in murine for immunosuppression (Krampera 
et al., 2013). 
In the current work, bone marrow mesenchymal stromal cells (BMSC) has been used to 
identify cells which were not formally characterised in vitro but derived from the bone 
marrow. Whereas bone marrow derived mesenchymal stem cells (BMMSC) or mesenchymal 
stem cells(MSC) are limited to cells which fulfil the criteria laid by the ISCT  (Dominici et al., 
2006). 
1.2.3 Rationale for using umbilical cord as cell source 
Several studies have now confirmed that cells derived from UC share the surface properties 
of MSC and their in vitro capacity of trilineage differentiation (Mennan et al., 2013, Secco et 
al., 2008). Isolation of MSCs derived from whole UCs or specific anatomical locations has 
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been described by enzymatic digestion, explant or a combination of mechanical 
disassociation followed by enzymatic digestion (Sarugaser et al., 2005, Seshareddy et al., 
2008, Pereira et al., 2008, Kadam et al., 2009, La Rocca et al., 2009, Gonzalez et al., 2010, 
Arufe et al., 2011, Bode et al., 2013, Yoon et al., 2013). Despite BMMSCs being the gold-
standard, using UC as a source of MSCs has the advantage of being a medical waste with 
minimal ethical concern. Moreover, these cells can be obtained without subjecting patients 
to an additional procedure and have a shorter culture time with a faster proliferation rate in 
comparison to BMMSC (Mennan et al., 2013).  
Additionally, these cells were found to be immune-privileged with a potential for allogeneic 
use in regenerative medicine (Deuse et al., 2011, Sarugaser et al., 2005). The potential for 
allogeneic transplantation of UC-derived MSCs is supported by their role in ameliorating 
immune responses both in vitro and in vivo animal models (Weiss et al., 2008, LeMaoult et 
al., 2005, Kim et al., 2015). Human UC matrix-stromal cells (hUCMSC) from WJ inhibit the 
proliferation of stimulated T-cells in two-way Mixed Lymphocyte Reactions (MLR); similarly, 
these cells do not elicit an appreciable T-cell proliferative response in a one-way MLR (Weiss 
et al., 2008). Also, these cells do not produce co-stimulatory molecules CD40, CD80 and 
CD86 (Weiss et al., 2008). The human leukocyte antigen (HLA)-DR expression in WJ cells 
treated with TNF-α and IFN- γ is absent with a marked reduction in expression of the same 
antigen in cord lining (CL) cells  following priming with high dose IFN- γ (Kita et al., 2010, 
Prasanna et al., 2010) .  
To summarise, UC-derived cells have multipotent differentiation capacities with 
immunomodulatory properties rendering them to be a suitable cell source for regenerative 
medicine. 
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1.2.4 Functional anatomy of UC 
 Human UC is a foetal-maternal communication developed in the fifth week of gestation and 
exists until parturition (Cunningham and Williams, 2010).  The full length of UC is usually 
equal to the length of the foetus (approximately 50 cm), but variation in size commonly 
exists (Standring, 2005).The UC connects the foetus to the developing placenta implanted 
into the myometrium of the uterine wall.  The UC is usually inserted near the centre of the 
placenta; in 7% of cases it is inserted near the margin of the placenta (‘marginal insertion’), 
while in 1% it is inserted outside the placenta and within the membranes (‘velamentous 
insertion’)  (Cunningham and Williams, 2010). It carries and protects one umbilical cord vein 
(UCV) and two umbilical cord arteries (UCA). These play a critical role in foeto-maternal 
gaseous and metabolite exchanges. The single UCV is a broad calibre vessel, and the two 
UCAs are intertwined along the axis of the UCV. The supporting stromal tissue surrounding 
these vessels is a loose proteoglycan-rich matrix constituting WJ (Cunningham and Williams, 
2010).  The WJ and the three vessels are encased in the CL (Cord lining) membrane which is 
continuous with the amnion of the placenta (Figure 1.1). The CL membrane has important 
fluid exchange functions.  The UC is twisted due to foetal movements. However, the WJ 
matrix protects the cord vessels and prevents them from being strangulated.  
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Figure 1.1 Cross-section of umbilical cord showing the four anatomical regions with two umbilical 
cord arteries and one umbilical cord vein surrounded in the supporting matrix, Wharton’s Jelly, all 
encased by the cord lining membrane 
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In the following section, an overview of the literature is undertaken to ascertain the 
potential of cells from UC and specific anatomical locations of UC in orthopaedic 
regenerative medicine, in particular on bone and cartilage formation. 
1.2.5 Literature search results 
The results of the search are chronologically presented below in Table 1.1. Abstracts of the 
available literature were reviewed to include relevant articles. Original articles describing 
isolation strategy of cells from human UC and different anatomical locations of the UC, 
culture methods and results that have potential implications for bone and cartilage 
regeneration were typically included. The review also highlights the variety of acronyms that 
have been used for cells derived from the UC (and different anatomical areas of the cord) 
which is further complicated by differences in isolation strategy, culture medium, 
differentiation potential and surface phenotype.   
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Authors Isolation strategy Culture medium Differentiation Surface phenotype 
Subram
aniam et 
al., 2015 
Cells from five compartments of the cord-
Aminion, Sub-Amnion, Peri-venous(PV) isolated 
enzymatically , WJ(aspirated and centrifuged), 
mixed cord(details not reported) 
DMEM-low glucose+L-
glutamine+ 
Antibiotics&Antimycotics 
Osteogenesis +ve, Adipogenesis +ve, 
Chondrogenesis +ve 
Flow cytometry +ve to 
CD29,CD73    CD90, CD105, HLA-ABC(>97%)  
and –ve to CD14, CD19, CD34, 
CD45, CD117, HLA-DR(3.7-22.4%) 
Chang et 
al., 2014 
Explant with microdissection of the vessel and 
cord lining to isolate WJ and subsequently 
centrifuged (cells termed as human umbilical 
cord WJ-MSC-hUCMSC) 
DMEMF12 +10%FBS+P&S 
Osteogenesis +ve from P1-P3 with no 
difference between cell passage, 
Adipogenesis +ve, Chondrogenesis 
+ve. In vivo osteogenesis in a mouse 
model(BALB/Cnu/nu) after 56 days. 
Flow cytometry from (P1 to P3)  
    CD73, CD90, CD105 and -ve  
             CD45, 
Mennan 
et al., 
2013 
Whole cord treated with 1mg/ml of Collagenase 
I for 1 h at 37 deg C ( cells termed 'mixed cord 
cells')/Explant of dissected artery, vein, WJ, cord 
lining 
DMEM F12+10% FCS+P&S(1%) Osteogenesis +ve, Adipogenesis +ve, Chondrogenesis +ve 
Flow cytometry of all cell 
preparations at P2-3 were +ve 
(>95%) CD73, CD90, CD105 and -
ve (<2%) CD14, CD19, CD31, 
CD34, CD45, HLA-DR 
Han et 
al., 2013 
WJ isolated after removing the vessels and 
aventitia from the cord and then minced 1mm 
pieces. Explant/0.1% Collagenase IV for 16-18 
hrs at 37 deg C/0.2% Collagenase II for 16-20 hrs 
at 37 deg C 
DMEM + 10%(v/v) 
FBS+Penicillin(1000U)+Streptom
ycin(100µg) 
Chondrogenic-not reported, 
Adipogenic +ve, osteogenic-Von Kossa 
+ve 
Immuno- fluorescence with +ve 
CD44 and CD90 but -ve CD31 and 
CD45 
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Authors Isolation strategy Culture medium Differentiation Surface phenotype 
Yoon et 
al., 2013 
WJ isolated after vessels are removed from the 
cord and minced into 2-3mm pieces. 
Explant/0.1% Collagenase II for 30 mins at 37 
deg C for isolation 
Low glucose 
DMEM+10%(v/v)FBS+P&S Not reported 
Flow cytometry(P2) +ve to 
CD105, CD13, CD 73, HLA Class I 
and -ve for CD34, CD45, CD31 
and HLA Class II 
Salehine
jad et 
al., 2012 
WJ isolated by careful dissection from the 
vessels and the cord lining and cells isolated by 
the following technique-
Explant/Collagenase+Trypsin/Trypsin+EDTA/Coll
agenase+Hyaluronidase+Trypsin (Collagenase 
Type-B was used) Incubation time was 2-3h at 37 
deg C (termed human umbilical cord derived 
mesenchymal(HUCM) cells) 
DMEMF12+10%(v/v)FBS+P&S&A
mphotericin 
Osteogeneic differentiation +ve, 
Adipogenic differentiation +ve, 
Chondrogenic differentiation not 
reported 
Flow cytometry -ve CD34, CD45 
and +ve CD44, CD105 but CD73 & 
CD90 expression was higher in 
explant group i.e 72.23± 3.6 and 
74.47± 0.67 
Marmot
ti et al., 
2012 
Explant from minced whole cord for isolation of 
cells (termed UC-Mesenchymal Stem Cells) 
DMEMF12+5%human platelet 
lysate+105FBS+NEAA+Sodium 
pyruvate+ Heparin(500IU)+P&S 
Osteogenesis +ve, Adipogenesis+ve , 
Chondrogenesis +ve 
Flow cytometry(P1)+ve for C73, 
C90, CD105, CD44, CD29 and -ve 
to CD34. Noted 40% cell s were 
absent to HLA-ABC and HLA-DR 
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Authors Isolation strategy Culture medium Differentiation Surface phenotype 
Fong et 
al., 2012 
Each cord was divided into 2cm pieces and the 
blood gently teased out, the cord is 
subsequently opened longitudinally to face the 
inner surface on a 60mm Petri dish containing 
2mg/ml of Collagenase I and II (each) in addition 
to 100IU/ml of Hyaluronidase contained in high 
glucose DMEM for 45mins at 37⁰C.  The cord 
pieces are then transferred o fresh DMEM, and 
WJ separated from the vessels and the cord 
lining and centrifuged 300g for five mins (Fong 
et al., 2007) and the pellets suspended in the 
respective media.  
Simple medium-DMEM-high 
glucose+20% FBS+1% 
NEAA+2mM L-
glutamine+0.1mMβ-
mercaptoethanol+antibiotics; 
Complex medium is simple 
medium+1%ITS +16ng/ml FGF2; 
Supercomplex medium is 
DMEM low glucose+MCDB 201 
medium+2% 
FBS+1%ITS+0.5g/ml albumax+ 
dexamethasone(10nmol/l)+Asco
rbic acid 2-
phosphate(100umol/L)+10M β 
Glycerophosphate 
+EGF(10ng/ml) +PDGF(10ng/ml) 
Chondrogenesis-cells cultured in 
complex medium and subsequently 
grown in the chondrogenic medium 
has the best in vitro chondrogenesis 
amongst the three culture conditions. 
Adipogenesis and osteogenesis not 
reported. 
Flow cytometry-+ve C29, CD44, 
CD13, CD105, CD146, CD10 and -
ve CD117, CD14. Consistent for all 
three media but CD105 ranged 
from 81.07% to 98.40% in three 
culture condition. 
Tsagias 
et al., 
2011 
Whole cord treated with 2.7mg/ml of 
collagenase type-I+0.7mg/ml of hyaluronidase 
for 3 hrs at 37 deg C followed by 2.5% Trypsin 
for 30 mins 
α -  modification of Eagles 
medium+10%FCS+100µ m of L-
ascorbic acid-2-phosphate+P&S 
Osteogenic +ve, Chondrogenic not 
reported, Adipogenic +ve 
Flow cytometry +ve for CD29, 
CD90, CD105, CD44 and -ve for 
CD34, CD45 
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Authors Isolation strategy Culture medium Differentiation Surface phenotype 
Tong et 
al., 2007 
Blood vessels are dissected from the whole cord 
and then used for explant or enzyme(0.4% 
Collagenase II and 0.01% DNAse I for 30 mins at 
37 deg C) or enzymatic mechanical 
dissociation(same enzymatic treatment followed 
by homogenisation of the tissue after the 
enzyme activity is inhibited) 
DMEM F12+Glutamax 
I+10%FBS+40ng/ml of bFGF+ 
P&S&A+ Gentamicin 
Osteogenic +ve, Adipogenic +ve, 
Chondrogenic not reported 
Flow cytometry +ve to CD105, 
CD73, CD90, C29 and -ve to CD34, 
CD45, HLA-DR 
Majore 
et al, 
2010 
Explant from whole cord with α- MEM +15% 
allogeneic  serum + 50µg/ml gentamicin(termed 
Mesenchymal Stromal Cells from UC) 
α- MEM +10% allologous serum 
+ 50µg/ml gentamicin 
Chondrogenesis +ve, Adipogenesis 
+ve, Osteogenesis-weak noted at 
appox 6 weeks 
Flow cytometry +ve CD44(99.9%), 
CD73(98.9%), CD90(99.9), 
CD105(98.8), and -ve CD31(0.9%), 
C34(1.4%), HLA-I(2.5%) 
Hartman
n et al, 
2010 
Whole cord with artery removed treated with 
collagenase(300U/l)+hyaluronidase(1mg/ml) for 
1 h than with 0.1%trypsin EDTA for 30 mins(cells 
termed umbilical cord derived mesenchymal 
stem cells-UCMSC) 
MesenCult ACF/StemProMSC 
SFM/FBS containing Grwith 
Medium(#1) 
Osteogenesis +ve,Adipogenesis +ve 
Flow cytometry +ve to CD73, 
CD90, CD105(nearly 100% all) and 
-ve to CD34, CD45, HLA-DR(for all 
types of media) 
Reza e 
al, 2010 
Explant of dissected cord lining membrane in 
Medium 171(Cascade Biologics, OR) to isolate 
MUCIN expressing Cord Lining Epithelial Cells-
CLEC-MUC) 
PTTe-1 medium+2.5% FBS+50µ 
g of IGF-1+50µ g Platelet 
Derived Growth Factor BB+5µ 
g/ml of transforming growth 
factor-β 1+ 5µ g/ml of Insulin 
Not reported 
Flow cytometry moderate 
positivity to CD105, weak 
expression of CD73 with relatively 
low CD34 and C45 expression, 
MHC Class I was positive and 
MHC Class II was consistently 
negative. 
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Authors Isolation strategy Culture medium Differentiation Surface phenotype 
Majore 
et al., 
2009 
Explant from whole cord with α- MEM +15% 
allologous serum+5g/l glucose + 50µg/ml 
gentamicin + Amphotericin +P&S 
α- MEM +10% allologous serum 
+ 50µg/ml gentamicin Not reported 
Flow cytometry-Smaller cells 
were more +ve to CD73, and 
CD90 in comparison to relatively 
larger cells but all cell types were 
+ve to CD73, CD90, CD105 and -
ve to CD34, CD45 
Ishige et 
al., 2009 
Explant technique after dissection of Umbilical 
cord artery (UCA), Umbilical cord vein (UCV) & 
Umbilical cord Wharton’s Jelly (UCWJ) (termed 
as UCA cells, UCV cells and UCWJ cells) 
α- MEM +10% FBS serum + P&S 
& Amphotericin 
UCWJ cells ha weakest osteogenicity 
in comparison to UCA and UCV. 
Chondrogenesis +ve but -ve to Type-
2collagen, Adipogenesis +ve 
Flow cytometry +ve for CD13, 
CD29, CD73, CD90, CD105, HLA-
ABC and -ve to CD31, CD34, 
CD45, CD133, CD271, HLA-DR 
Gonzale
z et al., 
2009 
Explants of cord lining with gelatinous part up 
with sterile coverslips on the top after the 
vessels and WJ is dissected at 37 deg C(termed 
umbilical cord lining stem cells-ULSCs) 
DMEM 
Glutamax+15%FBS+NEAA+Vitam
ins+P&S 
Chondrogenesis +ve, Adipogenesis 
+ve, Osteogenesis +ve 
Flow cytometry +ve to CD44, C73, 
C105, CD90, CD106, CD166, HLA-
ABC and -ve to C19, CD34, CD45, 
C117, CD133, HLA-DR 
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Authors Isolation strategy Culture medium Differentiation Surface phenotype 
La-
Rocca  
et al., 
2009 
Explant of whole UC being longitudinally opened 
but vessels not removed to isolate cells (termed 
human extraembryonic mesoderm stem cells-
HEMSC) 
DMEM low 
glucose+10%FCS+NEAA+2mML-
glutamine +antibiotics 
Osteogenesis +ve, Adipogenesis +ve, 
Chondrogenesis -not reported 
Immunocytochemistry -ve to 
CD31, C33, CD34, CD38, CD45 
CD79 and +ve to CD10, CD13. RT-
PCR +ve for C73, CD90, CD105, 
HLA-A, HLA-G and -ve for HLA-DR 
Qiao et 
al., 2008 
Explant culture of the whole cord after cord 
blood is removed. 
DMEM-LG+10% FBS+5% Horse 
serum+P&S 
Osteogenesis +ve, Adipogenesis +ve 
but chondrogenesis not reported 
Flow cytometry -ve to CD34, 
CD38, CD71, HLA-DR and +ve to 
CD13, CD29, CD44, CD105 and 
HLA class I 
Jo et al., 
2008 
Enzymatic isolation from the whole cord with 
0.1% collagenase for 2h followed by 0.25% 
trypsin for 1h in DMEM-LG with P&S 
DMEM-LG+10% FBS+10ng/ml 
basic fibroblast growth factor 
+P&S 
Osteogenesis+ve, Adipogenesis +ve, 
Chondrogenesis +ve (RT-PCR +ve for 
Type-2 Collagen) 
Flow cytometry (upto P9) showed 
>75% positivity to CD73, CD90 
CD105, CD117, CD166 and -ve to 
CD34, CD45, HLA-DR 
 17 
 
Authors Isolation strategy Culture medium Differentiation Surface phenotype 
Kadam 
et al., 
2008 
Enzymatic isolation of human umbilical cord 
vascular endothelial cells ( termed 
hUVEC)(exposure time 30 mins at 37 degC) and 
human umbilical cord matrix-stromal stem 
cells(hUCMSC) with dispase type II and 
collagenase type IV(exposure time one hr 
followed by EDTA and trypsin for 30 min at 37 
deg C). 
M199+20%umbilical cord blood 
serum(UCBS)+2mM L-
glutamine+5ng/ml Vascular 
endothelial growth factor 
+10µg/ml heparin+P&S for 
hUVEC; DMEM with Ham's 
F12(1:1 v/v)+ 10% UCBS for 
hUCMSC 
Chondrogenesis +, Osteogenic +ve, 
Adipogenesis +ve 
Flow cytometry +ve for 
CD44(66.7%),CD90(96.6%), 
CD73(33%), CD117(48.98%) and -
ve for CD33, CD34, CD45 and 
CD105 
Secco et 
al., 2008 
UC filled with 0.1% Collagenase for 20mins at 
37deg C DMEM LG+10%FBS+P&S 
OSteogenesis +ve,  Chondrogenesis 
+ve, Adipogenesis +ve and not 
different from cord blood  
Flow cytometry –ve to CD31, 
CD3, CD45, HLA-DR and +ve to 
CD90, CD29, HLA-ABC 
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Authors Isolation strategy Culture medium Differentiation Surface phenotype 
Karahus
eyinoglu 
et al., 
2007 
Minced UC with artery and vein removed is 
treated with  Collagenase B (1µg/ml) in DMEM-
Ham's F12 +10%(v/v)FBS +P&S &Amphotericin at 
37 deg C for 4 hrs in gentle orbital 
shaker(termed Human Umbilical Cord Stromal 
cells) 
DMEM-Ham's F12(1:1v/v) 
+10%(v/v)FBS +P&S 
&Amphotericin 
Chondrogenic differentiation +ve with 
+ve Type-2 Collagen, Osteogenic 
differentiation +ve, adipogenic 
differentiatio +ve at 40 days 
Flow cytometry(P2) +ve to 
CD105, CD44, CD73 and -ve for 
CD34, CD45, CD14 and HLA-DR 
Baksh et 
al., 2007 
Dissected vessels the three vessels (two arteries 
and one vein) with surrounding WJ looped and 
treated with 1mg/ml of Collagenase for 18-24h-
CD45 +ve cells removed with magnetic 
bead(termed human umbilical cord peri-vascular 
cells-HUCPV) 
(According to  Sarugaser et al., 2005) 
DMEM F12+10%FBS 
More osteogenic and adipogenic 
capacity than BMMSC; comparable 
chondrogenic properties including 
GAG content at ay 14 and 21 
Flow cytometry(P3) –ve CD31, 
CD34, CD45 and +ve to C90, 
CD49e, CD146(endothelial 
marker) 
Sarugas
er et al., 
2005 
Dissected vessels(x3) with surrounding WJ 
looped and treated with 1mg/ml of Collagenase 
for 18-24h-CD45 +ve cells removed with 
magnetic bead(termed human umbilical cord 
peri-vascular cells-HUCPV) 
75% α- MEM+15% FBS+ 
antibiotics 
Osteogenesis +ve, Adipogenesis and 
chondrogenesis not reported 
Flow cytometry +ve (>95%) CD44, 
CD73, CD90, CD105 and  MHC 
Class I and -ve to HLA-DR, CD34, 
CD45 
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Table 1.1 Summary of literature review for cells derived from the umbilical cord with potential for orthopaedic application
Authors Isolation strategy Culture medium Differentiation Surface phenotype 
Wang et 
al., 2004 
Dissected WJ from the vessels and the cord 
linings treated with collagenase(2mg/ml) for 16 
hrs and then 2.5% of Trypsin for 30 mins at 37 
deg C(termed as Wharton’s Jelly MSC-WJ MSC) 
DMEM+10%FBS+glucose(4.5g/l) 
Chondrogenesis +ve(+ve type-2 
collagen), osteogenic differentiation 
+ve, adipogenic differentiation +ve 
Flow cytometry +ve to CD105, 
CD44, C29, CD51 and -ve toCD34, 
CD45 
Panepuc
ci et al., 
2004 
Cord vein cannulated and filled with 1% 
Collagenase-this was clamped for 20mins at 
37deg C 
α- MEM+20% 
FCS+antibiotics+20mML-
glutamine+P&S 
Osteogenesis+ve, Adipogenesis +ve, 
Chondrogenesis +ve (Type-2 Collagen 
+ve) 
Flow cytometry +ve to CD13 
(93.9%), CD29(97.9%), CD44 
(85.6%), CD54(72.5%), 
CD90(98.2%), HLA-Class I(94.6%) 
and –ve to CD34(1.1%), 
CD45(0.006%), CD14(0.006%), 
HLA-DR(1.6%) 
Romano
v et al., 
2003 
UC vein was cannulated and filled with 
0.1%collagenase +Medium 199 for 15 mins at 37 
deg C; the endothelial and subendothelial cells 
were retrieved 
DMEM-LG+20mM  HEPES+ 
2mMl L-glutamine+1mM 
Sodium pyruvate +P&S 
Osteogenesis +ve, Adipogenesis +ve 
but Chondrogenesis not reported 
Flow cytometry initially(P1) 
revealed ASMA+ve MSC-like cells 
and vWF and PECAM+ve 
endothelial cells but -ve to CD34 
Covas et 
al., 2003 
UC vein was isolated  and catheterised to treat 
the lumen with 1% collagenase for 20 mins at 37 
deg C  
 α- MEM+20% 
FCS+antibiotics+20mML-
glutamine+P&S 
Osteogenesis +ve, Adipogenesis +ve 
but Chondrogenesis not reported 
Flow cytometry +ve to CD29, 
CD13, CD44, CD49e, CD54, CD90, 
HLA class I  and -ve to CD45, 
CD14, CD106, CD51/61, HLA-DR 
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1.2.5.1 Isolation Strategy: Several methods of isolation of cells from the UC and specific 
anatomical parts of UC were noted. These can be broadly classified into three groups: 
explant technique  (Chang et al., 2014, Ishige et al., 2009, La Rocca et al., 2009, Majore et 
al., 2009), enzymatic isolation technique  (Chang et al., 2014, Hartmann et al., 2010, Jo et al., 
2008, Kadam et al., 2009, Karahuseyinoglu et al., 2007) and combined mechanical 
disassociation with enzymatic isolation technique (Tong et al., 2011, Subramanian et al., 
2015). All these methods are reported with the successful isolation of cells, but each has 
intricate protocols.  
The UC tissue used for the explant technique can include a whole cord in-situ  (Majore et al., 
2009, Qiao et al., 2008), dissected tissue from one particular anatomical location such as WJ 
(Yoon et al., 2013, Salehinejad et al., 2012) or CL  (Reza et al., 2011) (Gonzalez et al., 2010). 
Furthermore, different UC tissues used include a longitudinally opened UC with vessels 
retained (La Rocca et al., 2009),  a UC with only the vessels removed (Tong et al., 2011, 
Chang et al., 2014) or distinct anatomical compartments separated from each cord for 
concurrent isolation from different locations (Mennan et al., 2013, Ishige et al., 2009, 
Marmotti et al., 2012). Use of a high magnification operating microscope has also been 
reported recently to improve the precision of dissection in separating the anatomical 
compartments for the explant technique (Subramanian et al., 2015, Chang et al., 2014).  
The method developed by Subramanian et al. (2015) describes WJ being precisely separated 
by dissection, followed by aspiration with a syringe under high magnification with a 
microscope; the amnion, sub-amnion and perivascular cells from the same cord were 
released by enzymatic digestion. Another protocol for using combined enzymatic 
mechanical disassociation describes the removal of the cord vessels followed by mincing 
and subsequent enzyme treatment of the tissue for 30 minutes with further mechanical 
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homogenisation and filtration was undertaken before cell seeding  (Tong et al., 2011). The 
above technique was reported to yield a higher number of nucleated cells in comparison to 
explant or enzymatic isolation methods alone, but the time to attain cell confluence in 
culture remained comparable to the explant method in the same study. 
Similarly, enzymatic isolation technique was used to isolate cells from a whole cord 
(Mennan et al., 2013, Tsagias et al., 2011, Jo et al., 2008), the endothelial compartment of 
an umbilical cord vein after it being cannulated and filled with enzyme (Romanov et al., 
2003, Covas et al., 2003). Methods describing vessels being ligated and dissected with 
surrounding cord matrix  (Baksh et al., 2007, Sarugaser et al., 2005), a cord with  only blood 
vessels being removed  (Tong et al., 2011) (Karahuseyinoglu et al., 2007) or a cord with only 
umbilical cord artery being removed (Hartmann et al., 2010, Seshareddy et al., 2008) are 
also noted in the literature. Separate areas of the cord region such as the WJ  (Han et al., 
2013, Salehinejad et al., 2012, Yoon et al., 2000, Wang et al., 2004) and concurrent isolation 
from the endothelial cells by cannulating the vein followed by enzymatic treatment of the 
remnant cord are few other techniques of tissue preparation before enzymatic isolation of 
cells  (Kadam et al., 2009). 
The enzyme used for isolating cells varied in type and concentration from 0.1% collagenase-
IV  (Han et al., 2013), 0.2% collagenase II  (Han et al., 2013), 0.1% collagenase II  (Yoon et al., 
2013), 1% collagenase (Panepucci et al., 2004), combined collagenase I (2.7mg/ml) with 
hyaluronidase (0.7mg/ml), collagenase (1mg/ml) (Sarugaser et al., 2005), collagenase-
I(1mg/ml) (Mennan et al., 2013), combined collagenase & EDTA/collagenase Type-B 
(Salehinejad et al., 2012), collagenase (300U/l) with hyaluronidase (1mg/ml) followed by 
2.5% trypsin (Tsagias et al., 2011), 0.4% collagenase with 0.01% DNAse  (Tong et al., 2011), 
collagenase (2mg/ml) followed by trypsin (2.5%) and dispase type-II with collagenase type-
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IV  (Kadam et al., 2009). Incubation period with the enzyme isolation techniques ranged 
from 20 minutes (Secco et al., 2008, Covas et al., 2003), 1hour  (Mennan et al., 2013, Jo et 
al., 2008), 2-3 hours (Salehinejad et al., 2012), 16-20 hours (Han et al., 2013) up to a 
maximum of  18-24 hours (Sarugaser et al., 2005). 
1.2.5.2 Differentiation potential of the cells 
Osteogenic differentiation pathway of progenitor cells: The orchestration of specific growth 
factors involved in differentiation MSC in vitro although complex is explored to underpin the 
stages of osteogenic differentiation of a progenitor cell. Broadly in vitro osteogenic 
differentiation consists of three phases- 
Phase of cell proliferation: This phase is marked by a significant early increase in the DNA 
content of the cells (first four days) followed by a gradual decrease over a period of 2 weeks 
due to confluence dependent apoptosis (Brezden and Rauth, 1996). This phase is also 
marked by upregulation VEGF which is shown to increase the number of osteoblasts and 
osteoid volume  (Hiltunen et al., 2003). VEGF also acts with BMP-4 at a critical ratio for cell 
recruitment, survival and promotion of early stages of endochondral ossification (Peng et 
al., 2002). Similarly, IGF-1 (Manduca et al., 1997) and PDGF (Gruber et al., 2002) is also 
upregulated during this phase which leads to proliferation of osteoprogenitors. 
Phase of cell differentiation: PDGF and TGF-β show a peak in this period. TGF-β is ascribed to 
have an encouraging role in osteoprogenitor differentiation during the early stages of 
differentiation however it can be inhibitory at later stages by inhibiting BMP-2 induced 
osteocalcin gene expression and ALP activity (Spinella-Jaegle et al., 2001b). The other two 
key factors promoting differentiation at this stage are FGF2 and BMP-2. FGF2 positively 
stimulates osteogenic differentiation of the progenitor cells by mitogen-activated protein 
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kinase (Mansukhani et al., 2000); additionally it also simultaneously stimulates osteocalcin 
acting in conjunction with cyclic adenosine monophosphate (Schedlich et al., 1994). The 
BMP-2, on the other hand, stimulates upregulation RUNX2 (Lee et al., 2003) and 
Osterix(Osx) (Celil and Campbell, 2005) both at mRNA and protein level at this stage 
promoting cell differentiation. 
Phase of maturation: BMP-2 and FGF-2 are maintained at a high level of both mRNA and 
protein expression at this stage suggesting their role in the maturation of osteoblasts. FGF 
signalling at this stage is also prevention of cell death at this stage which can be due to 
serum starvation (Hill et al., 1997) or peroxynitrite (Kelpke et al., 2001). It has also been 
proposed that FGF-2 inhibit apoptosis of immature osteocytes, however, promotes 
apoptosis of mature osteocytes and hence renews the osteoblast pool (Marie, 2003) 
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Osteogenic potential of UC derived cells: Cells from the whole cord, in addition to separate 
anatomical compartments, have been reported to have varying osteogenic potential. The 
first report of explant culture comparing the differentiation potential of cells from different 
cord locations concluded that WJ cells were the least osteogenic, even after prolonged 
culture, followed by cells from UCAs, whereas highest osteogenic capability was noted in 
cells grown from UCVs (Ishige et al., 2009). A comparative study has also confirmed that 
peri-vascular cells isolated enzymatically had greater osteogenicity than BMMSCs  (Baksh et 
al., 2007). Cells isolated from the whole cord using the explant technique (La Rocca et al., 
2009) or enzymatic isolation technique  (Qiao et al., 2008, Jo et al., 2008) were also reported 
to have an upregulation of osteogenic markers on RT-PCR after being osteogenically 
induced. Moreover, cells isolated enzymatically from the whole cord after the vessels being 
removed and cultured in three types of media (MesenCultACF, StemPro MSC SFM), showed 
no difference in their osteogenicity after being induced in vitro (Hartmann et al., 2010). 
However, explant culture of the whole cord grown in allogenic serum reported weak 
osteogenicity even after six weeks of culture in differentiation medium, despite the addition 
of 1,25-dihydroxy vitamin D3  (Majore et al., 2011).  
A further report of cells from four  locations of the UC (UCA, UCV, WJ and CL) by the explant 
technique along with enzymatic isolation of cells from the whole cord demonstrated cells 
from WJ and whole cords had better osteogenic differentiation in comparison to those from 
UCA, UCV and CL tissue assessed subjectively by cellular alkaline phosphatase (Mennan et 
al., 2013). Recent reports of cells from different anatomical locations separated 
meticulously also showed WJ cells had high expression of genomic markers, namely 
osteocalcin, osteopontin, bone sialoprotein and alkaline phosphatase significantly, in 
comparison to cells from perivascular, sub-amnion, amnion and mixed cord regions 
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(Subramanian et al., 2015). A separate study also demonstrated that the osteogenic 
potential of WJ cells was consistent from P1 to P3 with evidence of new bone formation in 
tissue-engineered demineralised bone matrix inserted into a periosteal defect created in a 
mouse model (BALB/Cnu/nu) at 56 days (Chang et al., 2014). 
Chondrogenic differentiation pathway: Chondrogenic differentiation of an MSC involves 
complex coordination of different signalling pathways, the key players are briefly described 
in this section. 
FGF signalling pathway: 
FGF2 promotes chondrocyte proliferation by enhancing TGF-β1 expression (Stevens et al., 
2004). Chondrocyte differentiation, on the other hand, is due to FGF2 mediated 
downregulation of TGF-b2 expression which is led by an increase in basal expression of Sox-
9 and inhibition of IGF-1 and TGF-β signalling (Handorf and Li, 2011). 
TGF-b/BMP signalling pathway: 
TGF-b/BMP signalling activates Smad-dependent signal transduction in target cells through 
two receptors (type1 and type2) (Cleary et al., 2015).  The TGF-B-mediated Smad 2/3 and 
Smad 1/5/8 signalling is essential for initial chondrogenic differentiation (Cleary et al., 2015). 
TGF-beta also activates mitogen-activated protein kinase (MAPK) proteins p38, ERK and JNK 
in MSC leading to downregulation of N-cadherin expression by blocking Wnt-mediated-b-
catenin nuclear translocation (Tuli et al., 2003). This reduces N-cadherin expression and 
promotes progression from cell condensation to chondrogenic differentiation (Tufan and 
Tuan, 2001, Tufan et al., 2002).BMP signalling also plays a key role in condensation, 
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promoting coalesce of chondroprogenitor cells into clusters in vitro, an essential step before 
differentiation (Pizette and Niswander, 2000). 
Wnt/b-catenin signalling pathway: 
The canonical Wnt/b-catenin is most studied with respect to chondrogenesis. The Wnt 
proteins(Wnt 5a and Wnt 5b) has been ascribed to play a central role in chondrogenic cell 
migration and condensation  (Bradley and Drissi, 2011).The chondrogenic effect of Wnt is 
also observed to occur through a canonical pathway involving downstream stabilisation of 
cytoplasmic b-catenin and formation of lymphoid enhancing factor(LEF)/T-cell factor-
induced gene transcription (Kirton et al., 2007).  
Hedgehog signalling pathways: 
a. Sonic Hedgehog(Shh) signalling pathway: 
BMP and Shh work in conjunction to establish a positive regulatory loop with Sox9 
and Nkx3.2 (a transcription factor that increases Sox9 expression) (Zeng et al., 2002). 
It also increases target cellular response to BMP (Murtaugh et al., 1999). Shh is 
traditionally observed to synergistically enhance chondrogenesis in the presence of 
FGF2 and FGF8 (Abzhanov and Tabin, 2004). 
b. Indian Hedgehog (Ihh) signalling pathway: 
Ihh promotes chondrogenic differentiation by the expansion of Sox-9 expression in 
addition to upregulation of FGF8 expression in MSC (Zhou et al., 2007). In growth 
plate, Ihh produced by hypertrophic and pre-hypertrophic chondrocytes increases 
expression of Pthrp which antagonises differentiation by protein-kinase-A mediated 
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mechanism, this feedback loop coordinates chondrocyte proliferation and 
differentiation (Deckelbaum et al., 2002). 
Notch signalling pathway: 
The Notch Intracellular Domain (NICD) is central to the Notch-mediated regulation of 
chondrogenesis. The NICD induces HES gene family that encodes for basic helix- loop- helix 
(bHLH) nuclear proteins which are suppressors of transcription (Kageyama et al., 2007). The 
Hes-1 and Hey-1, members of the HES gene family, binds to the Sox9 binding site for Col 2a1 
enhancer and inhibits Sox-9 mediated transcriptional activation of col2a1 (Grogan et al., 
2008). 
Hypoxia signalling: 
Hypoxia-inducible factors(HIF) are transcription factors that respond to the hypoxia in the 
cellular environment and forms key factors in the differentiation pathway as chondrocytes 
reside in a hypoxic environment (Brighton and Heppenstall, 1971b, Brighton and 
Heppenstall, 1971a). Specifically, HIF’s promotes chondrocyte expression of extracellular 
matrix and also enhance expression of col2a1, Sox9 and aggrecan and inhibit col1a1 and 
col1a2 (Adesida et al., 2012, Lafont et al., 2007, Koay and Athanasiou, 2008).There are six 
members of HIF family with HIF-1α  and HIF-2α are shown to be linked with chondrogenesis. 
HIF-1α plays a key role in the survival of chondrocytes in the hypoxic environment by cAMP 
response element-binding protein/p300 (Ke and Costa, 2006) and upregulation of heat 
shock protein (HSP) 90 and HSP 70 (Genin et al., 2008). HIF-2α promotes chondrocyte 
differentiation through transcription of Sox trio, aggrecan, Col2a1 and Col10a1 genes (Khan 
et al., 2007). 
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Vascular endothelial growth factor signalling (VEGF): 
Hypertrophic chondrocytes secrete VEGF promoting angiogenesis thereby reducing the 
severity of hypoxia required to maintain chondrocyte phenotype and promote 
differentiation to bone (Carlevaro et al., 2000, Gerber et al., 1999). Hence, regulating VEGF 
signalling is of prime importance to maintain cartilage tissue. However, it is also observed 
that in vitro administration of VEGF antibodies inhibit migration of chondroprogenitor cells 
(Carlevaro et al., 2000) and also leads to cell death in areas of col2a1 expression (Haigh et 
al., 2000). These results point towards a critical regulation of VEGF for chondrogenesis of 
progenitor cells. 
Transcription regulation of chondrogenesis: 
a. SRY-box 9(SOX9): 
SOX9 regulates condensation of the chondroprogenitor cells during earlier stages of 
differentiation followed by chondrocyte proliferation and differentiation by 
controlling chondrocyte-specific genes col2a1, col9a1, col11a2 and aggrecan 
(Akiyama, 2008). Additionally, it induces transcription of Sox5 and Sox6, forming Sox 
Trio, which synergistically increases the expression of gene targets of Sox9 (Ikeda et 
al., 2004). Sox9 also antagonises expression of Runx2 and ostetrix preventing 
osteogenesis of the progenitor cells (Leung et al., 2011). 
b. Runt-related transcription factor (Runx): 
Regulating Runx2 is of extreme importance for chondrogenesis of the progenitor 
cells which is achieved by Sox9 (Zhou et al., 2006). A direct transcriptional target of 
Runx2 is Col10a1, a collagen type expressed by hypertrophic chondrocytes destined 
for endochondral ossification (Zheng et al., 2003). It also acts with HIF to promote 
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angiogenesis promoting osteogeneis and threatening retention of chondrocyte 
phenotype (Kwon et al., 2011). However, Runx2 is also observed to regulate 
osteogenesis and chondrocyte proliferation through P13K-AKT signalling pathway 
along with simultaneous dominant control by Sox9 (Fujita et al., 2004). 
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Chondrogenic potential of UC derived cells: Cells from the UC and particular parts of the UC 
are reported to have variable chondrogenic potential, which has been mostly defined by the 
presence of glycosaminoglycans (GAGs) in the matrix through alcian blue or toluidine blue 
staining. Only three studies reported the presence of type-II collagen matrix by 
immunocytochemistry in three tissues. These are from chondrogenically differentiated cells 
from the whole cord (explant isolation) (Majore et al., 2011), UCV (enzyme isolation) 
(Panepucci et al., 2004), WJ (separated mechanically and then enzymatically digested) 
(Wang et al., 2004). Another study by Jo et al. showed an increase in GAG content in cells 
from the whole cord (enzyme isolation) after being chondrogenically induced, with no 
difference from P2-P9 assessed using a 1,9 dimethyl methylene blue (DMMB) assay (Jo et 
al., 2008). A recent report by Subramanian et al.,(2015) used quantitative reverse 
transcription PCR (qRT-PCR) to compare the chondrogenic potential of cells from four 
anatomical regions (amnion, sub-amnion, perivascular and WJ) of UC and whole cord. This 
demonstrated significant upregulation of genetic markers of chondrogenesis, namely, type II 
collagen (COL 2A), cartilage oligomeric matrix protein (COMP), fibromodulin (FMOD) and sex 
determining region box-9 (SOX9) in WJ cells in comparison to other cell preparations 
(Subramanian et al., 2015).  
Only one study compared chondrogenesis in WJ cells and human BMMSCs after being 
cultured in three types of media ( simple media, complex media and super complex media) 
with subsequent chondrogenic induction of these cells with/without 3D 
Polycaprolactone/Collagen II nano-scaffolds (Fong et al., 2012). Both cell types showed the 
presence of type II collagen on immunocytochemistry, irrespective of the presence of the 
scaffold, but qRT-PCR showed a significantly higher expression of the genetic markers of 
chondrogenesis in WJ cells in comparison to BMMSCs (Fong et al., 2012). The WJ cells also 
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had a significantly higher production of hyaluronic acid and GAG compared to BMMCs 
grown in the complex media, which was shown to be related to the presence of β fibroblast 
growth factor (FGF2) evident on immunohistochemistry (Fong et al., 2012). It is also 
important to note that an earlier study by Jo et al. on cells from whole cord grown in a 
medium containing FGF2 showed upregulation of aggrecan, type II and type X collagen with 
RT-PCR following in vitro chondrogenic induction (Jo et al., 2008). However, a similar study 
comparing cells isolated from UCA, UCV, CL, WJ and whole cord demonstrated tissue 
metachromasia by toluidine blue staining, although variations were noted between 
different cords with no particular region of the UC being consistently better (Mennan et al., 
2013). Likewise, the study by Ishige et al. demonstrated metachromasia in cells isolated 
concurrently from the UCV, UCA and WJ by explant technique but the presence of type II 
collagen was not reported (Ishige et al., 2009). 
Adipogenic differentiation pathway: Adipogenic differentiation pathway is broadly divided 
into two major steps, first being commitment of pluripotent stem cells to preadipocyte and 
the second being differentiation of the preadipocyte to adipose cells (Tang and Lane, 2012). 
The signalling pathway involved in adipogenic differentiation of MSC to adipocytes is briefly 
outlined in the following section. 
1. The commitment of pluripotent stem cells to preadipocyte- Four signalling pathways 
which influence this particular stage adipogenic differentiation are BMP (Huang et 
al., 2011), Wnt, Hedgehog and Retinoblastoma protein signalling. 
BMP signalling: BMP 2 and 4 are implicated for the commitment of pluripotent cells 
to preadipocytes. Proteomic analysis has shown three cytoskeleton-associated 
molecules [lysyl oxidase (Lox), translationally controlled tumour protein 1 (tpt 1), αβ 
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crystalline] are the three main downstream target genes of BMP signalling pathway 
influencing this particular stage (Huang et al., 2011). These proteins potentially 
determine the commitment of pluripotent cells by cell shape regulation. It has also 
been shown that knockout of these proteins inhibits the commitment of pluripotent 
cells to preadipocytes (Huang et al., 2011). 
Wnt signalling: Wnts act at two points in the adipocyte differentiation programme, 
during the early stage it promotes the commitment of the pluripotent cells however 
at a later stage it inhibits differentiation to adipocytes (Bowers and Lane, 2008, Ross 
et al., 2000). The canonical Wnt signalling pathway performs at early the stage of 
differentiation leading to accumulation of β-catenin inside the nucleus and 
subsequent activation of transcription factors, lymphoid enhancing factors (LEFs) 
and/or T-cell factors(TCFs) which trigger activation of downstream genes (c-myc and 
cyclin-D1) (Davis and Zur Nieden, 2008). At a later stage, Wnt10 inhibit adipogenic 
differentiation by inhibiting transcription factors  peroxisome-proliferator activator –
receptor γ (PPARγ) and CCAAT enhancer binding protein α (C/EBPα) (Ross et al., 
2000). It has been proposed that Wnt increases the numbers of preadipocytes during 
pluripotent commitment and mitotic clonal expression stage, however, it is 
terminated at growth arrest stage before terminal differentiation (Bowers and Lane, 
2008). 
Hedgehog signalling: This signalling pathway has a poorly understood mechanism of 
action rendering an inhibitory effect on adipogenesis (Spinella-Jaegle et al., 2001a). 
This is evident from the decrease in intracytoplasmic fat accumulation and reduction 
in expression of specific genes i.e. Smo, Gli1, Gli2 and Gli3 observed in calvarial MSC 
and mouse adipose derived stromal cells (James et al., 2010) . 
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Retinoblastoma protein signalling: The retinoblastoma protein (Rp) inhibits 
progression of the cell cycle by binding and inhibiting the activity of transcription 
factor E2F (Burkhart and Sage, 2008). During mitotic clonal expression, there is 
hyper-phosphorylation of Rp leading to release of E2F followed by transcriptional 
activation of genes required for s-phase of the cell cycle (Burkhart and Sage, 2008). 
However, it has also been noted the Rp can promote RUNX2 promoting osteogenesis 
of MSC (Thomas et al., 2001) at the same time inhibit peroxisome-proliferator 
activated receptor (PPARγ) c subunit, a regulator for adipogenesis (Fajas et al., 2002). 
So, it has been proposed that Rp has a key role in cell fate determination of an MSC 
by regulating both adipogenic and osteogenic differentiation pathways (Calo et al., 
2010). 
2. Differentiation of preadipocytes to adipocytes- The three main steps during this 
stage are the induction of adipogenic differentiation followed by mitotic expansion 
and subsequent activation of a cascade of transcription factors. 
Induction of differentiation: Preadipocytes reaches to growth arrest and enters the 
G1 phase of the cell cycle with induction of adipogenesis by specific differentiating 
medium containing high levels of insulin, dexamethasone and an agent in the serum 
that can increase cellular cAMP (MacDougald and Lane, 1995). These induce 
 the IGF1, glucocorticoid and cAMP signalling pathways following which all the 
preadipocytes synchronously enter into the mitotic clonal expansion stage (s-phase 
of the cell cycle) (Student et al., 1980). 
Mitotic clonal expansion: Following re-entry of preadipocytes to the s-phase of the 
cell cycle these cells undergo two mitotic divisions and DNA replication (Tang et al., 
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2003). Marked activation of C/EBPβ (Tang et al., 2005) and histone 4(H4) (Zhang et 
al., 2011) is also noted at the G1/S boundary of the cell cycle. 
Activation of a cascade of transcription factors: The cAMP regulatory element 
binding protein (CREB) has been proposed to be the key molecule for adipogenic 
differentiation (Zhang et al., 2004). The CREB gets activated by protein kinase-A 
mediated phosphorylation with subsequent activation of C/EBPβ which in turn leads 
to increase C/EBPα and PPARγ, the overall effect being increase in expression of 
adipocyte genes (like cyclin B, CDC25b) (Zhang et al., 2004, Niehof et al., 1997). 
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Figure 1.4: Schematic representation of adipogenic differentiation pathway 
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1.2.5.3 Surface phenotype: The surface phenotype of cells derived from different locations 
or whole UC measured with immunofluorescence was noted to be consistently positive for 
the recommended stem cell markers, CD73, CD90 and CD105 (Dominici et al., 2006), 
although these markers were not always reported in combination. The surface positivity of 
these antigens was also often not reported quantitatively and, if they were, considerable 
variations were noted, often being outside the range recommended by Dominici et al. 
(2006). The study by Salehinejad et al. compared the explant isolation technique with three 
types of combinations of enzymes, i.e., collagenase + trypsin, trypsin + EDTA and 
collagenase + hyaluronidase + trypsin, for isolation of cells from WJ (Salehinejad et al., 
2012). Cells derived from the explant technique had the highest expression of CD73 (74.5%) 
and CD90 (72.2%); CD105 expression was greatest in cells isolated with collagenase + trypsin 
(90.3%), while cells derived with explant technique were 83% positive (Salehinejad et al., 
2012). However, according to Salehinejad et al. none of the cells, irrespective of the 
isolation technique, quantitatively conformed to the ISCT criteria of surface phenotype for 
stem cells (Dominici et al., 2006, Salehinejad et al., 2012). Another study comparing the 
surface characteristics of WJ cells and BMMSCs grown in three types of media showed that 
CD105 expression can range from 81% to 98.4% in cells isolated from WJ but had a narrow 
range of 94.3% to 97.1% for BMMSCs (Fong et al., 2012). Furthermore, Kadam et al.,(2009) 
derived cells enzymatically from UCV and the whole residual cord with a combination of 
collagenase and dispase and cultured separately. The M199 medium (for human umbilical 
vascular endothelial cells, hUVECs) and DMEM with Ham’sF12 (for human umbilical cord 
matrix-stromal stem cells, hUCMSCs), both supplemented  with cord blood serum (20%), 
had no surface expression of CD105 by flow cytometry analysis (Kadam et al., 2009). 
Moreover, Majore et al.(2009)  isolated six sub-population of cells derived with the explant 
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technique from whole UC based on their sizes by using counterflow centrifugation 
elutriation. Smaller cells had a higher proliferative capacity with relatively more positivity 
for CD73 and CD90 in comparison to larger cells which were found to be more senescent 
with Senescence β-Galactosidase staining (Majore et al., 2009). Nonetheless, a comparative 
study of cells cultured in DMEM F12 and 10%FCS from the CL, UCA, UCV, WJ (isolated by the 
explant technique) and whole cord (enzymatic isolation procedure) reported no difference 
in CD73, CD90 and CD105 surface expression amongst the cells, with all being >95% positive 
on fluorometric analyses (Mennan et al., 2013). No differences in surface expression of 
CD73, CD90 and CD105 were also reported in cells cultured in DMEM-Low glucose with L-
glutamine derived from the amnion, sub-amnion,  perivascular region, whole cords and WJ, 
although quantification of these markers for each cell preparation was not available 
(Subramanian et al., 2015). Likewise, no difference was found between cells isolated from 
UCA, UCV and WJ cultured in α MEM and 10%FCS, with >90% being positive for the relevant 
surface markers, but separate comprehensive details of the surface profiles were not 
available in the article (Ishige et al., 2009). 
The study by Subramanian et al.(2015) also reveals a wide variation in the presence of the 
haematopoietic markers (CD14, CD19, CD34, CD45, C117) and HLA-DR (range 3.7 to 22.4%) 
with no significant difference amongst each cell source (Subramanian et al., 2015). The 
same study also showed a significantly higher percentage of CD40-positive cells from the 
amnion, sub-amnion and mixed cord in comparison to perivascular cells and WJ cells. Such 
CD40 positive cells are suggestive of non-stem cell contamination, for instance from 
epithelial cells, endothelial cells or fibroblasts. Conversely, expression of markers of 
pericytes such as CD146 and CD271 was significantly higher in WJ and perivascular cells 
(Subramanian et al., 2015). Previous reports of human umbilical cord perivascular (HUCPV) 
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cells by Bakshi et al. (2008) also showed the presence of  CD146 positive cells, an 
endothelial marker, but in the absence of CD31, these cells were noted to have tri-lineage 
differentiation capacity akin to MSCs (Bakhshi et al., 2008).  
Nevertheless, according to Mennan et al. (2013) cells derived from the CL, UCA, UCV, WJ 
and whole cord were all <2% positive for CD14, CD19, CD34 and CD45 and HLA-DR, in line 
with the ISCT criteria for MSC (Dominici et al., 2006). A further study also showed the 
absence of CD34 and CD45 from P1 to P3 in cells isolated by the explant technique following 
microdissection of the WJ tissue from the whole UC and cultured in DMEM F12 with 10% 
FBS  (Chang et al., 2014).  Similarly, a previous report of simultaneous isolation of cells from 
the UCA, UCV and WJ of the cord found them to be <1% positive for CD31, CD34, CD45, 
CD133, CD271 and HLA-DR (Ishige et al., 2009). Moreover, no difference was noted in two 
separate reports on WJ cells (Fong et al., 2012) and UCMSC (Hartmann et al., 2010) being 
cultured in three different media, particularly in the absence of haematopoietic markers and 
MHC Class II surface molecule. 
1.2.6 Summary  
Several techniques have described methods of isolating MSC from UC and/or different 
regions of UC. These cells can have wide variations in surface phenotype and differentiation 
potential, and their properties do not uniformly conform to the ISCT recommended criteria 
(Dominici et al., 2006). This heterogeneity can be due to several factors, such as the 
isolation technique, the anatomical region of the UC and the culture medium used, to name 
but a few. This has led to an extensive literature, often with contradictory results, rendering 
them poorly comparable.  
These cells have been observed to have consistent in vitro osteogenic and chondrogenic 
differentiation potential although few reports of conflicting results describing poor 
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differentiation capacity are also noted in the literature. The surface phenotype of these cells 
has also been variable with the quantitative parameters not always compliant with the ISCT 
criteria for defining an MSC (Dominici et al., 2006).  Nevertheless, UC is a potential 
alternative source for readily isolatable cells which have properties akin to MSCs, making 
them a suitable candidate for in vivo applications in regenerative medicine. These cells were 
also immune privileged with encouraging results during in vitro and in vivo results in animal 
models. 
Further, in vitro research on a uniform method of isolation of cells from four regions of the 
UC followed by characterisation need to be undertaken to identify the area with the best 
cell source. This will set the platform to compare the immunomodulatory and paracrine 
effects of these cells in the context of regeneration and hence, advance the translation of 
UC-derived cells in human orthopaedic regenerative medicine. 
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1.3 Potential of cell-based approaches for regeneration of bone in fracture nonunions 
1.3.1. Overview 
According to the US Federal Drug Agency, a nonunion is defined as failure to achieve bony 
union after nine months from the injury with no evidence of progression of healing for the 
last three months (USFDA, 1998). The reported incidence of nonunions following a new 
fracture can vary from 0.02%-10% (Court-Brown et al., 2010, Mills and Simpson, 2013). 
Nonunions are classified according to the presence of callus at the fracture site into 
hypertrophic and atrophic (Weber and Cech, 1976). Hypertrophic nonunions are 
hypervascular and respond to fracture healing by callus formation but fail to bridge the 
fractures because of instability at the fracture sites. Atrophic nonunions, on the other hand, 
have inert and biologically inactive fracture ends which fail to show any signs of healing with 
time evident by the paucity of callus formation (Weber and Cech, 1976).Although 
ascertaining vascularity at the fracture site can be a critical determinant of bone healing, it 
should not rely solely on the callus formation assessed with plain radiographs (Wu and 
Chen, 2000). Moreover, it has been established that blood supply to the human atrophic 
nonunion site is comparable to hypertrophic nonunions in the absence of infection (Reed et 
al., 2002). Nevertheless, animal models of atrophic nonunions have demonstrated fewer 
blood vessels in comparison to fracture which healed uneventfully at one week, but the 
difference was statistically insignificant at three weeks (Reed et al., 2003). It is also 
important to note that histological sections of atrophic nonunion in the study mentioned 
above continue to show the absence of fracture union despite restoration of 
interfragmentary vascularity up to 16 weeks (Reed et al., 2003). These findings are 
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suggestive of a strategy to enhance osteoprogenitor activity by local delivery of cells at the 
nonunion site to help to achieve fracture union. 
 1.3.2 Process of fracture union 
Fracture healing has been classified broadly into two categories: direct and indirect. Direct 
healing occurs with complete reduction of the fracture fragment leading direct remodelling 
of the lamellar bone, Haversian canals and blood vessels. On the other hand, indirect 
healing is the commonest method of fracture repair which includes endochondral and 
intramembranous healing (Gerstenfeld et al., 2006). This type of repair response has been 
noted in fractures with some degree of micro-motion.  
The five identifiable stages of the fracture healing process are: 
a. Stage of inflammation This phase corresponds to the formation of a fracture 
haematoma with subsequent infiltration of macrophages, neutrophils and platelets. 
The initial pro-inflammatory response peaks at 24 hours and can extend up to 7 days 
with the secretion of tumour necrosis factor-α (TNF-α), interleukin-1 (IL-1), IL-6, IL-11 
and IL-18, which promote migration of the inflammatory cells (Gerstenfeld et al., 
2003). The TNF-α is produced by the macrophages and inflammatory cells which act 
as a chemotactic agent in recruiting the inflammatory cells (Kon et al., 2001). The 
TNF-α is also observed to induce osteogenesis of the MSCs in vitro (Cho et al., 2006). 
The IL-1 produced by macrophages corresponds with TNF-α production along with 
the production of cartilaginous callus, angiogenesis and further induction of IL-6 in 
osteoblasts. The IL-6 promotes angiogenesis by vascular endothelial growth factor 
(VEGF) production and also promotes differentiation of osteoblasts to osteoclasts 
(Marsell and Einhorn, 2011) The MSCs are recruited to the fracture site from the 
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surrounding tissue, periosteum and bone marrow as well as the systemic circulation 
(Granero-Molto et al., 2009). Different hypotheses exist with regards to homing of 
the MSC to the fracture site. The two most common theories are the stromal cell-
derived factor 1 (SDF-1), and G-protein coupled chemokine receptor CXCR-4 axis 
(Granero-Molto et al., 2009) and the other being hypoxia-inducible factor-1α (HIF-
1α) controlled MSC trafficking (Wan et al., 2008). The HIF-1α operates on a hypoxic 
gradient with concomitant induction of VEGF to promote vascularisation during 
fracture repair (Wan et al., 2008). 
b. Endochondral ossification The generation of ‘soft-callus’ at this stage peaks at 7-9 
days with a proteoglycan and type-II pro-collagen matrix core, in addition to 
subperiosteal intramembranous ossification at the fracture site (Marsell and 
Einhorn, 2011). This stage depends on the recruitment of MSC with a molecular 
cascade of collagen I and collagen II production influenced by bone morphogenic 
protein (BMP) 2, 5, 6 and transforming growth factor-1 (TGF-1) superfamily 
members respectively leading to the endochondral ossification (Cho et al., 2002). 
c. Vascularisation This stage is predominantly dependent on the VEGF pathway 
expressed in hypertrophic chondrocytes and osteoblasts to promote blood vessel 
formation within the soft callus (Keramaris et al., 2008). The VEGF is also thought to 
promote proliferation and aggregation of the endothelial cells to support neo-
angiogenesis within the callus (Kanczler and Oreffo, 2008). VEGF acts in synergy with 
BMP and is also promoted by mechanical stimulation during this stage of repair 
(Kanczler and Oreffo, 2008). 
d. Mineralisation During this phase the chondrocytes at the fracture site continue to 
hypertrophy with resorption of the mineralised cartilage matrix by a cascade of 
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events linked primarily with macrophage colony stimulating factor (M-CSF), receptor 
activator of nuclear factor kappa B ligand (RANKL) and TNF-α (Gerstenfeld et al., 
2003). These factors also promote recruitment of osteoblasts and osteoclasts to 
form woven bone although the primary role of TNF-α at this stage is to induce 
apoptosis of the chondrocytes (Gerstenfeld et al., 2003, Marsell and Einhorn, 2011). 
The mitochondria of the chondrocytes contain calcium which is transported to the 
cytoplasm and finally to the extracellular matrix where it binds with phosphates 
forming the nucleus of apatite crystals (Ketenjian and Arsenis, 1975). 
e. Remodeling This stage consists of a balance between lamellar bone deposition by 
the osteoblasts and resorption by the osteoclasts. The hard callus is remodelled to a 
lamellar bone with a central medullary canal (Gerstenfeld et al., 2003). Biochemical 
harmonisation at this stage is achieved by high levels of IL-1 and TNF-α with the 
diminishing activity of members of the transforming growth factor (TGF)-β 
superfamily, such as BMPs (Marsell and Einhorn, 2011, Mountziaris and Mikos, 
2008). 
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Stage of inflammation 
 Fracture haematoma formation : infiltration of macrophage + neutrophil + platelet migration 
 Release of pro-inflammatory cytokines: TNF-α+ IL-1+ IL-6+ IL-11 + IL-18 
 Chemotaxis and recruitment of inflammatory cells 
 MSC homing to fracture site: SDF-1 & G-protein coupled  CXCR-4 axis and HIF-1α pathway 
Stage of Endochondral ossification 
 Generation of ‘soft-callus’ constituting of proteoglycan and type-II collagen  matrix core 
 Collagen-I and collagen-II production 
 Signalling through BMP 2, BMP 5, BMP 6 and TGF-β 
Stage of vascularisation 
 VEGF pathway expressed from hypertrophic chondrocytes and osteoblasts 
 Angiogenesis within the ‘soft-callus’ 
 
Stage of mineralisation 
 Resorption of the mineralised cartilage matrix: induced by M-CSF, RANK-L and TNF-α 
 Recruitment of osteoblasts and osteoclasts: induced by TNF-α  
 Formation of ‘hard callus’: chelation of calcium from chondrocytes followed by binding with 
phosphate leading to apatite crystal formation + osteoid matrix deposition by osteoblasts 
 Apoptosis of chondrocytes: induced by TNF-α  
Stage of remodelling 
 Remodelling of ‘hard callus’ to woven bone : balance between osteoblastic deposition of osteoid 
matrix and osteoclastic resorption  
 Restoration of microarchitecture of bone by forming medullary canal surrounded by lamellar 
bone 
Figure 1.5: Stepwise illustration of stages of fracture healing in bone 
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1.3.3 Pathogenesis of fracture  nonunion and the basis of cell therapy 
The human fracture haematoma contains cells which have multi-lineage differentiation 
potential, including an osteogenic differentiation capacity, and the phenotype of these cells 
is similar to bone marrow derived MSCs (BMMSCs) (Jagodzinski and Krettek, 2007, Dominici 
et al., 2006). It has also been observed that the colony forming unit-fibroblasts (CFU-F) of 
such BMMSCs from patients with atrophic nonunions can be significantly lower with weak 
proliferative capacities in comparison to healthy volunteers and patients with multiple 
traumas (Seebach et al., 2007). A significant reduction in extracellular bone matrix 
mineralisation and proliferation, with differentially expressed factors for osteogenesis in 
nonunion human osteoblasts, has also been reported (Hofmann et al., 2008). The growth 
factors related to osteogenesis in these cells were low; such distinct properties were 
ascribed to alteration in wingless-related integration site (Wnt), insulin-like growth factor 
(IGF), TGF-β and fibroblast growth factor (FGF) signalling pathways (Hofmann et al., 2008).  
Nonunion stromal cells grown from the human nonunion site were noted to have slower 
doubling time, lower osteogenic potential and a higher rate of apoptosis in comparison to 
BMMSCs from healthy donors (Bajada et al., 2009). The nonunion stromal cells were found 
to secrete Dickkopf-1 (Dkk-1) which is an antagonist to the Wnt signalling pathway and 
inhibits osteogenic differentiation and fracture healing (ibid). A study of nonunions in rats 
showed that the progenitor cells from atrophic nonunion sites had impaired differentiation 
potential due to a sub-optimal environment and suggested reactivation of these primary 
cells by adding growth factors or progenitor cells to induce bone formation (Tawonsawatruk 
T et al., 2013). In a clinical setting, all these evidence can be converted into two 
fundamental principles guiding bone healing in nonunions: enhance the biological viability 
and provide appropriate biomechanical stability at the fracture sites (Megas, 2005). 
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There is evidence suggesting migration to and augmentation of the fracture repair process 
by transplanted MSCs in a mouse model (Granero-Molto et al., 2009). BMMSCs are also 
reported to have better osteogenic capacity in athymic nude rats than embryonic stem cells, 
with no risk of aberrant bone formation or tumorigenicity (Undale et al., 2011). In a critical-
sized mouse calvarial defect, a novel tissue-engineered approach of using cultured human 
BMMSCs with hydroxyapatite (HT) or tricalcium phosphate (TCP) carrier successfully led to 
new bone formation (Mankani et al., 2006). Success in the human translation of bone tissue 
engineering to regenerate large bone defects by using in vitro expanded autologous BMSC 
and subsequently re-implanting them in scaffolds has also been described (Quarto et al., 
2001, Marcacci et al., 2007). Similar success in treating a nonunion with autologous bone 
marrow derived cells has also been reported in a clinical case study (Bajada et al., 2007).  
A review of the existing literature was undertaken to identify the current level of evidence 
for using bone marrow derived cultured cells for bone tissue regeneration in human fracture 
nonunion and bone defects related to trauma and limb lengthening procedures.  
1.3.4. Literature Search results: The summary of the literature review is presented in Table 
1.2. After reviewing the abstracts of the relevant articles generated following the search, 
only six articles were included and found pertinent to the topic (Table 1.2). Studies reporting 
the use of bone marrow aspirate to treat nonunion without being culture-expanded were 
excluded (Hernigou et al., 2005a, Hernigou et al., 2015). Similarly, use of culture-expanded 
bone marrow derived cells for calvarial defect, and mandibular defects were excluded. 
The six articles found comprised of one randomised control trial with the rest being case 
reports, case series and retrospective cohort studies (Table 1). The randomised control trial 
demonstrated a significant increase in callus formation in the treatment group compared to 
the control group after receiving an injection of pre-differentiated bone marrow derived 
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cells in average eight weeks old fractures (Kim et al., 2009). ).  It is important to highlight 
that Kim et al. devised a radiological scale in this study which scored the pre- and post-
treatment callus formation to account for the new bone formation after the trial 
intervention. The same study also showed a significant rise in callus formation in the 
treatment group after the injection at two months follow-up but not after one month when 
compared to the pre-treatment callus (ibid). 
Only one case report highlighted the successful outcome of treating hypertrophic nonunions 
using cells inserted with calcium sulphate carriers(Bajada et al., 2007). A further case series 
of eight patients reported the use of pre-differentiated bone marrow derived MSC along 
with fibrin clots and bone grafts for atrophic nonunions of the upper limb leading to the 
successful radiological union within 5-10 months(Giannotti et al., 2013). In these series, 
Giannotti et al. (2013) reported insertion of culture expanded and characterised cells along 
with a revision of surgical fixation at the same time achieving radiological union within 12 
months. Moreover, no significant adverse effects from the cell therapy were also reported 
at an average 76 months follow-up (ibid). The three other studies described successful 
outcome of a cell-based approach for bone regeneration in a setting of trauma with bone 
loss or limb lengthening procedure (Marcacci et al., 2007, Quarto et al., 2001, Kitoh et al., 
2009). However, Kitoh et al. demonstrated that healing time was significantly reduced with 
cell therapy for femoral lengthening, although this was not significantly different to the 
group not receiving cell-based treatment for tibial lengthening. 
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Author Cells/Carrier Site Treatment Outcome 
Quarto et al., 2001 
(Case series)  
Cultured bone 
marrow derived 
cells + HA 
porous 
bioceramic 
scaffolds 
Three patients 
(one tibia, one 
ulna, one 
humerus) 
Bone defect 
related to acute 
trauma and limb 
lengthening 
Union in 6-13 
months 
Maracci et al., 2007 
(Case series)  
Cultured bone 
marrow derived 
cells + HA 
porous 
bioceramic 
scaffolds 
Four patients 
(one tibia, two 
ulna and one 
humerus) 
Bone defect Union in 5-7 
months 
Bajada et al., 2007 
(Case series)  
 
Cultured bone 
marrow derived 
cells + Calcium 
Sulphate 
One 
patient(tibia) 
Hypertrophic 
nonunion 
8 weeks 
Kim et al., 2009 
(Randomised control 
study) 
Cultured pre-
differentiated 
bone marrow 
derived cells+ 
fibrin clot  
64 patients (31 
patients in the 
treatment group 
and 33 patients 
in the control 
group) 
Acute 
fractures(average 
eight weeks old) 
Radiological 
union in 2 
months 
Kitoh et al.,2009  
(Retrospective 
cohort)  
Cultured bone 
marrow derived 
cells +Platelet 
Rich Plasma 
51 bones(23 
femur an 28 
tibia) with 60 
controls 
Leg lengthening Significantly 
quicker healing 
in cell therapy 
group in 
comparison to 
controls 
Giannotti et al., 
2013 
(Case-series) 
Cultured pre-
differentiated 
bone marrow 
derived cells+ 
fibrin clots 
Eight patients 
with upper limb 
Atrophic 
nonunions 
Union in 5-10 
months 
 
Table 1.2 Summary of literature review describing the human application of bone marrow derived 
cultured cells for bone regeneration in long bone defects and nonunions 
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1.3.5 Summary 
Therapeutic application of bone marrow derived cells for regeneration of long bones in 
human fracture nonunions is a promising arena, but no randomised controlled trials have so 
far been reported in this area. There is only one case report of using bone marrow derived 
cultured cells in fracture nonunion  (Bajada et al., 2007). Further reports of atrophic 
nonunions following fractures of the upper limb showed encouraging results with 
progression to the radiological union in eight cases (Giannotti et al., 2013). The only 
randomised control trial in this arena has shown a significant rise in the new bone formation 
after injection of pre-differentiated cells at the fracture site (Kim et al., 2009).   Moreover, 
cell therapy has also been shown to produce bone healing following acute bone loss and 
limb lengthening procedures (Kitoh et al., 2009, Marcacci et al., 2007, Quarto et al., 2001). It 
is also important to identify at this stage that every fracture has unique local biology and 
patient-related systematic factors which can affect union despite cell-based treatment 
(Kitoh et al., 2009). Comparing the outcome of treatment especially in such cases may be 
significantly confounded by the host factors, which can, for example, include age, the 
presence of infection and systemic factors like diabetes.   
A self-controlled randomised study of lower limb nonunions is evaluated in the present 
thesis to ascertain the efficacy of bone marrow derived stromal cells (BMSC) in new bone 
formation. A standardised isolation strategy of BMSC was established followed by a uniform 
method of ‘in-vitro’ expansion in autologous serum.  Every patient in this particular study 
acted as their control (i.e. self-controlled) with one side of the nonunion receiving BMSC 
with the carrier and the opposite side receiving carrier in isolation. The primary outcome 
was bone formation on serial radiographs evaluated by multiple independent assessors. 
 52 
 
1.4 Potential of Autologous Chondrocyte Implantation in repair of chondral defects with 
underlying subchondral bone defects or malalignment in the knee 
1.4.1 Overview 
The incidence of osteochondral defects is 15-30 per 100,000 persons (Chui et al., 2015). A  
prospective study based on MRI in 120 patients with haemarthrosis of the knee following 
trauma showed acute subcortical femoral or tibial fracture in 72% patients with a 
substantial proportion of these progressing to an osteochondral defect at 6-12 months on 
further scans (Vellet et al., 1991). Such focal articular cartilage defects extending to the 
underlying subchondral bone can effectively generate defects which are grade 4 on the ICRS 
cartilage injury scale (Brittberg and Winalski, 2003). Likewise, ICRS Grade III and IV 
osteochondritis dissecans (OD) will also produce osteoarticular defects which extend to the 
subchondral bone. These cartilage defects extending to the subchondral bone may require 
concurrent bone graft during cartilage repair surgery (Brittberg and Winalski, 2003).  
Similarly, more than 31,000 knee arthroscopies revealed approximately 53,000 hyaline 
cartilage lesions with Grade IV defects being commonly located on the medial femoral 
condyle (MFC) (Curl et al., 1997). A subsequent study of more than 25,000 knee 
arthroscopies confirmed this observation and highlighted the frequent association of medial 
meniscus tears (37%) and anterior cruciate ligament tears (36%) with such cartilage defects 
(Widuchowski et al., 2007). High grade focal chondral defects can progress to OA of the 
affected compartment with significantly higher risk for joint replacement surgery in these 
patients (Hernborg and Nilsson, 1977, Carnes et al., 2012). Moreover, the pain and 
functional impairment in patients with focal cartilage defects is not significantly different 
from patients awaiting total knee replacement for osteoarthritis (Heir et al., 2010). It has 
 53 
 
also been reported that outcomes of partial knee replacement to address arthritis confined 
to one compartment of the knee in younger patients are not satisfactory, with poor patient-
reported outcome and implant survival (Liddle et al., 2014). The treatment of symptomatic 
articular cartilage defects is, however, more challenging if it co-exists with malalignment of 
the mechanical axis in the lower limb. Techniques for the biological restoration of the joint 
in such cases include realignment osteotomy around the knee joint to correct the 
mechanical axis, alongside methods to repair the articular cartilage (Franceschi et al., 2008, 
Bauer et al., 2012, Sterett et al., 2010).  
In the following section, we examine the structure of the articular cartilage and the types of 
cartilage defects. We also review the existing evidence of treating these cartilage defects, 
particularly when associated with subchondral bone defects or malalignment in the knee.  
1.4.2 Anatomy of articular cartilage 
Synovial joints are lined by extremely smooth hyaline articular cartilages bathed with 
synovial fluid that allows minimal friction during movement. The articular cartilage helps it 
bear load by withstanding shearing and compressive forces during weight-bearing and 
movements. The thickness of the articular cartilage varies between 1-7 mm and can alter 
with the geometry of the joint surface. The articular cartilage has four structural zones.  
Zone 1 is the superficial or tangential layer with a high collagen content and small, oval or 
flat relatively inactive cells aligned parallel but compact to the surface. Zone 2 is the 
transitional or intermediate layer with active spherical chondrocytes surrounded by oblique 
collagen fibres. In Zone 3, the cells are round and can be arranged in vertical columns with 
radial collagen fibrils; Zone 4 is the deepest, calcified zone adjacent to the subchondral bone 
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with reciprocal inter-digitations resisting shearing stresses between the adjacent layers. The 
junction between Zone 3 and Zone 4 is called the ‘tide mark’ (Fig 1.5).  
Articular cartilage is hypocellular, aneural, avascular and alymphatic and consists mainly of 
water (80%). It derives nutrition from the adjacent synovial membrane, synovial fluid, 
vascular subchondral bone and occasional blood vessels traversing the calcified cartilage 
(Bora and Miller, 1987). The unique property of this cartilage is due to the interaction of the 
chondrocyte with the extracellular matrix, which is primarily composed of collagen, 
proteoglycans and non-collagenous proteins.  
The type II, IX and XI collagens form a fibrillary network which renders tensile strength to 
the matrix, whereas Type VI collagen helps chondrocytes to attach to the matrix. The large 
proteoglycan, aggrecan comprises of 35% of dry cartilage weight and contributes by 
supporting the high compressive load on the cartilage (Izadifar et al., 2012). Aggrecans also 
provides swelling pressure, and small proteoglycans provide structural stability to the matrix 
(Buckwalter and Mankin, 1998). Structurally, the aggrecan molecule has a polypeptide core 
with side chains which are chondroitin sulphate and keratan sulphate polysaccharide 
(glycosaminoglycans). The link protein attaches the aggrecan molecules with hyaluronan 
polysaccharide chain creating a large proteoglycan complex embedded within the 
predominantly type-2 collagen fibril network. The presence of high negative charge 
densities of the keratan and chondroitin sulphate chains within the aggrecan monomer 
draws water to the extracellular matrix (Izadifar et al., 2012). A schematic representation of 
the articular cartilage with its structural components and different layers is illustrated in 
Figure 1.5. 
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Figure 1.6 Principal components and zonal organisation of articular cartilage tissue :(A) fibrils of 
type II collagen, proteoglycan complexes composed of aggrecan and hyaluronan, and 
chondrocytes cells (reproduced from Izadafir et al., 2012); (B) zonal chondrocytes; and (C) zonal 
collagen fibres.(Images (B) and (C) are reproduced from Buckwalter et al., 1994) 
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1.4.3 Defects of articular cartilage 
Articular cartilage defects have been classified according to the depth of the defects. These 
can be either full thickness, partial thickness (or flap defect) and osteochondral defects, 
which are full thickness defects extending into the subchondral bone (Bhosale and 
Richardson, 2008). The International Cartilage Repair Society (ICRS) classified hyaline 
cartilage lesions macroscopically into four broad grades with sub-types (Brittberg and 
Winalski, 2003) (Fig 1.7) - 
 ICRS Grade 0- Normal hyaline cartilage 
 ICRS Grade 1a- Cartilage with superficial fibrillation and or softening 
 ICRS Grade 1b- Cartilage with superficial lacerations or fissures 
 ICRS Grade 2- Cartilage defect extending < 50% of the thickness 
 ICRS Grade 3-Cartilage defects extending >50% of the thickness 
 ICRS Grade 3a-Cartilage defects superficial to the calcified layer. 
 ICRS Grade 3b-Cartilage defects extending up to calcified layer 
 ICRS Grade 3c- Cartilage defects extending up to subchondral bone 
 ICRS Grade 3d-Cartilage defects with superficial blisters 
 ICRS Grade 4-Cartilage defect extending into the subchondral bone (A) and these 
defects can also lead to extensive cavitation of the subchondral bone (B) 
The articular cartilage defects extending up to the subchondral bone (ICRS Grade 4) are 
essentially osteoarticular defects with two sub-types i.e. defects associated with or without 
cavitation of the subchondral bone (Brittberg and Winalski, 2003). Such high-grade cartilage 
defects can benefit from bone graft in addition to cartilage repair to restore the underlying 
bone plate (Brittberg and Winalski, 2003). Joints with idiopathic malalignment can also 
generate localised areas of high contact stresses leading to cartilage defects (Sharma et al., 
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2008). Restoration of alignment forms the basis of minimising the principal stresses on the 
chondral surface upon loading in such joints (Bhosale and Richardson, 2008). 
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Fig 1.7 The ICRS Cartilage injury classification of four grades of cartilage defects (from the ICRS 
Cartilage Injury Evaluation Package [www.cartilage.org]) 
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1.4.4 Pathogenesis and classification of Osteochondritis dissecans  
The aetiology of Osteochondritis dissecans (OD) remains unclear, but it initially affects the 
subchondral bone and progresses to the overlying cartilage (Edmonds and Polousky, 2013). 
While the presence of OD has been reported in the wrist, elbow and ankle, the commonest 
site is the knee (Erickson et al., 2013).  
There are two principles for classifying OD, based on the skeletal maturity of the patient and 
the stability of the lesion. According to skeletal maturity, OD can be ‘juvenile’ (patients with 
open physis) and ‘adult’ (skeletally mature patients) (Ochs et al., 2011).The stability of OD 
has been classified arthroscopically by the ICRS into four distinct types. These are stable and 
continuous lesion with no discontinuity but softened cartilage (ICRS type-I), a lesion which 
has partial discontinuity but remains stable on probing (ICRS type-II), a lesion which is 
completely discontinuous from the adjacent tissue but is not dislocated (ICRS type-III) and a 
lesion which is dislocated with a residual full-thickness cartilage and subchondral defect 
(ICRS type IV) (Brittberg and Winalski, 2003). The MRI scan criteria for defining the stability 
of OD are based on four parameters: (1) high T2 signal surrounding the OD, (2) subchondral 
cyst, (3) focal articular cartilage defect and (4) high T2 signal implying fracture through the 
cartilage (Kijowski et al., 2008). It is important to comprehend that ICRS type-III and type-IV 
OD are essentially osteoarticular defects comparable to ICRS Grade IV cartilage defect and 
hence amenable to bone graft in conjunction with cartilage repair strategy. 
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1.4.5 Literature review of autologous cell-based strategies for restoration of osteoarticular 
defects of the knee. 
Different operative techniques are described for treating osteoarticular lesions, including 
drilling (Kocher et al., 2001, Edmonds et al., 2010), fixation (Kouzelis et al., 2006, Makino et 
al., 2005), excision of the fragment (Wright et al., 2004), osteochondral autografting (Laprell 
and Petersen, 2001), microfracture (Gudas et al., 2006, Gudas et al., 2012) and autologous 
chondrocyte implantation (ACI) with bone grafts (Bartlett et al., 2005), (Vijayan et al., 2012). 
However, the benefit of using ACI as a restorative surgery for such types of cartilage defects 
lies in its versatility to address defects larger than 2.5cm²(Erickson et al., 2013) and more 
than 8-10mm depth by concurrent autologous bone graft (Peterson et al., 2003), (Bentley et 
al., 2012). In the following section, a literature review has been undertaken to examine the 
level of current evidence in using ACI with bone graft for restoration of osteoarticular 
defects. We also examined the clinical and structural outcome of the repair site following 
use of such techniques, when available.  
1.4.5.1 Literature Search results: The results of the literature review are summarised in 
Table 1.3. After reviewing abstracts of the relevant articles generated from the literature 
search, only seven articles were included and found relevant to the topic. One article was in 
German. Hence, only the abstract was reviewed. The articles included for review have been 
chronologically listed in Table 1.3. 
Peterson et al. first described the use of concurrent bone graft with first-generation ACI for 
OD, in defects more than 1cm deep (Peterson et al., 2003). Their results demonstrated 
significant improvement in functional outcome in all 58 cases, but the results of 7 patients 
receiving concurrent bone graft with ACI (termed ‘sandwich’ technique) was not separately 
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reported. The first ‘sandwich’ technique had a bilayer of periosteum, one being anchored 
with the bone graft and the other attached to the adjacent cartilage with chondrocytes 
injected between these two layers (Peterson et al., 2003).  This was subsequently modified 
with MACI to the bilayer collagen membrane technique (BCMT), with satisfactory clinical 
outcome in cases with OD (Bartlett et al., 2005). A further report from the same centre 
described the technique to be successful in cases of trauma and OD with osteoarticular 
defects (Vijayan et al., 2012). Two studies have drawn a correlation between the defect size 
and clinical outcome, stating that larger defects can potentially have the poorer outcome 
(Steinhagen et al., 2010, Filardo et al., 2012). Most of the studies except one (Bartlett et al., 
2005) had a medium-term follow-up (mean 4-6 years) (Filardo et al., 2012, Ochs et al., 2011, 
Steinhagen et al., 2010, Vijayan et al., 2012). The studies found a trend of significant clinical 
improvement in comparison to the preoperative clinical scores for the first 12-24 months 
and subsequently the score was maintained at final follow-up. 
Bone grafts were harvested from the distal femur (Vijayan et al., 2012, Ochs et al., 2011) 
(Bartlett et al., 2005), proximal tibia (Filardo et al., 2012, Steinhagen et al., 2010, Peterson et 
al., 2003) or iliac crest (Peterson et al., 2003, Ochs et al., 2011) but none of the studies 
describes donor site morbidity. The grafts were either loose cancellous bone (Bartlett et al., 
2005, Filardo et al., 2012, Peterson et al., 2003, Vijayan et al., 2012) or cortico-cancellous 
cylinders harvested by a hollow diamond cutter (Steinhagen et al., 2010, Ochs et al., 2011). 
The study by Ochs et al. describes the use of glue between the bone cylinders when more 
than one cylinder was used. The study of Steinhagen et al. describes excising the cortical 
portion of the bone cylinders, actually rendering them to be cancellous bone cylinders, 
before impaction into the subchondral bone defect to restore the bone plate. 
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Vijayan et al.(2012) described the structural outcome of the BCMT in 8 out of 14 patients 
treated. Three samples of repair cartilage were fibrocartilage, two samples were mixed fibro 
and hyaline cartilage, two were fibrous tissue, and one was not defined (Vijayan et al., 
2012). The study by Bartlett et al. also described histological outcome after BCMT in two 
patients, with one being fibrocartilage and one being hyaline. Importantly, both showed 
good integration of the repaired cartilage with the subchondral bone (Bartlett et al., 2005). 
Furthermore, radiological evidence of cartilage repair was first reported by Ochs et al. 
demonstrating a MOCART score of 62 out of a maximum score of 100 at a follow-up of 40 
months (Ochs et al., 2011). The study by Ochs et al. also showed that filling of the defect 
and remodelling of the lamina formed between grafted bone and repair cartilage had a 
direct correlation with the clinical outcome of the patients undergoing MACI with bone graft 
(Ochs et al., 2011). Likewise, a subsequent observational study of 34 patients by Filardo et 
al. reported over 50% cartilage fill in 15 out of 17 patients. Most of these patients had no 
subchondral oedema and showed an isointense signal of the repair on available MRI scans 
(Filardo et al., 2012). 
Macroscopic features of the graft site were reported by Bartlett et al. in four out of eight 
patients, with two being scored to be nearly normal(ICRS II) and two abnormal(ICRS II) as 
per the ICRS grading of cartilage repair (Bartlett et al., 2005). No further details were 
available for review. The report by Vijayan et al. indicates restoration of the osteoarticular 
height in nine patients during arthroscopic evaluation but again no objective scoring or 
further details were available for review (Vijayan et al., 2012). 
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Author & 
Year 
Patient 
characteristics Intervention Bone graft Clinical outcome MRI feature Histology Arthroscopy 
Peterson et 
al., 2003 
58 patients (OD) 
mean age 26.4 years, 
mean defect size 5.7 
sq.cm, mean depth 
7.8mm (only seven 
patients deeper than 
1cm treated with 
bone graft)  
the sandwich technique 
with bilayer periosteum 
patch(1st generation 
ACI) with bone 
graft(only in7 patients) 
Loose cancellous 
bone from iliac crest 
or proximal tibia 
FU for mean 5.6 years. 
Modified Cincinnati score, 
Brittberg- Peterson score VAS, 
Tegner Wallgren score and 
Lysholm score significantly 
improved at two years but no 
sig difference from 2 years up 
to 10 years. No concrete 
results of ‘sandwich’ technique 
13/15 patients with 
the appearance of 
normal looking 
cartilage at 3.5 years, 
deeper defects had 
cyst. Suggestion of 
bone remodelling 
and filling but no 
concrete results for 
‘sandwich’ technique 
No histology 
22 patients, 
arthroscopic score 
of graft integrity  
mean 11.2/12 for 
all patients(no 
reports of patients 
requiring bone 
graft) 
Bartlett et 
al., 2005 
Eight patients (5 OD), 
mean age 26.4 years, 
mean defect size 5.2 
sq. cm 
MACI +cancellous graft 
(bilayer collagen 
membrane technique, 
BCMT-3rd generation 
ACI) 
Loose cancellous 
bone graft from 
distal femur 
FU for one year, Improvement 
in modified Cincinnati knee 
score, Visual analogue, 
Stanmore functional score(p-
value-NA) 
Not done 
One 
fibrocartilage 
and 1 mixed 
fibro/hyaline 
cartilage with 
good integration 
Two patients ICRS 
grade nearly 
normal and two 
patients abnormal 
Maus et al., 
2008(article 
in German) 
13 patients with OD* 
(ICRS Grade 4) with 
mean defect size 8.1 
sq.cm 
MACI + cancellous 
bone chips or 
monocortical 
cancellous graft 
autologous graft clinical improvement in IKDC, Brittberg and ICRS score Not available No histology No Arthroscopy 
Steinhagen 
et al., 2010 
22 patients with OD* 
(ICRS 3 and 4)mean 
age 29.3 years, mean 
defect size 6.57sq cm 
MACI (Single 
layer)+Bone plug  
proximal tibia with 
diamond cutter 2-3 
depending  
Significant improvement in 
Lysholm, IKDC up to 12 months 
which was maintained for 36 
months. Defect > 6 sq.cm 
inferior outcome 
No MRI scan No histology No Arthroscopy 
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Author & 
Year 
Patient 
characteristics Intervention Bone graft Clinical outcome MRI feature Histology Arthroscopy 
Och's et al., 
2011 
26 pts with OD* (ICRS 
3 and 4), mean age 
29.2, mean defect 
size 5.3 sq. cm and 
depth 8.7 mm,  
MACI (Single 
layer)+Bone plug 
monocortical 
cancellous 8mm 
diameter plug from 
the iliac crest or 
lateral part of the 
femoral condyle(for 
one plug)with a 
hollow diamond drill 
with glue in between 
the plugs 
Mean FU 39.8 months with 
significant improvement in 
Lysoholm-G an IKDC score at 
one year which was 
maintained subsequently, 
filling of the defect and bone 
remodelling significantly 
correlated with Lysoholm-
Gillquist and Tegner scores 
Overall MOCART 
62.4 +/- 18.9.Lamina 
remodelling grade 
increased 
significantly over 
time during  follow-
up 
 No histology  No arthroscopy 
Vijayan et 
al,. 2012 
14 patients, ( 6 
trauma + 8 OD*), 
mean age 23.6 years, 
defect size 7.2 sq.cm, 
depth > 8mm 
MACI + Cancellous 
bone graft (BCMT) 
 
Loose cancellous 
bone graft from 
medial femoral 
condyle 
Mean FU-5.2 years, Significant 
improvement in modified 
Cincinnati knee score, Visual 
analogue, Stanmore functional 
score (no time point) 
Not reported 
Eight biopsy 
samples (mixed 
3, fibrocartilage 
2, fibrous 2, 
non-diagnostic 
1) 
Nine arthroscopies 
at one year 
showed firm graft 
with stable margin 
and restored 
osteoarticular 
height (no scores) 
Table 1.3 Summary of literature review for treatment of osteochondral defects or Osteochondritis dissecans using ACI and bone graft  
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1.4.5.4 Summary: Use of concurrent bone graft with ACI to restore osteoarticular defects 
has been shown to produce significant clinical improvement in mid-term follow-up studies. 
Larger defects are correlated with poor clinical outcome. A correlation of the filling of the 
defect and remodelling of the lamina with clinical outcome was also established. 
Further evidence of the degree of integration of the bone graft, both histologically and from 
MRIs, and its correlation with clinical outcome, will be important to support full restoration 
of the bone defect. Assessing the surface appearance of the graft based on arthroscopic 
findings will also enhance the evidence base of the technique. No reports of the second 
generation ACI are available on this type of defects that require a concurrent bone graft. To 
summarise, simultaneous bone graft with ACI is a promising technique in challenging cases 
with loss of not only full thickness cartilage but also underlying bone. Further studies are 
required to study the structural outcome of such techniques. 
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1.4.6 Literature review of Autologous Chondrocyte Implantation with concurrent 
realignment for repair of articular cartilage in the malaligned knee joint 
Techniques such as ACI (Minas et al., 2010, Minas et al., 2014), microfracture, abrasion 
arthroplasty (Matsunaga et al., 2007) and osteotomy around the knee (Saithna et al., 2014, 
Niinimäki et al., 2012) are commonly reported to treat cartilage defects with co-existent 
malalignment of the knee with variable degrees of success. However, a randomised 
controlled trial (RCT) established better clinical outcome in patients treated with ACI in 
comparison to microfracture (Saris et al., 2009). Furthermore, a mid-term report of the 
same group of patients at five years showed that patients receiving ACI early after the onset 
of symptoms (within three years) had a significantly better outcome in comparison to those 
receiving microfracture (Vanlauwe et al., 2011). Likewise, an RCT comparing the results of 
MACI with microfracture demonstrated significant clinical improvement in  KOOS score after 
being treated with  MACI and had significantly higher numbers of treatment failures in the 
microfracture group at two years follow-up (Saris et al., 2014). The existing evidence of 
treating malalignment together with cartilage defects in the knee using realignment 
osteotomy augmented with ACI is summarised in Table 1.4. 
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Authors Patients Technique FU Histology Radiology Predictors of failure 
Ferruzi et 
al., 2014 
56 patients with 
medial compartment 
OA + full thickness 
MFC cartilage 
loss(ICRS 3/4),  
Comparison of HTO with 
ACI (18 patients) or MF(18 
patients) and HTO alone(20 
patients). All HTO's were 
medial opening wedge 
type. 
11 years follow-up showed 
patients treated with HTO and 
ACI or HTO alone had 
significant improvement in HSS 
and WOMAC scores 
None 
Pre-op median varus in HTO 
9 ⁰, HTO +ACI is 8  ⁰, HTO + 
MF is 7  ⁰, and post-op 
median valgus for the 
whole series is 4⁰(range 2⁰ 
varus to 7⁰ valgus) 
High BMI, Correction 
of varus < than 12  ⁰ 
and pre-op grade of 
OA-related to the 
failure.  
Previous 
meniscectomies are 
not linked to the 
failure. 
Minas et 
al.,2014 
33 patients with HTO 
and three patients 
with Distal femur 
varus osteotomy 
(DFVO)  for 
malalignment of >3⁰ 
with a concurrent 
cartilage defect 
Mechanical axis aimed to 
be restored neutral except 
in cases with kissing lesion 
where overcorrection of 2⁰ 
was performed with 
simultaneous ACI 
15 years FU showed significant 
improvement in graft 
survivorship in comparison to 
the non-HTO group but there 
was no significant difference in 
clinical outcome at final FU 
None No data of the achieved correction  
HTO improved graft 
survival. 
Bauer et 
al., 2012 
18 patients with full 
thickness cartilage loss 
in MFC, 15 patients 
with concomitant 
lesions of the 
tibia(kissing lesion) 
17 lateral closing wedge 
HTO and one opening 
wedge medial HTO. All 
patients received MACI 
FU showed significant KOOS 
score improvement up to 24 
months which was maintained 
for 36 months but dropped at 
60 months 
One patient 20 
months post 
HTO+MACI 
demonstrated 
hyaline-like 
cartilage with 
abundant 
proteoglycan 
matrix  
Pre-op varus was median 6 
⁰(range 5-8⁰), and post-op 
median valgus is 2⁰(range 
6⁰ varus to 8⁰valgus). MRI 
post op 12 months score 
2.37(fair) 
Defect size, 
concurrent tibial 
lesion,patelo-
femoral OA, 
correction angle, 
BMI, previous 
meniscectomies, 
gender and age, are 
not significant 
predictors for 
successful MACI as 
evident on MRI scan 
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Table 1.4 Summary of existing evidence for concurrent realignment with ACI in knee for repair of cartilage defect
Authors Patients Technique FU Histology Radiology Predictors of failure 
Bode et al., 
2012 
Retrospective study comparing 
only ACI(24 patients) with ACI and 
Osteotomy(19 patients) for 1-5⁰ 
varus knees with ICRS 3-4 MFC 
defect; excluded patients with 
concomitant lesion in medial 
compartment, lateral 
compartment defect, limited 
range of movement, previous 
trauma 
 
19 patients received 
medial opening 
wedge HTO with 
simultaneous ACI 
FU at median 71.9 
months showed no 
significant difference 
in both groups of 
patients evaluated 
with KOOS and 
WOMAC scores, but 
concurrent HTO 
significantly reduced 
reintervention  
None 
The pre-op varus for 
HTO+ACI was 3.53+/-
1.09⁰ and only ACI was 
2.25+/-0.99 ⁰, mean 
postoperative 
femorotibial angle was 
8.16⁰+/-2.77⁰ 
Significantly high failure 
rates defined as 
requirement for further 
surgical intervention for 
patients with only 
ACI(10 patients) in 
comparison to patients 
with concomitant ACI(2 
patients) 
Minas et al., 
2009 
Total 155 patients: 48 patients 
received HTO, 44 patients received 
TTO, and the rest did not receive 
osteotomy. No further specific 
details on the HTO group 
reported. 
HTO-opening wedge 
(36), closing wedge 
(11) and distal 
femoral osteotomy 
1. These procedures 
were performed 
with concurrent ACI. 
FU showed significant 
improvement in 
clinical outcome 
although no 
significant difference 
in patients 
with/without 
osteotomy  
None 
Pre-op >2⁰ varus 
malalignment 
corrected to 2⁰(onto 
the tibial spine) 
None 
Franceschi et 
al., 2008 
8 patients with   3 cm ²chondral 
defects(Outerbridge III or IV) on 
the tibial plateau in idiopathic 
varus knee; excluded patients >60 
years, meniscal pathology, diffuse 
arthritis, concomitant MFC lesion 
or 'kissing' lesion 
Arthroscopic 
MACI+opening 
wedge medial HTO 
FU at 28 
months(range 25-31), 
significant 
improvement of 
Lysholm, IKDC and 
VAS scores 
None 
pre-op varus 
8.1⁰(range 4⁰-14⁰) and 
post-op valgus was 
2.8⁰(range 1⁰-4⁰) 
None 
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1.4.6.4 Summary: In summary, treating varus deformity of the knee with an underlying 
cartilage defect is a viable option. Successful outcome is reported for isolated MFC defects, 
medial tibial plateau chondral defects and also ‘kissing lesions’ of the medial compartment 
at short-term follow-up. Moreover, patients receiving HTO with ACI in the presence of 
underlying cartilage defects are additionally shown to have improved graft survival and 
decreased failure rates at long-term follow-up. However, long-term studies fail to identify a 
significant difference in clinical outcome scores after ACI with HTO and HTO alone 
statistically. There is also no consensus on the desired correction angle in this group of 
patients, but previous surgeries or meniscectomies do not seem to influence the outcome. 
A striking absence of reports on the structural outcome of the repair site was noted in the 
existing literature, except in one study which described the MRI outcome in 15 patients. The 
report by Minas et al. describes the treatment of valgus knees with lateral compartment 
cartilage defect by using  ACI and varus osteotomy but does not report the clinical outcome 
in these patients separately (Minas et al., 2014). In the present work, we evaluate the 
results of both varus and valgus osteotomy for lateral and medial compartment cartilage 
defect in the malaligned knee with reports of the structural outcome of the repair site as 
well as mid-term clinical follow-up in these patients.  
 
 
 
 
 
 70 
 
1.5 Aims 
The objectives of the present work are the following: 
 To explore the potential of cartilage and bone formation by cells isolated from four 
anatomical parts of the umbilical cord and quantification of their surface phenotype 
according to the International Society for Cellular Therapy (ISCT) criteria for the 
definition of mesenchymal stem cells (MSC). 
 To examine the efficacy of bone marrow stromal cells (BMSC) in new bone formation 
in a setting of nonunions in the fracture. 
 To investigate the clinical, radiological and histological outcome of the concurrent 
bone graft with Autologous Chondrocyte Implantation in osteochondral defects of 
the knee. 
 To assess the outcome of combined realignment and Autologous Chondrocyte 
Implantation in cases of idiopathic malalignment associated with an underlying 
cartilage defect. 
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Chapter 2: Cells from four regions of the Umbilical Cord by Explant Technique: 
A potential for Orthopaedic Regenerative Medicine 
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2.1 Introduction 
Mesenchymal Stem Cells (MSCs) are self-renewing, plastic adherent cells with specific 
surface properties and immunoregulatory functions (Krampera et al., 2013, Dominici et al., 
2006, Horwitz et al., 2005). First defined by Caplan in 1991, MSCs are found in tissues 
derived from the embryologic mesoderm; these cells have multi-lineage differentiation 
capacities triggered by environmental cues and their genetic potential (Caplan, 1991).   
MSCs can be isolated from different developmental (adult vs foetal) or anatomical tissues, 
e.g. fat, bone marrow and umbilical cord (UC) (Chao et al., 2012) with standard defining 
characteristics (Dominici et al., 2006) and potential clinical applications. Bone marrow has 
been the most frequently used source of stem cells for research and clinical applications 
(Choudhery et al., 2013). UC-derived MSC has also been considered safe for the human 
clinical use with positive results in steroid-resistant graft versus host disease (GVHD) (Wu et 
al., 2011). Subsequently, these cells have been used as an adjunct to haematopoietic stem 
cell transplantation (HSCT) to enhance engraftment and leucocyte recovery without any 
reported adverse effects. Such applications suggest these cells have an immunomodulatory 
role in clinical settings (Wu et al., 2011, Chao et al., 2012, Wu et al., 2013). 
The UC can be used as a readily available source of MSC and a possible alternative to bone 
marrow without subjecting patients to additional procedures to obtain the cells. There is 
minimal ethical concern in procuring cells from the UC since the cord is considered to be a 
biological waste, making it a globally available standardised resource for MSC- based 
research (Jeschke et al., 2011).  
 73 
 
Stem cells from the UC have distinct advantages over bone marrow derived MSCs in their 
faster proliferation and innate immunoregulatory properties, making them an appealing 
donor source (Baksh et al., 2007, Mennan et al., 2013). Stem cells isolated from perinatal 
tissues such as the UC are intermediate between embryonic and adult stem cells in 
possessing pluripotent potentials and multipotent tissue maintenance properties  
(Taghizadeh et al., 2011). Cells from the UC have been reported to express Sox-2, Nanog and 
Oct-4, in addition to their capacity to transdifferentiate for tissue maintenance and 
homoeostasis (Carlin et al., 2006, Sarugaser et al., 2005).  
UC-derived MSCs from the entire cord or particular anatomical locations have been isolated 
via explant cultures, enzymatic digestion or a combination of the two, with variable 
efficiencies (Sarugaser et al., 2005, Seshareddy et al., 2008, Pereira et al., 2008, Kadam et 
al., 2009, La Rocca et al., 2009, Gonzalez et al., 2010, Li and Cai, 2012, Han et al., 2013, Yoon 
et al., 2013). The explant culture system is based on the cellular migration potential 
commonly referred to as ‘plate and wait’ whereas in enzymatic isolation the cord 
extracellular matrix is digested to release the cells. A comparative review found the explant 
technique to be more time consuming but reliable in contrast to enzymatic isolation which 
was shown to be faster but more labour intense, with the risk of over-digestion of the tissue 
resulting in decreased cellular viability and altered function (Li and Cai, 2012).  
Furthermore, explant cultures of the Wharton’s Jelly (WJ) for isolation of MSCs showed high 
levels of FGF2 in the culture medium for 14 days in comparison to the enzymatic isolation 
technique which showed much smaller release for the same duration of time (Yoon et al., 
2013). This is of particular importance because of the regulatory effect of FGF2 on both 
osteogenic and chondrogenic differentiation of MSC (Montero et al., 2000, Yoon et al., 
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2013, Ng et al., 2008). Additionally, the cell yield and viability at passage 0 (P0) was noted to 
be significantly better in the explant group in comparison to those isolated enzymatically 
(Yoon et al., 2013). However, a recent study comparing cells isolated from four different 
regions of umbilical cords  by the explant technique and enzymatic digestion of the whole 
cord suggested an absence of significant difference in their growth kinetics and MSC surface 
profile, although cells were derived more quickly and easily with the enzymatic technique 
(Mennan et al., 2013). Nevertheless, there are considerable variations in enzymatic isolation 
procedures used depending on the types of enzymes used, their concentration and the 
incubation time (Li and Cai, 2012). The diversity of such approaches has to be taken into 
account when comparing the in vitro and in vivo performance of these cells (Christodoulou 
et al., 2013). 
The current International Society of Cellular Therapy (ISCT) working proposal has highlighted 
the need to characterise the immunoregulatory mechanism of MSCs fully and has outlined 
the multitude of experimental approaches, culture conditions, quantitative and qualitative 
methods and in vitro and in vivo models to assess such functions (Krampera et al., 2013). 
The heterogeneity in the intricacies of the methodology has led to a significant amount of 
scientific literature with poorly comparable results. Hence, the ISCT has recommended 
uniform methods of assessing the immunomodulatory effects of MSCs to obtain more 
consistent and reproducible data that may validate MSC-based therapeutic approaches for 
treating clinical conditions (Krampera et al., 2013). 
This study reports the isolation of cells from four separate anatomical regions of the UC by 
the explant technique. These cells were culture-expanded by a uniform method and 
characterised according to the ISCT criteria for defining MSCs (Dominici et al., 2006); 
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additionally, the immunophenotype and expression of pluripotency markers in these cells 
were also investigated in the current work. 
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2.2 Materials and Methods 
This study has been approved by the National Research Ethics Service, UK (Ref.no.  
10/H10130/62). UCs were collected from the maternity unit at the Robert Jones and Agnes 
Hunt Orthopaedic Hospital, Oswestry, UK. All patients consented to the donation of the 
umbilical cord during an antenatal assessment in this midwife-led obstetric unit. Only 
umbilical cords from patients with normal deliveries were collected for this study. 
2.2.1 Isolation technique and cell culture    
UCs from five subjects were collected and stored in Dulbecco’s phosphate buffered solution 
(DPBS) (Gibco, UK) at 4°C for up to 24 hours before tissue culture. The cords were divided 
into 5-6 cm long pieces which were longitudinally opened to expose and dissect the cord 
lining membrane (CL), Wharton’s Jelly (WJ), umbilical cord artery and umbilical cord vein 
separately from within the whole cord (Figure 2.1- Illustration of the dissected UC). A 
histological section of the dissected umbilical cord artery and vein revealed remnants of the 
surrounding matrix and hence were described as umbilical cord peri-arterial (PA) tissue and 
umbilical cord peri-venous (PV) tissue in the present work (Figure 2.2- illustration of the 
histological section of the whole cord, PV and PA explant tissue). 
These four types of tissues were separately dissected, minced into approximately 1-2mm³ 
pieces and weighed.  The minced tissues from the four layers of each cord were grown in 
four separate six-well plates (Starstedt, Leicester, UK). All types of explants were cultured in  
basal medium comprising of Dulbecco’s modified Eagle’s medium (DMEM) Glutamax (Gibco, 
UK), 15% (v/v) Foetal calf serum (FCS) (Life Sciences, UK), 1% (v/v) non-essential amino acid 
(Gibco, UK), 1% (v/v) Minimum Essential Medium (MEM) vitamins (Gibco, UK), 1% (v/v) 
penicillin and streptomycin (Life Sciences, UK) (Gonzalez et al., 2010). The plates were 
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incubated at 37°C and 5% (v/v) CO₂ for 21 days, and the medium was changed every 3-4 
days.                            
During three weeks of culture, fibroblast-like adherent cells migrated from each type of 
explant. Extended periods of digitised images of cells migrating out of a peri-arterial explant 
were captured using phase contrast microscope connected to a  digital video camera (TK-
1280E; JVC, London, UK)  kept in the tissue culture incubator. The series of digital images 
was converted to a video file by using Media Studio Video Editor Software (version 3.5, 
Ulead Systems, Karst, Germany). Adherent cells were detached using 0.25% (w/v) trypsin-
EDTA solution (Invitrogen) followed by an equal volume of medium containing FCS (10%) to 
inhibit the activity of trypsin (passage 0 or P0). Cells were then centrifuged at 112g for 10 
minutes (Harrier 18/80) to form pellets. These pellets were re-suspended in medium, and a 
viable cell count was performed with trypan blue exclusion on a haemocytometer. The cells 
were reseeded and cultured in monolayer for further expansion with the same medium. 
Cells were seeded at a density of 5000/cm² in 25 cm2 tissue culture flasks (Corning Falcon, 
UK) for growth kinetics and 75 cm2 tissue culture flasks (Corning Falcon, UK) for expansion. 
Media was changed 2-3 times per week. Cells were passaged successively at 80% confluence 
and reseeded. All experiments were performed at the third passage (P3) and fourth passage 
(P4). 
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Figure 2.1 Dissection of the umbilical cord to obtain tissue from four regions for explant 
culture 
 
Figure 2.2 Histological section of (A) whole cord (without cord lining membrane) (B) dissected 
umbilical cord vein and (C) artery before explant culture. The cross-sectional image of umbilical 
cord artery and vein demonstrates the presence of supporting matrix (i.e. Wharton’s Jelly) 
adherent to the outer surface following dissection of the vessels (scale bar represents 1000 µm) 
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2.2.2 Cell viability 
At each passage cell viability was assessed by a trypan blue exclusion test. This was 
performed to ascertain the total number of viable cells obtained at confluence so that 
seeding density for further expansion and growth kinetics could be calculated. The principle 
of the test is based on the fact that viable cells have intact cell membranes and hence will 
not be stained whereas cells with disrupted cytoplasmic barriers will be stained blue from 
the dye. 
After cells had been passaged and centrifuged to form pellets, these were resuspended in 
1ml of the medium. A total of 10µl of the cell suspension was mixed thoroughly and added 
to an equal volume of 0.4% (w/v) trypan blue (Sigma-Aldrich) which was then loaded to a  
haemocytometer (Sigma-Aldrich) to calculate the number of viable cells. 
2.2.3 Growth Kinetics 
Cells from four separate layers of the UC (n=5) were grown to P3 in 25 cm² tissue culture 
flasks to ascertain the growth pattern of cells from different layers. The population doubling 
time between each passage from P0 to P3 was calculated by using the following equation: 
Doubling Time (DT) = (t₂-t₁) x ln (2)/ln (n₂/n₁) 
where t₂-t₁ represents the final and initial time points, ln represents the natural logarithm, 
n₂ represents the final cell number harvested, and n₁ represents the initial number of cells 
seeded (Jordan and Smith, 2nd edition, 2000). 
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2.2.4 Cryopreservation of cells 
Following the viable cell count described in section 2.2.2, a total of 1x106 cells were re-
suspended per 1ml of cold 10% (v/v) dimethyl sulphoxide (DMSO; Sigma-Aldrich) in FCS and 
stored in cryovials (Nunc, Fisher Scientific, Loughborough, UK). These vials were transferred 
to a liquid nitrogen container in designated boxes for long-term storage. 
2.2.5 Cell recovery after cryopreservation 
The cryovials were rapidly thawed in running hot tap water, and subsequently, 1 ml of the 
culture medium was added over a period of 1 minute to the thawed cell suspension. The 
culture medium was cooled on ice before being added by drops in the thawed cells. The cell 
suspension and the cold medium were left undisturbed for a further one minute. Next, 20ml 
of the medium was added in drops over 10 minutes. The cell suspension was then 
centrifuged for 10 minutes at 115g).  Cell pellets were further resuspended in 20ml medium 
and centrifuged as described before. A trypan blue viable cell count as outlined in section 
2.2.2 was undertaken before these cells were plated for monolayer culture at a density of 
5000 cell/cm2 at 37⁰C with 5% CO2 (v/v). 
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2.2.6 Tri-lineage mesenchymal differentiation  
Differentiation potential was ascertained for cells from each of the four layers of UC (n=5) at 
P3. Cells were differentiated at 37⁰C and 5% (v/v) CO₂ with a change of media after every 3-
4 days for 21 days. 
2.2.6.1 Osteogenic differentiation: Cells from each layer of the cord were seeded at a 
density of 5x10³ per cm² into six-well plates separately and grown to 80% confluence. 
Osteogenic medium was prepared in DMEM F12 with 10% (v/v) FCS and antibiotics 
(penicillin and streptomycin, Life Sciences, UK) supplemented with 50μM ascorbate 2-
phosphate, 10nM dexamethasone (Sigma) and 10mM β-glycerophosphate (Sigma-
Aldrich)(Jaiswal et al., 1997a). Three wells were treated with osteogenic medium (‘test 
wells’), and the remaining wells (‘control wells’) were treated with media having no 
osteogenic supplements for three weeks. Osteogenesis was assessed by using the following 
methods: 
 2.2.6.1.1 Cellular alkaline phosphatase (ALP) staining 
The alkaline phosphatase activity was determined via hydrolysis of the naphthol phosphate 
ester substrate (naphthol AS-BI phosphate) by the enzyme, the intermediate product then 
reacts with diazonium salt (fast red-TR) to form an insoluble azo dye indicating the site of its 
activity (Jaiswal et al., 1997b). 
A solution was prepared with 25 mg naphthol AS-BI phosphate in 0.5ml of 
dimethylformamide (Sigma-Aldrich) which was mixed with 50ml of 0.2M hydroxymethyl 
hydrochloride (Tris-HCl buffer) to obtain a pH of 9 assessed with a pH metre (BDH 
Laboratory Supplies, Lutterworth, UK). A total of 50mg of Fast Red TR (BDH Laboratories, 
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UK) was added to the solution and mixed thoroughly and filtered (Whatman No.1 filter 
paper, Maidstone, UK) before use. 
Control and test culture cells, each in three separate wells, were washed twice with PBS and 
fixed for 10 minutes with 4%(v/v) formalin (BDH Laboratories, UK) in PBS. Each well of the 
six-well plate was subsequently treated with 1ml of the staining solution and incubated for 1 
hour at room temperature. The stain was thoroughly washed with PBS at room 
temperature. Formation of red colour indicated positive alkaline phosphatase activity 
(Jaiswal 1997). 
 2.2.6.1.2 Assay of ALP activity 
The culture medium from osteogenically differentiated and control cell preparations was 
measured in triplicate; that is culture medium from three control, and osteogenically 
differentiated wells for cells from four layers of the cord were collected separately. The ALP 
buffer was made with 50mM sodium carbonate added to 50mM Tris to pH 9.5. The buffer 
(45ml) was then mixed with 0.3ml of 0.5M magnesium chloride and 0.556g of para-
nitrophenol phosphate (Sigma-Aldrich, UK). 50μl of the culture medium was added to 150μl 
of the ALP buffer and incubated for one hour at  37°C and 5% CO₂ (v/v) (Kubota et al., 2002). 
Colorimetric analysis of the ALP activity was measured by absorbance at 405nm wavelength 
using 650nm as a reference wavelength on a Bio-Tek Synergy HT plate reader. 
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2.2.6.2 Chondrogenic differentiation  
A total of 5x10⁵ cells from each layer of UC were placed in a 1.5ml eppendorf (Sarstedt, UK) 
and centrifuged at 500g for 5 minutes in a microfuge (Henderson Biomedical, Beckenham, 
Kent, UK) to form pellets. These pellets were cultured in chondrogenic media containing 
DMEM Glutamax, 2% (v/v) FCS, 100μg/ml Gentamicin, 10μg/ml Insulin Transferrin Selenium 
 (ITS)(Invitrogen), 0.1 mM ascorbate 2-phosphate (Sigma), 10nM dexamethasone and 
10ng/ml transforming growth factor (TGF) β1 (Pepro Tech, UK). Pellets were incubated at 
37°C and 5% CO₂ (v/v) and inverted after the first three days of culture (Johnstone et al., 
1998, Williams et al., 2010). Media were changed every three days for 3-4 weeks.  
 2.2.6.2.1 Preparation for tissue sections 
The cell pellets were snap frozen in liquid nitrogen and stored at −80°C until use. These 
pellets were taken out and attached to a specimen holder kept at -200C with an embedding 
matrix (Cell Path, UK). Pellets were sectioned on a cryostat (Bright Instrument Co., Ltd., 
Huntingdon, UK) at 7µm thickness and collected on poly-l-lysine coated slides. These slides 
were labelled appropriately and stored at -200 C until further use. 
 2.2.6.2.2 Toluidine blue staining 
 The sections were fixed for 10 minutes with 4% (v/v) formalin (BDH Laboratories, UK) in 
PBS. Subsequently, the slides were washed with PBS before staining with 1% aqueous 
toluidine blue stain to identify the presence of glycosaminoglycans (GAGs). A coverslip was 
finally applied on perspex mountant (Cell Path) following the staining. 
 2.2.6.2.3 Immunofluorescence for Type-II Collagen 
The poly-l-lysine coated slides were left at room temperature for 5-10 minutes to defrost, 
and then the sections of the pellets were delineated with a hydrophobic pen. 4800U/ml 
Hyaluronidase (Sigma, UK) was prepared in 0.025M sodium chloride and 0.05M sodium 
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acetate in distilled water at a pH of 5. This was stored in 1ml aliquots at -200 C. 
Chondroitinase ABC (MP Biomedicals, UK) was obtained at a concentration of 5 units per 
vial. A total of 100µl of buffer was prepared with 1.29g of TRIS and 0.8g of sodium acetate in 
100µl of distilled water at pH 8. This was stored as 5µl aliquots at -200C with each vial 
containing 0.25U of chondroitinase ABC. 
An aliquot of hyaluronidase (1ml, 4800U/ml) was combined with chondroitinase ABC (5µl, 
0.25U/vial). This was added to the slides for 2 hours at room temperature and subsequently 
washed with PBS three times. Following washing, the slides were treated with 10% (v/v) 
buffered formalin in PBS for 10 minutes and washed with PBS three times. The slides were 
blocked with 5% (v/v) goat serum (Vector Laboratories) in PBS for 1 hour at room 
temperature with a further three washes in PBS. The slides were incubated overnight at 40 C 
with an antibody against type II collagen (IgG2a, CIIC1, Developmental Studies Hybridoma 
Bank, US) at 1:10 concentration in PBS or with mouse IgG2a at 1:500 concentrations as a 
control. A further negative control was treated with PBS alone. Positive controls comprised 
sections of human articular cartilage. 
The next day the slides were washed with PBS thrice and incubated with the fluorescein-
conjugated secondary antibody (Alexa Fluor, Thermo Fisher Scientific) at a concentration of 
1:200 in PBS at room temperature for 1 hour in the dark. They were further washed with 
PBS thrice and mounted using Vectashield mountant containing 4', 6-diamidino-2-
phenylindole (DAPI), followed by application of a coverslip for microscopic assessment using 
a fluorescent microscope (Leica) where green fluorescence indicated positivity for type-II 
collagen. 
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2.2.6.3 Adipogenic differentiation 
Cells from the four regions of the UC were seeded at a density of 5x10³ per cm² into six-well 
plates and grown to 80% confluence. Adipogenic medium was prepared in DMEMF12 with 
10% (v/v) FCS and antibiotics (penicillin and streptomycin, Life Sciences, UK) supplemented 
with 1μM dexamethasone (Sigma), 1% (v/v) Insulin Transferrin and Selenium (Invitrogen), 
500nM 3-isobutyl -1-methylxanthine (IBMX) and 100μM Indomethacin (Sigma-Aldrich)  
(Pittenger et al., 1999). Three ‘test’ wells were treated with adipogenic medium, and the 
remaining three wells were ‘controls’ treated with a medium having no adipogenic 
supplements. Adipogenesis was evaluated by Oil-Red-O staining, evident as red in areas of 
intracellular lipid vacuoles. 
 Oil Red-O staining 
Triglycerides and cholesterol esters bind to Oil-Red-O, and hence this was used to determine 
intracellular lipid accumulation after adipogenic differentiation (Ramirez-Zacarias et al., 
1992).The stain was freshly made by using 0.5g Oil-Red-O in 100ml of isopropyl alcohol (IPA) 
to prepare the stock solution. A total of 6ml of the stock was added to 4ml of distilled water 
to prepare the stain. This was filtered (Whatman No.1 filter paper, Maidstone, UK) before 
use. Control and test culture cells, each in three separate wells, were washed twice with PBS 
and fixed for 10 minutes with 4% (v/v) formalin (BDH Laboratories, UK) in PBS. A total of 1ml 
of staining solution was added to each well and then incubated for 1 hour at room 
temperature. The stain was then thoroughly washed with PBS at room temperature. 
Positive staining was evident with red staining of the intracellular lipid vacuole. 
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2.2.7 Mesenchymal stem cell surface markers 
The BD Flow cytometer FACS scan™ was used to assess the immune profile of cell surface 
antigens on the cells obtained from four layers of the five UCs at P3. The surface markers 
tested were according to the ISCT recommendation for defining MSCs, i.e., ≥ 95% of cells 
must express CD105, CD90 and CD73; also, these cells should have ≤ 2% positivity for CD14, 
CD19, CD34, CD45 and HLA-DR (Dominici et al., 2006). 
One million cells of each type were suspended in 1ml of blocking solution containing 10% 
(v/v) human IgG (Flebogamma DIF, Grifols UK Ltd, Cambridge, UK) made up in 2% bovine 
serum albumin (BSA) in DPBS. Cells were incubated on ice for 1 hour. The cells and blocking 
mixture were centrifuged at 500g for 5 minutes to form a pellet. This pellet was re-
suspended in 2% BSA (in PBS), 100μl of this cell suspension was incubated in the dark for 30 
minutes after the addition of  the following  phycoerythrin (PE) conjugated antibodies: CD14 
(1:50), CD19 (1:50), CD31 (1:50), CD34 (1:100), CD45 (1:200), CD90 (1:200), CD105 (1:50), 
HLA-DR (1:200) (Immuno Tools, Germany) and CD73 (1:20) (Beckton Dickson and Company, 
UK). An isotype-matched control with IgG1 (1:50) and IgG2a (1:50) antibodies (Immuno 
Tools, Germany) was used for analysis. The cell and antibody mixture was incubated on ice 
placed on a gently moving platform in the dark to ensure thorough mixing. These cells were 
subsequently centrifuged twice with 1ml of 2% BSA in PBS to wash off the antibodies and 
finally were suspended in 200μl of BSA (2% in DPBS) for flow cytometry.  
Computer-generated dot plots of unstained cells for each cell preparations were obtained 
with forward scatter on the x-axis denoting cell size and side scatter on the y-axis indicating 
granularity of the cells during flow cytometry (Fig 2.3). Each dot in this plot represents a cell 
or a cell debris fragment. The voltage and ampere setting of the viable cell population was 
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adjusted so that the majority of these cells appear in the middle of the dot plot. The viable 
cells typically had a pattern of being together, with cellular debris being the outliers.  These 
viable cells were gated manually and cellular debris, which primarily appeared to the left of 
the dot plot, was excluded. The voltage and ampere setting were noted and the same 
procedure repeated for each type of cell preparation. Only gated cells were used for 
assessing the fluorescence intensity for each antigen.  A collection criterion of 10,000 gated 
events was used for each type of antibody for analysis. Cell Quest Pro software (Beckton 
Dickson and Company, UK) was used to analyse the results.  
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Figure 2.3 Gating of viable cells at the centre of dot-plot with the x-axis representing forward 
scatter (FSC) and the y-axis representing side scatter. The cell population excluded on the left-
hand corner of the graph represents unviable cells or debris 
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2.2.8 Pluripotency markers 
A list of pluripotency markers ascertained in these cells is detailed in Table 2.1. Different 
techniques have been improvised to identify the presence of these markers which are also 
elaborated in the following section. 
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Pluripotency markers Characteristics features 
TRA 1-60 Antigen expressed in podocalyxin, a large keratan sulphate 
membrane proteoglycan expressed in embryonic stem cells and 
embryonic cancer cells (Schopperle and DeWolf, 2007). TRA 1-60 
antibody reacts with neuraminidase sensitive epitope of the 
proteoglycan molecule (Zhao et al., 2012) 
TRA 1-81 Antigen expressed in podocalyxin, a large keratan sulphate 
membrane proteoglycan expressed in embryonic stem cells and 
embryonic cancer cells (Schopperle and DeWolf, 2007). TRA 1-81 
antibody reacts with neuraminidase insensitive epitope of the 
proteoglycan molecule (Zhao et al., 2012) 
ALP Enzymatic marker noted to have high expression in both human 
and mouse embryonic stem cell (Draper and Fox, 2003, 
Koestenbauer et al., 2006) 
SOX-2 Member of the SOX family of transcription factor regulating 
pluripotency, it works in conjunction with Oct3/4 and acts as a 
‘molecular rheostat’ in embryonic cells to promote differentiation 
(Boer et al., 2007) 
Nanog A highly divergent homeodomain containing protein expressed in 
pluripotent embryonic stem cells (Silva et al., 2009) 
Oct-3/4 Member of POU family transcription factor, structurally an 
octamer binding protein expressed in embryonic stem cells 
promoting differentiation and the type of cell formed depends on 
the level of expression of Oct3/4 (Niwa et al., 2000)  
REX-1 Member of the Ying Yang (YY) subfamily of transcription factor is a 
marker of pluripotency independent of Oct4 which influences 
mitochondrial fission required for appropriate cell cycle 
progression required for pluripotency (Son et al., 2013) 
SSEA-1 Glycolipid molecule controlling cell surface interaction during 
development noted in human germ cells, teratocarcinoma cells, 
oviduct cells and epididymis with conspicuous increase in 
expression following differentiation (Zhao et al., 2012) 
SSEA-3 Cell surface glycoprotein noted in embryonic cells at an early-
cleavage stage playing potential role in early embryogenesis 
(Kannagi R et al., 1983) 
SSEA-4 Early embryonic glycolipid antigen used as a marker of 
undifferentiated pluripotent human embryonic stem cells (Gang et 
al., 2007) 
Table 2.1: Description of the pluripotency markers ascertained on the cells from four cord regions 
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2.2.8.1 Immunocytochemistry: This was used to determine the expression of pluripotency 
markers with antibodies against Nanog (R&D Systems), REX-1 (Abcam) and OCT 3/4 (BD 
Biosciences) (Table 2.2) on cells derived from the four regions of UC cultured in monolayer 
at P4. Cells from CL, WJ, PA and PV were seeded onto chamber slides (BD Biosciences) at a 
density of 5000 per cm2.   Once cells had adhered (after three days), media was removed, 
and cells were washed twice with PBS before being fixed with 4% paraformaldehyde (w/v) 
for 20 min. Slides were washed twice with PBS before being blocked with buffer made up of 
BSA (1%), Triton X-100 (0.1% made in PBS) and either 10% donkey serum (for antibodies 
against Nanog) or 10% goat serum (for antibodies against REX-1 and OCT3/4) in PBS for 1 
hour at room temperature.  Slides were washed twice in PBS before being stained with the 
primary antibodies in freshly prepared respective blocking buffers. The following 
concentration of primary antibodies was used - Nanog (1:50), REX-1 (1:100) and Oct 3/4 
(1:100) and incubated overnight in the dark at 4oC.  Primary antibody was subsequently 
removed, and slides were washed twice with PBS. Cells were stained with Alexa-Fluor 488 
(1:250) (Invitrogen) conjugated with the respective secondary antibodies in blocking buffer 
and incubated for one hour at room temperature in the dark. The isotype controls for each 
antibody and PBS controls were also used alongside the primary antibodies (Table 2.2). 
Slides were washed twice with PBS before DAPI stain with Vectashield mounting medium 
(Vector Laboratories) was added under a coverslip, and cells were viewed under 
a fluorescent microscope (Leica Microsystems). 
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Primary 
antibodies 
Primary antibody 
source 
Secondary 
antibody 
Isotype control 
Isotype control, 
Primary & 
Secondary 
antibody conc. 
Rex-1 
Polyclonal rabbit 
IgG 
Goat Anti-rabbit 
Polyclonal IgG  
Rabbit IgG 1:100 
Oct3/4 
Polyclonal mouse 
IgG 
Goat Anti-mouse 
Polyclonal IgG  
Mouse IgG 1:100 
Nanog 
Polyclonal goat 
IgG 
Donkey Anti-goat 
Polyclonal IgG  
Goat IgG 1:50 
Table 2.2 Antibodies used for pluripotency markers 
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2.2.8.2 Flow cytometry:  Fluorometric assay was used to determine the expression of 
pluripotency markers TRA 1-60, TRA-1-81, SSEA-1, SSEA-3, SSEA-4 and alkaline phosphatase 
(ALP). A total of 9x 105 cells from each of the four layers of UC (n=4) were suspended in 0.9 
ml of blocking solution (details in section 2.2.7). Cells were incubated on ice for one hour. 
The cells and blocking mixture were centrifuged at 500g for 5 minutes to form a pellet. This 
pellet was re-suspended in 2% BSA (in PBS). 100μl of this cell suspension (total 600μl) was 
incubated in the dark for 30 minutes after the addition of the pluripotency markers. The 
concentration of fluorescein isothiocyanate (FITC) conjugated pluripotency markers used 
was: TRA 1-60 (1:10), TRA-1-81(1:10), SSEA-1 (1:10), SSEA-3(1:10), SSEA-4(1:100) and 
alkaline phosphatase (ALP) (1:20) (all donated by Mark Jones from the Sheffield University, 
UK). Additionally, 100μl of this cell suspension was used for isotype-matched control with 
FITC IgG (1:50) antibodies (Southern Biotech). These cells were subsequently centrifuged 
twice with 1ml of 2% BSA in PBS to wash off the antibodies, and finally, they were 
suspended in 200μl of BSA (2% in PBS) for flow cytometry. The rest of the method of flow 
cytometry is described in section 2.2.7. 
2.2.8.3 Fixation and permeabilisation followed by flow cytometry:  This technique was 
undertaken to determine the presence of for Sox-2 antigen, another marker of a pluripotent 
state.  The remaining 200μl of cell suspension was divided equally amongst PE-conjugated 
Sox-2 (1:50)(BD Bioscience), and PE-conjugated IgG2 (1:50) isotype-matched control 
(Immunotools, Germany) which were incubated separately for 30 minutes in ice placed on a 
gently moving platform to ensure thorough mixing. The cell suspension (100μl each) was 
fixed and permeabilised with 250μl of fixation and permeabilisation buffer (BD 
Cytofix/CytopermTM plus) for 30 minutes. This was subsequently washed with 1000μl BD 
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Perm/WashTM buffer and resuspended in 100μl of the same buffer before staining with the 
PE-conjugated Sox-2 antibody (2μl), and PE-conjugated IgG2 isotype control (2μl) for 30 
minutes in the dark on ice for intracellular staining. Next, the cell suspensions with the 
antibody were washed twice with 1000μl BD Perm/ WashTM buffer again and resuspended 
in 200μl of 2% BSA (in PBS) for flow cytometry. The Cell Quest Pro software was used to 
analyse the results for both FITC and PE-conjugated antibodies with their controls. 
2.2.9 Immunoprofile of cells  
Flow cytometry was also used to ascertain the immune profile of the cells derived from the 
four regions of the UC at P4. The method of flow cytometry is the same as described in 
section 2.2.7. The following PE-conjugated antibodies were used: HLA-ABC (ImmunoTools, 
Germany), CD-40 (BD Biosciences), CD-80(BD Biosciences) and CD-86 (BD Biosciences).  PE-
conjugated IgG1 or IgG2a (1:50) antibodies (both ImmunoTools, Germany) were used as 
isotype controls. The BD Flow cytometer FACS scan™ was used according to the protocol 
described in section 2.2.4 for flow cytometry and analysed with Cell Quest Pro software. 
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2.2.10 Statistical analysis 
A Shapiro-Wilks test was used to ascertain the normality of the data. The relationship 
between the numbers of cells isolated (x10⁶) per gram of explant tissue was determined by 
Pearson’s correlation coefficient. A one-way ANOVA was used to determine the difference 
between the DT’s of cells (dependent factor) derived from the four UC regions (independent 
factors/groups) during each passage with a posthoc test (Bonferroni) to identify differences 
in the DT’s between or within groups for each cell preparation over three passages. The data 
for ALP activity was not normally distributed hence it was log transformed to achieve 
normal distribution (ascertained by Q-Q plot). A mixed model analysis was performed with 
the four regions of the cord and the treatment to the respective cell preparations 
(osteogenic differentiation and control) as fixed effects with the ALP activity as dependent 
variable to obtain the intercept (random effect. All analyses were done using SPSS software 
(Version 22.0.0.0, IBM United Kingdom Ltd, Portsmouth, UK). For all analyses, a two-tailed 
p-value of 0.05 or below was assumed to denote significance. 
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2.3 Results 
2.3.1 Isolation technique and cell culture    
All four layers of the UC (n=5), WJ, CL, PA and PV, produced plastic adherent fibroblast-like 
cells within 21 days of explant culture (Figure 2.4). Moreover, these cells had heterogeneous 
morphology, particularly cells derived from PA and PV tissues appeared predominantly 
smaller in size. A live video image of these cells emanating from the PA explant (refer to 
video image) showed these cells to change its shape and size constantly. 
  The weight of each cord region and the cell yield at P0 were found to be normally 
distributed (Shapiro-Wilks test p>0.05). There was no statistically significant correlation 
between explant weight and cell yield from the different layers of the UC at P0 (p-
value>0.05). However, a significant correlation was noted between the numbers of cells 
isolated (x10⁶) per gram of explant tissue from the PA, PV and CL, but not with cells per 
gram of WJ explant tissue. This implied a mutual relationship of the PA, PV and CL explant 
tissue weight to the number of cells retrieved from each of this region of the cord. The 
relationship between the cells isolated (x10⁶) per gram of explant tissue from the PA, PV and 
CL and WJ are shown in Table 2.3 and 2.4. 
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Cord Layers 
(n=5) 
Mean Explant Weight 
± SD 
(in gm) 
Mean Cell 
yield ± SD 
(x10⁶) 
Mean no. of cells ± 
SD (x10⁶) per gram of 
explant tissue 
p-value(between 
explant weight 
and cell yield) 
CL 1.3±0.72 2.3±3.1 1.4±1.4 0.2 
PA 0.74±0.9 1.4±1.7 3.01±3.4 0.8 
PV 0.4±0.35 1.2±1.16 4.01±4.8 0.8 
WJ 0.62±0.66 0.70±0.75 2.3±3.6 0.7 
 
Table 2.3 Relationship between weight of explant and number of cells at P0 
 
 
PA cells per 
gm 
PV Cells per 
gm 
CL Cells per 
gm 
WJ Cells per 
gm 
PA cells per gm Pearson 
Correlation 
1 .957* .937* .563 
Sig. (2-tailed)  .011 .019 .323 
N 5 5 5 5 
PV Cells per gm Pearson 
Correlation .957
* 1 .994** .306 
Sig. (2-tailed) .011  .001 .616 
N 5 5 5 5 
CL Cells per gm Pearson 
Correlation .937
* .994** 1 .258 
Sig. (2-tailed) .019 .001  .675 
N 5 5 5 5 
WJ Cells per gm Pearson 
Correlation .563 .306 .258 1 
Sig. (2-tailed) .323 .616 .675  
N 5 5 5 5 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
N is the number of the umbilical cord. 
Table 2.4 Correlation between cell yield (in 10⁶) per weight(in gm) of respective explant tissue at 
P0 
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Figure 2.4 Cells at P0 isolated from four separate anatomical regions of the umbilical cord by 
explant culture technique 
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2.3.2 Growth Kinetics 
The mean DT of all four types of cells was compared for three consecutive passages (P1 to 
P3) from four UCs. Mean DT from P1 to P3 for PA were 2.9± 0.17 (CI 1.9-3.9) days, PV cells 
were 3.8± 0.48(CI 2.6-5) days, CL cells were 3.5 ± 1.3 (CI 0.4-6.6) days, and  WJ cells were 2.9 
±0.83 (CI 0.9-4.9) days. There was no statistically significant difference between the mean 
DT of cells from four UC regions (p-value < 0.05). A one-way ANOVA, with cells from all four 
UC regions being the independent factor (groups) and DT of cells during each passage being 
dependent with the posthoc test (Bonferroni) revealed no significant difference in cell 
doubling time between cells from the different regions for all three passages. The DT of cells 
from four anatomical regions of UC from P1 to P3 is illustrated in Figure 2.5. 
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Figure 2.5 Mean doubling time of cells from four regions of the umbilical cord at three consecutive 
passages 
(Error bar represents one standard deviation) 
(PA-Peri-arterial cells, PV-Peri-venous cells, CL-Cord lining cells, WJ-Wharton’s Jelly cells and the 
number script represent respective passages) 
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2.3.3Tri-lineage mesenchymal differentiation potential 
2.3.3.1 Osteogenic differentiation 
 2.3.3.1.1 ALP staining 
Cellular ALP staining was positive in ‘test’ wells of cells from all four types of explants. Cells 
derived from PV tissues were noted to produce consistently better and uniform cellular 
staining subjectively in comparison to the other three cell preparations (Figure 2.6). 
 2.3.3.1.2 Semi-quantitative estimation of ALP activity 
The ALP activity was measured in triplicate in the culture medium for each type of cell 
preparations (3 wells containing control and 3 with osteogenically differentiated cells for 
each region from each cord). The ALP activity data was log-transformed to ensure a normal 
distribution which was ascertained by a Q-Q plot. ALP activity in the osteogenic medium was 
higher than their respective controls (p=0.002) for each type of cell preparation from the 
four distinct anatomical areas (Figure 2.7). A mixed model analysis showed osteogenic 
media from WJ cells had significantly less ALP activity in comparison to the osteogenic 
media from PA, PV and CL cells (p-value<0.05). 
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Figure 2.6 Alkaline phosphatase staining of cells from all four regions  of the umbilical cord-Peri-
arterial cells, Peri-venous cells, Cord lining cells and Wharton’s Jelly cells at 21 days following 
osteogenic differentiation at P3 (scale bar represents 25 µm) 
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Figure 2.7 Alkaline phosphatase activity of the culture media from osteogenically differentiated 
cells and controls cells derived from four cord regions after 21 days at P3 
(PA-Peri-arterial, PV-Peri-venous, WJ-Wharton’s Jelly, CL-Cord lining) 
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2.3.3.2 Chondrogenic differentiation  
 2.3.3.2.1 Toluidine blue staining  
The staining for matrix metachromasia varied for different cell preparations after 
chondrogenic differentiation. The WJ and PV cell types showed consistently more staining in 
comparison to PA and CL cells, implying higher glycosaminoglycan content (Figure 2.8).  
 2.3.3.2.2 Immunofluorescence for Type-II Collagen  
All four cell preparations from the separate anatomical regions of the cord were tested for 
the presence of type II collagen (n=3). Only one pellet from WJ cells from one cord had a 
single area immunopositive for type II collagen staining. All other pellets from all four types 
of cell preparations were found to be negative for type II collagen following chondrogenic 
differentiation after 3-4 weeks. 
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Figure 2.8 Toluidine staining following chondrogenic differentiation of Peri-venous cells, Peri-
arterial cells, Cord lining cells and Wharton's Jelly cells (scale bar represents 100µm) 
 
 
 
 
 
 
 
Peri-arterial 
Cord lining 
Peri-
Wharton’s 
 106 
 
 
 
2.3.3.3 Adipogenic differentiation: This was observed by Oil Red-O staining of all cell 
preparations after culture in adipogenic differentiation medium for 21 days. Intracellular 
lipid accumulation was evident in all types of cell preparation although it was more 
pronounced in WJ cells (Figure 2.10). Spontaneous adipogenesis was not observed in any 
control wells.  
 
 
,  
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Figure 2.9 Oil Red-O staining following adipogenic differentiation of cells from the four cord 
regions after 21 days (scale bar represents 25 µm) 
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2.3.4 Mesenchymal stem cell surface markers 
Cells from four regions (PA, PV, CL & WJ) of five UC were studied for characterising the 
surface profile of CD-antigens according to the ISCT guidelines for the definition of MSC 
(Dominici et al., 2006). All cell preparations showed immunopositivity for CD105, CD90 and 
CD73 with minimal expression of the CD14, CD19, CD34, CD45 and HLA-DR. However, 
quantitative analysis revealed that only two PV and one WJ cell preparation from two UC 
complied exactly with the limits defined by Dominici et al. (2006) to fulfil the criteria of MSC 
(Figure 2.11). 
The frequency of cells positive for CD105 and CD73 varied widely for cells derived from all 
four regions with cells from PA and PV being more closely comparable. The CD90 expression 
was noted to have the least variability amongst these cells from all the areas of UC except 
WJ-derived cells. All PV cell preparations had ≤ 2% positivity for CD14, CD19, CD34, CD45 
and HLA-DR rendering them compliant to the ISCT definition for these markers. Cells from 
all four regions of a single UC were noted to be extreme outliers (represented by *).  The 
trend of the surface marker expressions for all the four types of cell preparations is 
demonstrated in Figures 2.12 and 2.13. 
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Figure 2.10 Representative flow cytometry profile of cells isolated from Wharton’s Jelly complying 
with the criteria of ISCT for definition of MSC (Dominici et al., 2006) 
(The blue shaded area represents the surface expression of isotype-matched controls, and the 
green line graph represents the expression of the respective surface markers on the cells) 
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CD34 CD45 CD73 
CD90 HLA-DR CD105 
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Figure 2.11 Positive CD markers on cell preparations of umbilical cords (n=5) from four regions 
(*shows outliers). The horizontal line denotes the defined quantitative levels according to the 
International Society for Cellular Therapy (Dominici et al., 2006). CD 90 was noted to have the 
least variability between cells derived from all the regions except Wharton’s Jelly. 
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Figure 2.12 Negative CD markers on cell preparations of umbilical cords (n=5) from four regions 
(*shows outliers). The horizontal line denotes the defined quantitative levels according to the 
International Society for Cellular Therapy (Dominici et al., 2006). The cells from peri-venous 
regions complied with the quantitative criteria of less than 2% expression of the surface marker. 
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2.3.5 Pluripotency markers 
Cells from all four regions of UC (n=4) were immunopositive for REX-1 (Figure 2.13), but 
none of the cell populations was positive for Nanog or Oct 3/4 on immunofluorescence 
microscopy. 
Similarly, the four cell populations from the cord (n=4) had a positive surface expression of 
SSEA-4, ALP and SOX-2 in comparison to their isotype controls. In contrast, cells derived 
from all four layers lacked expression of TRA 1-60, TRA 1-81, SSEA-1 and SSEA-3.  
 
2.3.6 Immunoprofile of cells  
All cells from the four regions of the cord at P4 had a surface expression of HLA-ABC, but 
there was a total absence of co-stimulatory molecules of CD-40, CD-80 and CD-86. 
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Figure 2.13 Positive immunocytochemical staining for REX-1 on cells from four layers of the 
umbilical cord (scale bar represents 25 µm) 
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2.4 Discussion 
In this work the isolation of plastic-adherent cells has been reported after three weeks of 
explant culture. Four anatomical regions within the UCs were used as explant tissue, and a 
distinct culture medium previously reported to isolate cells only from cord lining membrane 
was used (Gonzalez et al., 2010). Cells obtained from these four regions had a different 
morphology but noted to be predominantly fibroblastoid in appearance with the potential 
for tri-lineage differentiation, and they express surface markers of stem cells according to 
the ISCT criteria (Dominici et al., 2006), although they do not conform uniformly to these 
standards quantitatively.  
Consistent isolation of cells (termed human ‘extraembryonic mesodermal stem cells’) from a 
UC explant culture system with vessels in situ has been demonstrated, although the surface 
antigens on these cells were not quantified (La Rocca et al., 2009). Isolating cells from the 
UC by explant culture of the entire cord has also been reported  (Majore et al., 2011). These 
cells had the same surface phenotype expression of MSCs according to the ISCT criteria but 
lacked evidence of osteogenic differentiation; hence, the term “multipotent mesenchymal 
stromal cells” was used to describe these cells (Majore et al., 2011).  Isolation  of cells from 
three anatomical regions of cord- WJ, umbilical cord artery (UCA) and umbilical cord vein 
(UCV) using explant culture has been described, and three distinct types of MSCs were 
characterised although the precise nature of the UCA and UCV explants was not 
histologically defined (Ishige et al., 2009). The histological presence of the supporting matrix 
(i.e. WJ) around the umbilical cord artery and vein explants has been demonstrated in the 
present work, despite meticulous dissection of the UC before isolation. Hence, it was 
preferred to term them peri-arterial and peri-venous explants, respectively.  
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For the first time, a significant correlation of the cell yields per weight of explant between 
CL, PA and PV has been reported in this work, but no correlation was found with WJ-derived 
cells of the UC. This highlights the importance of the explant weight of these three particular 
regions for the total cell yield, particularly during industrial-scale production of UC-derived 
stem cells using this technique. Direct comparisons of the doubling time (DT), although 
different, were not statistically significant for cells isolated from the four distinct anatomical 
parts of the cord.  The DT from the previous study published by our group confirmed these 
findings, also reporting significantly shorter DTs for cells derived from different cord regions 
in comparison to BMMSC (Mennan et al., 2013). The present work shows PA and WJ cells 
have the shortest average doubling time (2.9 days), whereas the doubling time of CL and PV 
cells were 3.5 days and 3.8 days respectively, although there was considerable variability, 
however, the differences were not statistically significant. These results also conform to 
previous trends of a slower population doubling time for cells derived from UCV in 
comparison to UCA and WJ, although this group of researchers only evaluated population 
doubling time for nine days in culture (Ishige et al., 2009). 
Cells derived from the four areas of the UC demonstrated tri-lineage differentiation in the 
current study. A further unique finding of the study was demonstrated by semi-quantitative 
estimation of the ALP activity in the culture medium of the control and osteogenically 
differentiated cells. At 21 days, a significant rise in ALP activity in culture medium from 
differentiated cells was demonstrated in comparison with their controls for cells from all 
four areas of the UC. Moreover, the culture medium of osteogenically differentiated WJ 
cells had significantly poorer ALP activity in comparison to CL, PA and PV cells. Ishge et al. 
(2009) noted the same findings on poor osteogenicity of WJ cells. A  significant elevation of 
ALP activity was only reported in osteogenically differentiated UCV cells in comparison to 
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their respective controls but not in UCA cells for up to 28 days in addition to a complete 
absence of ALP activity in WJ cells till 49 days  (Ishige et al., 2009). Such differences 
observed in our work can be caused by differences in culture conditions, including basal 
media and supplements used in our work during culture expansion or osteogenic 
differentiation.   
The isolated cells from different anatomical locations in the present work differed in their 
expression of surface markers. Only PV cells were consistently negative for haematopoietic 
cell markers (<2 percent) with flow cytometry analyses. This is dissimilar to our previous 
report (Mennan et al., 2013) where all cells from all locations lacked surface expression of 
haematopoietic markers. An earlier study on MSCs from the sub-amnion of the cord lining 
membrane derived with the explant technique was noted to be positive for CD14, which 
was thought to be related to T-cell modulation, although its precise role was not established 
(Kita et al., 2010). Furthermore, a study on characterising CL cells showed CD34 positivity of 
9.44±SD2.75% and CD45 positivity of 9.09±SD4.03%. The surface phenotypes of these cells 
were suggested to share epithelial and MSC properties (Reza et al., 2011).  
Positive markers for stem cells were within the recommended threshold (>95%) for only 
three cell preparations, i.e. one WJ and two PV derived cells. For the rest of the cell 
preparations, it was not observed to be >95% at P3. A previous study also reports a very low 
CD90 (0.6%) and CD105 (1.5%) expression of enzymatically isolated WJ cells from UC at P3, 
which was noted to be >99% at P5 (Bakhshi et al., 2008). A similar observation was noted in 
WJ cells isolated with enzymes and mechanical disassociation from UCs, with a reported 
increase of surface expression of CD105 from 28.3% to 78.2% and CD90 expression from 
90.0% to 94.9% from P2 to P10 (Fong et al., 2010). 
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 Explant culture of the entire UC in allogenic serum has demonstrated heterogeneous cell 
groups which can be separated into six distinct groups by counterflow centrifugal elutriation 
(CCE) based on cell size (Majore et al., 2009). Quantitative flow cytometry in the same study 
revealed significantly higher positivity to CD73, CD90 and CD105 in smaller cells in 
comparison to cells with larger diameters (Majore et al., 2009). This study also reports 
better growth and differentiation of the fraction of cells with smaller diameters in 
comparison to the larger cells, which were found to be more senescent on SA-β-gal staining 
compared to their smaller counterparts (Majore et al., 2009). Fluorometric analyses of the 
CD antigens on cells from the four distinct anatomical layers of the cord grown in 10% FCS 
and antibiotics with no additional supplement conversely demonstrated >95% positivity of 
CD73, CD90 and CD105 with a uniform absence of haematopoietic markers by our group at 
P3 (Mennan et al., 2013). 
In summary, the variation in surface expression of CD antigens noted in the current study 
can be multi-factorial and may be explained by different culture conditions used, which 
includes the basal medium of DMEM Glutamax supplemented with relatively high serum 
content (15% FCS) in addition to NEAA and vitamins. A different sub-population of cells can 
be potentially selected during isolation and culture expansion of cells from distinct 
anatomical parts of the UC with this media. Moreover, the surface expression of antigens 
alters with the passage and the present work reports only at P3, which may vary at later 
passage. However, all the surface antigens in the present work were precisely evaluated 
during fluorometric analysis and had isotype-matched control to eliminate confounding of 
the results due to false positivity. 
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A scientific control group forms an essential part of an experimental design to exclude the 
influence of confounding variables and bias on the results, in addition, generates a baseline 
data. There are extraneous variables that can influence the outcome of the experimental 
study - hence it is critical to identify and minimise their effects (Johnson and Besselsen, 
2002). The two commonly used controls are positive and negative controls. Positive controls 
essentially demonstrate the response that is being sought through the experiment thereby 
validating the experimental design and reduces the chance of false negatives. It also can act 
as a standard for measurement of the outcome in the study group (Johnson and Besselsen, 
2002). On the other hand, the negative control is a valuable tool in identifying a non-causal 
association between ‘effects of exposure’ and the ‘outcome’ (Lipsitch et al., 2010).  A 
negative control is designed with conditions to produce no results and verified that it has 
indeed produced no results. This strategy underpins the possibility of confounding variables 
influencing the outcome if any and prevents false positives (Lipsitch et al., 2010). 
All cell preparations in the present work expressed the Major Histocompatibility Complex 
(MHC) class-I molecule (HLA-ABC) but no MHC class II (HLA-DR) and co-stimulatory 
molecules, CD40, CD80 and CD86. The immunophenotype of these cells from four UC 
regions is a novel observation in our work. Additionally, these cells expressed SSEA-4, a 
surface marker for undifferentiated pluripotent embryonic stem cells (Gang et al., 2007), 
with positive expression of both SOX-2, a marker of self-renewal and pluripotency of 
embryonic MSC (Rizzino, 2013) and also REX-1,  a pluripotency marker of undifferentiated 
embryonic stem cells.  All cell types also had a positive expression of ALP, an enzymatic 
marker for embryonic stem cells (Zhao et al., 2012). However, none of the cell types 
expressed the embryonic stem cell marker Oct3/4 or Nanog (Loh et al., 2006). Nor did these 
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cells express the markers TRA1-60 and TRA1-81, associated with the heavily glycosylated 
membrane protein, podocalyxin,  which is noted in embryonal carcinoma cells and 
pluripotent stem cells (Schopperle and DeWolf, 2007). 
In conclusion, the present work has demonstrated a technique for successful isolation of 
cells which are akin to MSCs but unique in their surface antigen properties at early passage. 
These cells were noted to express some pluripotency markers indicating their self-renewal 
capacity, which is accompanied by their ability for tri-lineage differentiation, although the 
potential for WJ-derived cells to become osteogenic appears weaker than for cells from 
other locations of UC. These cells were also observed to uniformly exhibit MHC Class I 
molecule (HLA-ABC) in the absence of HLA-DR or co-stimulatory molecules, which suggests 
that they are suitable candidates for allogeneic transplantation. Further studies about their 
immunological profile after priming these cells before and after differentiation should be 
undertaken to ascertain their usefulness in specific locations and disorders for regenerative 
medicine. 
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Chapter 3: Bone Marrow Stromal Cells Do Not Increase New Bone Formation in 
Recalcitrant Nonunions: Results of a Double Blinded Randomised Controlled Trial 
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3.1 Introduction 
A total of 850,000 new fractures are reported annually in the UK. The majority of these 
fractures progress to uncomplicated healing, except in 5-10% of patients whose fractures do 
not heal (Court-Brown et al., 2010). Recent Scottish data estimates the overall annual 
incidence of nonunions at 19 per 100,000 people, equivalent to the incidence of revision hip 
replacements (Mills and Simpson, 2013, Court-Brown et al., 2010). Lower limb nonunions 
make up 6.7 per 100,000 people, with a treatment cost of $11,500 to $132,000 per person 
to the National Health Service, excluding the morbidity and loss of earnings (Mills and 
Simpson, 2013).  
The human fracture haematoma contains cells which have multi-lineage differentiation 
potential including osteogenic differentiation capacity, and the phenotype of these cells are 
similar to bone marrow MSCs (BMMSCs)(Jagodzinski and Krettek, 2007). Nonunion stromal 
cells grown from human nonunion were noted to have slower doubling time, lower 
osteogenic potential and a higher rate of apoptosis in comparison to BMMSCs from healthy 
donors(Bajada et al., 2009). These cells were found to secrete Dickkopf-1(Dkk-1) which is an 
antagonist to the Wnt signalling pathway and inhibits osteogenic differentiation and 
fracture healing (ibid). A study of nonunions in rats showed that the progenitor cells from 
the atrophic nonunion site had impaired differentiation potential due to the sub-optimal 
environment, nevertheless suggested reactivation of these native cells by adding growth 
factors or progenitor cells to induce bone formation(Tawonsawatruk T et al., 2013). 
However, successful case studies of bone tissue engineering approaches to regenerate large 
bone defects in patients by using in vitro expanded autologous Bone Marrow derived 
Stromal Cells (BMSC) and subsequently re-implanting them in scaffolds have been 
reported(Quarto et al., 2001, Marcacci et al., 2007). In vitro studies have also demonstrated 
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no difference in the osteogenic capacity of BMSCs from the iliac crest in patients with 
atrophic nonunions and healthy volunteers (Mathieu et al., 2013). Reports of treating 
nonunions successfully with autologous bone marrow derived cells were also published 
consistent with in vitro studies (Bajada et al., 2007, Hernigou et al., 2005).  
We report the first randomised self-controlled trial to compare new bone formation in 
recalcitrant nonunions treated with carrier plus in vitro expanded autologous BMSCs against 
the carrier alone (control). Secondary aims were to analyse predictors of the union in these 
patients and describe adverse events at final follow-up. 
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3.2 Methods 
Patients were invited to participate in a single centre double-blinded self-controlled 
randomised trial by a single specialist nonunion surgeon. The trial was approved by National 
Research Ethics Service, South Staffordshire Local Research Ethics Committee (Ref. No. 
02/42/RJH). 
Patient inclusion criteria were: 
a. Nonunion following fracture of tibia or femur. 
b. An established nonunion according to the US Food & Drug Administration 
criteria(1998). 
Patient exclusion criteria were: 
a. Skeletal immaturity. 
b. Pregnant or breastfeeding. 
c. Nonunion following pathological fractures. 
d. Positive to Hepatitis-B, Hepatitis-C or HIV.  
e. Infection during BMSC culture.  
Patients with diabetes or bone loss and smokers were not excluded. 
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3.2.1 In vitro BMSC culture 
Bone marrow aspirates from the iliac crest of the patients with nonunion were harvested 
with aseptic precaution in the theatre. A Jamshidi needle attached to a heparanised syringe 
(Becton Dickson Medical Supplies, Cowley, UK) was used to aspirate bone marrow which 
ranged from 2-10ml. The BMSC’s were isolated and cultured from the aspirate according to 
the previously published protocol from our centre (Wright et al., 2008).  
The bone marrow aspirate was mixed with phosphate buffer solution (PBS), and the mixture 
was subsequently layered over two aliquots of 10ml of Lymphoprep (Fresenius Kabi Forge).  
The mononuclear cells were isolated by density gradient centrifugation at 900g for 20 
minutes. A ‘buffy coat’, predominantly containing mononuclear cells was obtained; this was 
separated with a 19 gauge needle and 5ml syringe (Becton Dickson Medical Supplies). The 
harvested ‘buffy-coat’ layer from the two tubes was then pooled and added to 10ml of 
DMEM F12 (Gibco, UK),  supplemented with 20% FCS, penicillin and streptomycin. The cell 
suspension is then centrifuged for 10 minutes at 750g. The cell pellet obtained was 
suspended in DMEM F12 with 20% FCS, and subsequently, a viable cell count was 
performed with trypan blue exclusion. These cells were plated at a density of 2x107 cells per 
250ml flask (Polystyrene Tissue Culture Flask, BD Biosciences, Cowley, Oxford, UK) with 
20ml of the media. After 24 hours the non-adherent cells were removed by removing the 
media and then washing the flask with PBS. The adherent cells were continued in monolayer 
culture with DMEMF12 with 10%FCS and antibiotics at 370C, 5% (v/v) CO2 until it reached 
70% confluence. At confluence, these cells were passaged by trypsinisation and routinely re-
seeded at 5x103 cells/cm2 density. 
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Cell numbers at the end of each passage were noted to calculate the doubling time of these 
cells using the following equation: 
Doubling Time (DT) =(t₂-t₁)x ln(2)/ln( n₂/n₁) where: 
 t₂-t₁ represents consecutive time points,  
ln represents the linear log,  
n₂ represents the final cell numbers harvested and 
           n₁ represents the initial number of cells(Jordan and Smith, 1997). 
Autologous BMSC’s were culture-expanded for three weeks. The discarded medium was 
sent to the microbiology department routinely for infection screening.  
Following randomisation, two universal containers - one with cells in serum and the other 
containing serum alone- were sent out to the operating theatre for insertion at the fracture 
site. Each container was marked medial/ anterior and lateral/ posterior, respectively, based 
on the surgical approach to the nonunion site. 
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3.2.2 Surgical Technique 
The nonunions of fractures were stabilised with internal or external fixation devices. The 
femoral fractures were internally fixed, and tibial fractures were predominantly fixed with 
external fixation systems. The nonunion site was exposed and decorticated. Depending on 
the surgical approach, the nonunion site was considered to have either a medial and lateral 
or an anterior and posterior side, although no physical partition was applied. The contents 
of each universal container were mixed individually with a carrier by the surgeon, who was 
blinded to the contents of the container. Carriers were β tricalcium phosphate (Allogran®-R, 
Biocomposites, Keele, UK), calcium sulphate (CaSO4; Stimulan®, Biocomposites, Keele, UK), 
hydroxyapatite (Allogran® N, Biocomposites, Keele, UK), combination of β tricalcium 
phosphate and calcium sulphate or simply patient’s serum (Table 3.1).  
An ideal carrier material should have good biomechanical properties to withstand loading at 
the fracture site in conjunction with its biodegradability and porous architecture allowing 
implanted cells to thrive until the new bone is formed.  Evidence of such osteoconductive 
carrier material at the outset of the trial was inconclusive with β tricalcium phosphate being 
easily resorbed however lacked the mechanical strength at the same time hydroxyapatite 
had a high strength to take the load but had poor resorption from the fracture site 
(Cancedda R et al., 2007).  The choice of carrier in this study was guided by the degree of 
bone loss and the volume of pre-existing callus and differed between patients. However, 
each patient received the same type of carriers to preclude its influence on the ‘control’ and 
‘test’ side, if any. Moreover, a total of eight patients received no carriers but autologous 
serum, to act as a control to the synthetic carriers used for the cells, to identify the influence 
of carrier material on the outcome during sub-group analysis. The two mixtures were left for 
10-15 minutes to allow attachment of cells to the carrier. The operating surgeon then 
 127 
 
inserted each mixture on the side indicated by the label on the container, thus putting the 
cells at their randomly allocated side. An overview of the whole method is illustrated in 
Figure 3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 128 
 
 
Carrier type Number of cases (%) 
β tricalcium phosphate with calcium sulphate 
β tricalcium phosphate 
Calcium sulphate 
Hydroxyapatite 
Serum 
16 (46%) 
6 (17%) 
4 (11%) 
1 (3%) 
8 (23%) 
Table 3.1 Overview of carriers used in the trial 
 
 
Figure 3.1 Overview of the trial methodology from bone marrow harvest to trial intervention 
showing separate ‘test’ side receiving cells with carriers and ‘control’ side receiving only carriers. A 
total of five type of carriers including serum was used in the study, however, each patient received 
only one type of carrier (SC-Bone marrow stromal cells; image adapted from Bajada et al., 2009) 
 
 
 
 129 
 
3.2.3 Primary Outcome 
The primary outcome measure was the formation of new callus and cortical bridging, 
assessed from preoperative and multiple postoperative radiographs and CT-scans up to 12 
months. New callus was defined as new bone noted in postoperative radiographs which was 
adjacent to the bony cortices of the nonunion site whereas new fracture bridging was 
defined as new bone formation noted at the fracture gap of the nonunion site, both being 
compared with the immediate preoperative radiographs.  These images were divided into 
early (3-6 months) and late (6-12 months) groups. Hence, the primary outcome was 
categorized as early new callus and cortical bridging (3-6 months) and late cortical bridging 
and new callus (6-12 months).   Nonunions were assessed from anonymised slides by four 
reviewers (two radiologists and two orthopaedic surgeons) blinded to the side of cell 
insertion. None of the assessors was directly involved in recruitment or clinical care of these 
patients in the trial.  Each slide had a preoperative radiograph for comparison with postoperative images but no 
indication of time since surgery was available to the reviewer. These preoperative 
radiographs were to be compared with postoperative films which were marked as Image 1, 
Image 2 and onwards. The slides only showed a medial/ lateral or an anterior/ posterior 
view of the nonunion site depending on the surgical approach. A sample slide is presented 
in Figure 3.2. 
 A total of 232 postoperative images were assessed for the 35 patients by the four 
reviewers. At least three representative images of the CT scans were used to determine the 
nonunion site by the reviewers in the coronal or sagittal plane.  All the preoperative images 
were within three months before the BMSC insertion. Every reviewer was presented with a 
questionnaire for assessing each image to indicate any change in callus and fracture bridging 
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as illustrated in Fig 3.3. If appreciable new bone formation on both sides of the fracture was 
noticed, as, in Fig 3.2, such observations in the assessment box of the questionnaire were 
also recorded. For radiographs showing both tibia and fibula fractures, only the tibia was 
used for assessment. 
At first, each reviewer indicated the side with the largest callus and most cortical bridging 
preoperatively. Then each reviewer examined subsequent radiographs to indicate the side 
with the most substantial change in the formation of new callus and cortical bridging. This 
was based purely on their subjective assessment of the postoperative radiographs which 
was always compared with the preoperative image available in each slide. Furthermore, the 
second round of evaluation was undertaken by the four reviewers with at least on 
radiograph from each patient to assess the intra and inter-observer reliability. The second 
series of assessment was three months after the first to avoid recollection bias. All 
preoperative radiographs were also included in the same layout, as used during the first 
evaluation. 
The primary outcome for each postoperative radiograph was assessed with a probabilistic 
model of labelling images termed as Generative models of Labels, Abilities and Difficulties 
(GLAD) (Whitehill et al., 2009a). Three parameters are taken into account in this method of 
assessment: 
i. Expertise of the assessor 
ii. Difficulty of the image 
iii. Observed outcome of the image 
In this probabilistic model to infer the true label of the image depends directly on the 
expertise of the reviewer and inversely to the difficulty of the images (Whitehill et al., 
2009a). The use of a GLAD algorithm by Whitehill et al. is shown to be superior to identify 
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the actual label of an image and outperforms the conventional majority vote system 
particularly in situations where the outcome of images was split between the reviewers. 
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Figure 3.2 A typical slide used for assessment of new callus and cortical bridging. The image 
labelled pre-op radiograph (on the left) shows the outline of the callus (marked green) before cell 
insertion, and image one (on the right) shows the outline of new callus (marked yellow) and 
cortical bridging (marked red) following insertion of BMSC. 
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SSC-01 
Slide-1: Pre-op radiographs 
Which side has more callus? 
 
Which side has more fracture bridging? 
Lateral side 
 
Lateral side 
Medial side 
 
Medial side 
Slide-1: Image-1 
Which side has more new callus in 
comparison to the pre-op radiographs? 
Which side has more new fracture bridging 
in comparison to the pre-op radiographs? 
Lateral side 
 
Lateral side 
Medial side 
 
Medial side 
 
Figure 3.3 A typical questionnaire for assessment of the primary outcome by independent 
reviewers 
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3.2.4 Secondary Outcomes 
Radiological fracture union at final follow-up and change in the EQ-5D index at one year 
were used as secondary outcome measures. The radiological union was defined as cortical 
bridging and obliteration of the nonunion site in two perpendicular planes assessed on plain 
radiographs or CT scan. Safety was determined by the occurrence of any postoperative 
adverse events until final follow-up.  
3.2.5 Power calculation 
The sample size was calculated for the trial using specialised software (G*power version 2, 
Heinrich Heine University, Düsseldorf, Germany); it assumed a single sample binomial test 
to analyse the primary outcome. We hypothesised that at least three-quarters of the test 
sides needed to show more callus and bridging for the cells to be deemed effective, 
corresponding to an effect size of 0.25. Given a two-sided critical p-value of 0.05 and 80% 
power, the trial needed a minimum of 30 patients (Figure 3.4). A total of 35 patients were 
recruited to allow for drop-outs and loss to follow-up. 
3.2.6 Randomisation technique 
A test container with BMSCs in autologous serum and a control container with autologous 
serum alone were randomized using computer software (Stratos, Orthopedic Institute, 
Oswestry, UK) for insertion at the medial/ anterior or lateral/ posterior side of the 
nonunion. This created a self-controlled trial with patients serving as their own control. The 
cell manufacturing laboratory maintained a record of the side of cell insertion linked with a 
unique patient ‘OsCell’ number. The patients, operating surgeon and the assessors were 
blinded to the side of cell insertion. 
 
 
 135 
 
 
 
Figure 3.4 Power analysis with G*power software showing a total sample of thirty patients 
required to ascertain an effect size of 0.25 over a constant proportion of 0.5 
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3.2.7 Statistical Methods 
Fleiss’ kappa coefficient was used to assess the inter-observer reliability of the four 
reviewers, and the Spearman-Brown formula to determine their combined reliability 
(Kraemer, 1979). The GLAD algorithm was used to obtain the overall decision of reviewers. 
This method obtains a collective decision in all cases even when the vote is split and 
outperforms majority voting (Whitehill et al., 2009b). A single sample binomial test was 
used to ascertain differences in most new callus formation or bridging between test and 
control sides.  
To find univariable predictors of fracture union, Fisher’s exact test and penalized logistic 
regression were used to analyse categorical and continuous variables, respectively. Multiple 
penalized logistic regressions were used in a multivariable analysis to determine if combined 
independent variables gave a better prediction. For this analysis, all univariable predictors 
with p<0.25 were considered potential candidates for inclusion in the model (Hosmer and 
Lemeshow, 2000). Nagelkerke’s R2 was used as an overall measure of model performance 
(Nagelkerke, 1991).  
A multilevel model with a random intercept was used to determine the difference in the EQ-
5D index before and one year after treatment. This method was chosen to include all 
patients, even when one of their pre or postoperative EQ-5D score was missing. Statistical 
analyses were performed using the Optimal Label Inference Software(Whitehill et al., 
2009b) and R version 3.0.2, using the packages “irr”, “logistf” and “nlme”. A two-sided p-
value below 0.05 was assumed to denote statistical significance. 
 
 
 
 137 
 
3.3 Results 
3.3.1 Patient Demographics 
A total of 37 patients were initially recruited for trial participation; one patient was excluded 
due to having a  nonunion of ankle fusion undertaken for OA and hence did not meet the 
inclusion criteria, and one patient declined participation. Hence, 35 patients (21 males, 14 
females) with a mean age of 50.6 years (range 17-75) were recruited (Table 3.2). The 
median duration of established nonunion was 2.9 years (range 1-33); patients had 
undergone a median of 4 surgical interventions (range 1-14) prior to cell insertion at the 
fracture site. This group of patients was defined to have ‘recalcitrant’ nonunions because 
they had an average age of more than 50 years with persistence of established nonunion for 
at least one year, in addition, to at least one previous failed surgery to treat the nonunion. 
Twenty-nine patients had atrophic nonunions, whereas six had hypertrophic nonunions; 19 
patients had femoral, and 16 had tibial fracture nonunions. There was no drop-outs or loss 
to follow-up during the first 12 months except one death at three months. A CONSORT 
diagram schematically represents the patients in the trial for 12 months (Fig3.5) (Hopewell 
et al., 2008). 
 
 
 
 
 
 
 
 
 138 
 
 
 
 
 
Parameter Value  
Demographics  
Sex Male 21 (60%), female 14 (40%) 
Age at accident (years) Mean 45.2 (SD 12.4; range 16-71) 
Age at trial intervention (years) Mean 50.6 (SD 12.5; range 17-75) 
Time from accident to trial 
intervention (months) 
Mean 56.4, median 35 (range 12-396) 
Fracture and nonunion 
characteristics 
 
Site Femur 19 (54%), tibia 16 (46%) 
Velocity High 20 (57%), low 15 (43%) 
Open or closed Open 18 (52%), closed 13 (37%), Unknown 4 (11%) 
Atrophic or hypertrophic Atrophic 29 (83%), hypertrophic 6 (17%) 
Number of operations before trial Mean 2.8, median 2 (range 1-14) 
Number of cases with previous 
autologous bone graft or BMP 
Graft 10 (29%), BMP 0, Both 2 (6%) 
Comorbidities  
Smoking Yes 8 (23%), No 27 (77%) 
Alcohol Yes 16 (46%), No 13 (37%), Unknown 6 (17%) 
Diabetes mellitus Yes 5 (14%), No 30 (86%) 
Table 3.2 Baseline demographics and clinical characteristics of patients included in the trial 
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Assessed for eligibility (n=37) 
Excluded (n= 2) 
   Not meeting inclusion criteria (n=1) 
   Declined to participate (n=1) 
Sides analysed at 3-6 months (n=31)  
Excluded from early time point analysis (n=4) 
No radiographs within 3-6 months (n=4) 
Sides analyzed at 6-12 months (n=33) 
Excluded from late time point analysis (n=1) 
No radiographs at 6-12 months (n=1) 
Lost to follow-up at 3-6 months (n=0) 
Lost to follow-up  at 6-12 months  (n=1)  
Patient died at 3 months (n=1) 
Discontinued intervention (n=0) 
Side allocated to ‘test’ intervention (n=35) 
   Side received BMSC’s+ Carrier (n=35) 
Lost to follow-up at 3-6 months (n=0) 
Lost to follow-up  at 6-12 months  (n=1)  
Patient died at 3 months (n=1) 
Discontinued intervention (n=0) 
Side allocated to ‘control’ intervention (n=35) 
    Side received ‘control’ intervention (n=35) 
Sides analysed for early 3-6 months (n=31)  
Excluded from early time point analysis (n=4) 
No radiographs within 3-6 months (n=4) 
Sides analyzed for late 6-12 months (n=33) 
Excluded from late time point analysis (n=1) 
No radiographs at 6-12 months (n=1) 
Allocation 
Analysis 
Follow-Up 
Randomized 35 patients to ‘test’ and ‘control’ arm (n=35); each patient acting as their own control 
Enrollment 
Figure-3.5 CONSORT Flow-diagram of patients in the trial 
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3.3.2 In vitro BMSC culture 
Autologous BMSC’s were culture-expanded for three weeks with an average cell doubling 
time of 7.2 days (range 2-31, SD-6.24) and without any evidence of infection in the media. A 
mean of 5.5x106 BMSCs (range 2-10x106, SD 1.99x106) was inserted into the test sides of the 
nonunions. Twenty-seven patients (77%) received a carrier based on β-TCP, calcium 
sulphate or combination of both or hydroxyapatite. For eight patients (23%) autologous 
serum alone served as the carrier (Table 3.1). 
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3.3.3 Primary Outcome 
Radiographs of 31 patients were available for review at early (3-6 months) time points and 
of 33 patients at late (6-12 months) time points. Fleiss’ kappa coefficient for assessing new 
callus was 0.46, and new fracture bridging was 0.43. By using the combined opinion of all 
four assessors, their overall reliability as calculated by the Spearman-Brown formula was 
0.77 for callus and 0.75 for fracture bridging, implying excellent reliability (Fleiss et al., 
2003). 
At 3-6 months, 12 out of 31 patients (39%; 95% CI 24-56%, p=0.28) had more new callus on 
the cell insertion side, whereas at 6-12 months 15 out of 33 patients (45%; 95% CI 30-62%, 
p=0.73) had more new callus on the cell insertion side (Fig. 4). More new fracture bridging 
at the cell insertion side was found in 16 out of 31 patients (52%; 95% CI 35-68%, p=1.00) at 
3-6 months and in 19 out of 33 patients (58%; 95% CI 41-73%, p=0.49) at 9-12 months (Fig 
3.6).  
No influence of carriers were noted on the primary outcome i.e. more new callus at 3-6 
months (p=0.61)/at 6-12 months (p=0.16) and more new fracture bridging at 3-6 months 
(p=0.77)/6-12 months (p=0.63). When restricting the analysis to the most common carrier 
(β-TCP with calcium sulphate; 16 patients), 4 out of 14 patients (29%; 95% CI 12-55%; 
p=0.18) had more callus at the cell side at 3-6 months and 4 out of 16 (25%; 95% CI 10 to 
50%; p=0.08) at 6-12 months. In these patients, 6 out of 14 (43%; 95% CI 22-68%; p=0.79) 
had more bridging at the cell side at 3-6 months and 7 out of 16 (44%; 95% CI 23 to 67%; 
p=0.80) at 6-12 months. 
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Figure3.6 New callus and fracture bridge formation at early and late time points from cell 
implantation 
(The red bar represents the mean, and the horizontal hashed line represents 50% distribution. The vertical bar 
represents 95% confidence interval) 
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3.3.4 Secondary outcomes 
3.3.4.1 Fracture union: A total of 21 out of 35 patients (60%; 95% CI 44-75%) achieved 
radiological fracture union at a mean follow-up of 2.6 years after cell implantation (range-
0.24-8.24). The vast majority of categorical independent variables, among which the type of 
carrier used, had a small and non-significant effect on the union rate (Table 3.3). The only 
exception was having diabetes, the effect of which was not significant (p=0.06) yet it 
reduced the odds of achieving union by over 8-fold (Table 3). Among the continuous 
predictors, the number of previous operations and the cell doubling time during in-vitro 
culture of BMSCs were significant predictors of the union (Table 3.4). 
In the multiple penalized logistic regression analysis, we used four univariable factors with 
p<0.25 as potential predictors, namely having diabetes, number of previous surgical 
interventions, age at cell implantation and cell doubling time. Age at accident and years 
since accident were excluded due to their strong correlation with age at implantation 
(Spearman’s rho = 0.86; p<0.001) and number of previous operations (Spearman’s rho = 
0.60; p<0.001), respectively. According to the regression model, the chance of union was 
larger in patients with a lower age at cell implantation, fewer previous surgical 
interventions, cells with a shorter doubling time and non-diabetic patients (Table 3.5). The 
model explained 90% of the variation in outcome (Nagelkerke’s R2=0.90). 
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Factor OR (95% CI) p-value* 
Gender (Male) 1.4 (0.27-7.0) 0.73 
Fracture site (tibia) 1.7 (0.35-9.2) 0.50 
Type of fracture (open) 0.82 (0.15-4.4) 1.0 
Type of nonunion (hypertrophic) 3.6 (0.34-192) 0.37 
Infection at insertion 7.46 (0.43 to 129) 0.48 
Alcohol 1.1 (0.16-7.1) 1.0 
Diabetes 0.12 (0.0022-1.4) 0.06 
Smoking 0.39 (0.046-2.8) 0.39 
Previous bone graft treatment 0.40 (0.06 to 2.3) 0.27 
Previous BMP treatment 0.60 (0.06 to 2.3) 1.0 
Carrier type - 0.61 
* p-values determined using Fisher’s exact test 
Table3.3 Univariable analysis of categorical predictors of union (OR-Odds Ratio) 
 
Factor OR (95% CI)* Nagelkerke’s R2* p-value* 
Age at accident 0.97 (0.91 to 1.02) 0.06 0.25 
Years since accident to implantation 0.92 (0.63 to 1.03) 0.08 0.17 
Number of previous operations 0.58 (0.29 to 0.95) 0.22 0.02 
Age at cell implantation 0.96 (0.89 to 1.01) 0.11 0.12 
Cell number (106) 1.1 (0.78 to 1.6) 0.01 0.56 
Cell doubling time (hrs) 0.87 (0.68 to 0.99) 0.20 0.04 
OR and their 95% CI, Nagelkerke’s R2 and p-values determined using penalized logistic 
regression 
Table 3.4 Univariable analysis of continuous predictors of healing (OR-Odds Ratio) 
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Factors Coeff. (95% CI)* OR (95% CI) * p-value* 
Age at implantation 
 
-0.15 (-0.36 to -0.02) 0.86 (0.69 to 0.98) 0.02 
Number  previous 
interventions 
 
-0.48 (-2.3 to -0.11) 0.62 (0.097 to 0.90) 0.008 
Doubling time 
 
-0.19 (-0.63 to 0.01 0.82 (0.53 to 1.01) 0.07 
Diabetes 
 
-4.9 (-11 to -1.5) 0.008 (3·10-5 to 0.24) 0.003 
* Coefficients, ORs and p-values determined using penalized logistic regression. For the mode, Nagelkerke’s R2 
was 0.90. 
 
Table3.5 Results of the multiple logistic regression analysis (OR-Odds Ratio) 
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3.3.4.2 Health-related quality of life 
The mean preoperative EQ-5D index was very low (0.09; Table 3.6). Despite increasing 
significantly by 0.34 points, it was still low one year after the trial intervention (Table 3.6). A 
detailed sub-group analysis of the five dimensions of the EQ-5D showed noticeable 
improvement in scores relating to anxiety/depression, pain/discomfort and usual activity, 
minimal differences in mobility and no changes in self-care at 12 months (Fig 3.7). 
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Outcome Mean pre-op (SD) Mean post-op (SD) Difference* (95% CI) p-value 
EQ-5D index 0.09 (0.45) 0.32 (0.41) 0.34 (0.11 to 0.58) 0.01 
* Difference calculated using random intercept multilevel model. This difference does not equal the difference 
between the pre-op and post-op columns but does provide a better estimate by properly accounting for 
repeated measures. 
 
Table 3.6 Change in Eq5D at one year from the trial 
 
 
 
Figure 3.7 Self-reported health outcome according to five dimensions of the EQ-5D index  
(pre- and 1-year post-intervention) 
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3.3.5 Adverse events 
One patient developed sepsis following the trial intervention, requiring intensive hospital 
care. The patient recovered uneventfully without overt residual infection. Two patients died 
before final follow-up. One died within three months of the intervention due to an aorto-
enteric fistula, and the other died three years after the intervention due to heart failure on a 
background of tricuspid regurgitation. One patient was reported to have a benign gastric 
tumour six years after the BMSC insertion. The patient was doing well at three years follow-
up after the surgical excision of the  tumour.  
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3.4 Discussion 
This study reports the results of the first randomised controlled trial reporting the efficacy 
of in vitro culture expanded BMSCs in new bone formation in fracture nonunions. It is a self-
controlled trial that minimises the confounding effects of fracture configuration and biology. 
This trial design, common in dentistry, maxillofacial surgery (“split-mouth design”) and 
dermatology (Machin et al.) has been used in spinal fusion trials in orthopaedics (Alexander 
et al., 2001, Cammisa FP Jr et al., 2004, Machin et al.). To our knowledge, this is its first use 
in a trial of fracture nonunions.  
The current work failed to demonstrate a significant difference in radiological new callus 
formation or fracture bridging between ‘test’ and ‘control’ sides at early (3-6 months) and 
late (6-12months) time points.  The trial also presents with patient characteristics which 
represent a group of ‘recalcitrant’ nonunions of fracture. The cohort of patients in this study 
had nonunion for at least one year (median duration of 2.9 years) with at least one surgical 
intervention (median of 4 surgical interventions) before insertion of BMSC to achieve 
fracture union. Such a background of patients included in the study reflects the resistance to 
progress to a bony union or new bone formation in these patients from the outset.  
However, failure in demonstrating new callus or fracture bridging on the ‘test’ side in the 
trial can be potentially due to ineffective cell implantation, carry-across effects by the 
implanted cells to the control sides, or failure to identify the side with most new callus and 
bridging radiologically. Nevertheless, one of the novel findings of the study is the 
identification of in-vitro autologous BMSC doubling time in these patients as a predictor of 
fracture union. 
At the onset of the trial, evidence on the choice of osteoconductive material as the carrier 
was inconclusive, with HA and other calcium phosphate ceramics regarded the most 
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promising(Cancedda R et al., 2007). Combining BMSCs with an osteoconductive carrier, used 
in most cases in our study, is supported in the literature (Cancedda R et al., 2007, Meijer et 
al., 2007). The cell implantation method involved mixing cells in serum with a carrier, resting 
the mixture and placing the mixture at the fracture site. A total of eight patients received 
cells with serum  (no other specific carriers were used) on the ‘test’ side and only serum on 
the ‘control’ side to avoid any confounding effect on the primary outcome from the choice 
of the carrier material.   However, the analysis of the influence of carrier material on the 
primary outcome when restricted to the commonest carrier in our study (β-TCP with 
calcium sulphate) showed no conclusive evidence to support its impact on the formation of 
new callus or bridging in comparison to the control side. The choice of carriers was also 
found to have no influence in fracture union amongst these patients.  Nonetheless, a recent 
study comparing bone formation by BMSCs on four different ceramic scaffold materials 
suggests that coral may be preferable over β-TCP (Viateau V and Manassero, 2013(in 
press)), indicating carriers can potentially influence the outcome although such a finding is 
not discernible in the present study.  
Carry-across effects from the cell implantation to the control side of the fracture could 
reduce the validity of the self-control trial design in this study (Machin et al.). The carry-
across effect in self-controlled spinal fusion trials in the literature is due to the influence of 
one healing side on the other by altering the mechanical conditions (Alexander et al., 2001). 
The faster healing side stiffens the fracture, affecting the healing process on the other side. 
However, the frequency of radiological follow-up in the trial would have potentially allowed 
the assessors to identify any faster healing side. A second carry-across effect is the 
mechanism by which BMSCs are now known to exert their influence. At the trial onset, 
donor MSCs were considered to repair damaged tissues by replacing the function of 
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damaged cells (Tolar et al., 2010). However, since 2009 it has been observed that MSCs 
secrete large volumes of bioactive molecules in response to injury, which recruits immune 
and reparative cells at the recipient sites (Tolar et al., 2010). This secretory effect is likely to 
carry across from the implantation to the control side, diminishing any side to side 
differences. 
Callus size, cortical continuity and persistence of fracture gap are the three most commonly 
used parameters to assess fracture union (Bhandari M et al., 2002). Callus size and fracture 
bridging (cortical continuity) were chosen as the primary outcome measures in this work. 
Defining the fracture gap from plain radiographs was deemed unreliable, especially in 
hypertrophic nonunions. Preintervention radiographs were included on each assessment 
slide for assessors to identify new bone formation in the post-intervention radiographs 
accurately. Inter-observer agreement on defining the side with most new callus or bridging 
was, however, low (κ=0.43-0.46). Having multiple assessors judging each radiograph or CT 
scan independently and using their combined opinion is known to increase reliability 
(Kraemer, 1979). Moreover,  having four assessors increased the reliability to 0.75-0.77, 
implying excellent inter-observer agreement(Fleiss et al., 2003). The GLAD algorithm,  which 
is more reliable than ‘majority-voting’,  further improved on this number by taking into 
account the agreement of each assessor with the others and the quality of each 
image(Whitehill et al., 2009b). Hence, inaccurate radiological assessment does not explain 
the lack of difference between ‘test’ and ‘control’ sides in this trial. 
Since carry-across effects threaten the validity of the primary outcomes of this study, its 
secondary outcomes are probably more relevant. The overall union rate in the trial was 
60%, which is low compared to union rates in other studies of lower limb fracture 
nonunions. A systematic review of biologic enhancement remedies for nonunion (bone 
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autograft and/or BMP-7) found thirteen studies with a pooled healing rate of 94% 
(Pneumaticos SG et al., 2013). Several case series reports the results of percutaneous 
injection of concentrated bone marrow with a typical union rate of around 90% (Connolly JF 
et al., 1991, Hernigou et al., 2005). The difference in union rates between the present work 
and the other studies may be related to case severities. Patients in the trial were defined as 
having recalcitrant nonunions, they had a higher mean age, a larger median number of 
previous treatments and included a larger proportion of diabetic patients in comparison to 
patients in other studies (Pneumaticos SG et al., 2013, Hernigou et al., 2005, Connolly JF et 
al., 1991). Moreover, the results of the study demonstrated these three factors were 
important determinants of healing and hence can explain the lower union rate in these 
patients.  
Diabetes and age are well-known risk factors contributing to nonunions (Calori GM et al., 
2007) and perhaps, to their persistence. The number of previous treatments characterises 
the persistence of a nonunion, and therefore, its emergence as a risk factor for failure to 
heal is expected. The injury mechanism or type of fracture (open versus closed) were not 
significant predictors of nonunion, in agreement with the findings of the SPRINT trial for 
tibial fractures (Fong K  et al., 2013).  
A longer cell doubling time during passage one reduced the likelihood of achieving union 
whereas the number of implanted cells was inconsequential. Doubling time was reported 
important in a study comparing osteogenic potentials of culture expanded human BMSCs 
(Janicki P and Boeuf, 2011). The study found considerable donor variations of in-vivo 
osteogenic potential and identified a longer cell doubling time during in vitro expansion as 
the best predictor of poor osteogenicity. This suggests that weak osteogenic capacity of the 
patients BMSCs may have been an additional factor explaining the relatively low union rates 
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in this study. The data from this study might help define future quality criteria for BMSCs in 
bone regeneration. The irrelevance of cell numbers seems to contradict a study of 
percutaneous bone marrow grafting in which larger numbers of injected cells increased the 
odds of fracture union (Hernigou et al., 2005). However, the smallest number of implanted 
cells in the reported trial (2 million) vastly exceeds even the largest number in that study 
(70,000). Cell numbers may be important, but unlikely within the range in the present study 
(2 to 10 million). 
The two deaths reported in this study were due to heart failure and a bleeding aorto-enteric 
fistula, unrelated to BMSC implantation. One case of  benign gastric tumour was reported 
six years after BMSC implantation and was also considered unrelated to the implantation. 
The tumour was surgically excised, and no recurrence was reported at final follow-up. A 
report on the safety of stem cells for orthopaedic regeneration also reported a tumour 
(liver), likewise considered unrelated (Centeno CJ et al., 2010). The lack of related serious 
adverse events in the study highlights the safety of using autologous in vitro expanded 
BMSCs to treat nonunions. BMSCs in this study were grown for a maximum of three 
passages to minimise the risk of genetic changes associated with long-term culture and 
expansion (Wang et al., 2012). These cells were cultured in autologous serum, removing 
risks of prion or virion transmission from bovine-derived serum (Wang et al., 2012). Finally, 
the cells were implanted locally rather than administered intravenously, reducing risks of 
aberrant remote proliferation (Goldring et al., 2011). 
Twelve months after cell implantation, the EQ-5D index had improved significantly by 0.34 
points, suggesting substantial overall improvement. Despite such improvement, the EQ-5D 
index remained low at twelve months; such observations were highlighted in a previous 
study of patients with fracture nonunions (Zeckey C and Mommsen, 2011). This lack of a 
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direct relationship can be explained by factors such as age, education, psychological state 
and clinically important distress (Whynes, 2008). 
Although the current study failed to demonstrate new bone formation at the site of cell 
insertion in fracture nonunions, it is imperative to highlight the areas potential weakness 
which can influence the outcome of the present study. The study has been designed to be 
randomised, and self-controlled i.e. cells were randomly inserted in the ‘test’ side. However, 
we cannot rule out the migration of BMSC to the ‘control’ side of the non-union neither can 
the paracrine effect of BMSC to the ‘control’ side be dismissed. This phenomenon can 
essentially nullify the differences in the primary outcome observed between the test and 
control arms of the study. The further pitfall in the methodology was the use of multiple 
carrier types in different patients for cell insertion making the results difficult to be 
compared due to the differences in the osteoconductive properties of the carrier material. 
The primary outcome was assessed mainly on plain radiographs which limits to the two-
dimensional interpretation of the change in new bone formation in postoperative films. 
Moreover, the time points for the radiographic assessment were early (3-6 months) and late 
(6-12 months). Radiographic interpretation of change in new bone formation during these 
time scales can be conceived as wide particularly in identifying subtle differences between 
the ‘test’ and the ‘control’ side. Nevertheless, the study uniquely highlights a positive 
correlation between shorter in vitro cell doubling time with fracture union. More 
importantly, it has demonstrated the safety of using autologous BMSC in patients with no 
untoward adverse events. The results also confirm the previous findings to support 
diabetes, increasing age and a higher number of previous surgeries to be detrimental to the 
healing of nonunions. 
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Future studies to assess the potential of cell therapy in fracture nonunion should have 
defined patients receiving the BMSC and the controls receiving none. Moreover, all the 
patients should receive single carrier material for cell delivery so that the outcome between 
patients can be compared. An important aspect would be to study the in-vitro 
characteristics of the BMSC of these patient groups to identify any potential risk factors 
including genetic markers that can influence the outcome of the cell therapy in non-union. 
Further studies should also account for regular high-definition CT scans at much more 
frequent intervals to perform volumetric analysis of the change in new bone formation if 
any. 
In conclusion, the current work showed no significant difference in new bone formation at 
the site of cell insertion in cases with recalcitrant fracture nonunion.  However, this study 
has demonstrated that a faster cell doubling during in vitro culture and three patient 
characteristics (lower age, the absence of diabetes and a smaller number of previous 
operations) were strongly correlated with fracture healing. Further studies are required to 
identify subtle differences in new bone formation following cell therapy in nonunion. An 
emphasis on in vitro characterising BMSCs from patients with nonunion should also be 
undertaken to identify any risk factors to the successful outcome of such treatments. 
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Chapter 4: AUTOLOGOUS BONE PLUG SUPPLEMENTED WITH AUTOLOGOUS 
CHONDROCYTE IMPLANTATION IN OSTEOCHONDRAL DEFECTS OF THE KNEE 
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4.1 Introduction 
Treating full-thickness cartilage loss associated with an underlying subchondral bone defect 
in young patients can be challenging. The most commonly reported aetiology which 
represents such a situation is osteochondritis dissecans (OD), a condition that primarily 
affects the subchondral bone before progressing to the overlying cartilage (Edmonds and 
Polousky, 2013). High-grade OD (ICRS Grade 3 and 4) can lead to full thickness cartilage loss 
extending to the subchondral bone, potentially beyond 10 mm in depth. Isolated 
osteochondral defects (OCDs) can also extend below the subchondral bone plate into the 
cancellous bone (ICRS Grade 4, severely abnormal cartilage) and are usually observed after 
trauma (Brittberg and Winalski, 2003).  It has been suggested that such defects, with 
underlying ‘cavitation’ of the bone, are amenable to bone graft during cartilage repair 
surgery including Autologous Chondrocyte Implantation(ACI)   (Brittberg and Winalski, 
2003). Different operative techniques have been described including drilling (Kocher et al., 
2001, Edmonds et al., 2010) or fixation (Kouzelis et al., 2006, Makino et al., 2005)  and the 
excision of the fragment (Wright et al., 2004)  in OD. Restoration of the articular surface 
with osteochondral autograft (OAT) (Laprell and Petersen, 2001) or microfracture (MF) 
(Gudas et al., 2006, Gudas et al., 2012) are other techniques and both have resulted in 
significant clinical improvement,  although results after OAT were better than after MF in 
patients with OD or isolated osteochondral defects. A ‘sandwich’  technique with bone graft 
and ACI has also been described in seven patients with OD, specifically used to treat defects 
deeper than 10mm by using a bilayer periosteal patch. The technique places one patch over 
the bone graft with the other being anchored to the adjacent cartilage with chondrocytes 
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injected between the layers although results from this procedure were not reported 
separately (Peterson et al., 2003).  
A subsequent modification of the ‘sandwich’ technique with matrix-induced ACI (MACI) and 
autologous cancellous bone graft, termed the bilayer collagen membrane technique 
(BCMT), reported encouraging results in patients with OD and OCD (Bartlett et al., 2005, 
Vijayan et al., 2012). The benefit of using ACI as a restorative surgery in such cases lies in its 
ability to address defects larger than 2.5cm² (Erickson et al., 2013) and deeper than 8-10mm 
by employing a concurrent autologous bone graft (Peterson et al., 2003, Vijayan et al., 
2012). A further technique of autologous cancellous graft and single layer MACI has also 
been described to treat ICRS Grade 3 and Grade 4 OD (Ochs et al., 2011, Steinhagen et al., 
2010).  Progressive remodelling of the subchondral lamina and filling of the cartilage defect 
following the use of this particular technique was demonstrated on serial MRI scans from 26 
patients. Remodelling and filling were observed to be positively correlated with the 
functional outcome (Ochs et al., 2011). However, none of the previous reports describes the 
structural result of the subchondral bone graft and its potential clinical implications. 
Additionally, a striking paucity of information exists with regards to the structural 
integration of the grafted bone and repair cartilage interface. 
In the current study, we describe the ‘Osplug’ technique of using a single precise 
monocortical autologous bone cylinder graft with first or second generation ACI to 
simultaneously restore the subchondral bone and cartilage defect in patients with OD (ICRS 
Grade 3 and 4) and isolated OCD (ICRS Grade 4) of the knee joint.  Additionally, we report 
the clinical, arthroscopic, MRI and histological outcome of patients treated with this 
technique.  
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4.2 Materials and Methods 
The present study was approved by the Audit Committee of our hospital with regards to the 
clinical and imaging review. The histological analyses of the biopsies were approved by the 
local research ethics committee as part of the Retrospective Assessment of ACI (REACT) 
study (REC number: 09/H1203/90).   All cases were operated by the senior author (JBR) from 
2003-2008. All patients had preoperative MRI scans to confirm the presence of cartilage and 
subchondral bone defects. Patients with a minimum of 5mm of defect depth were included 
in the study. Radiographs were undertaken to ascertain the absence of malalignment in the 
knee. Previous surgeries to treat the condition were recorded, excluding the first stage of 
ACI. Failure was defined as a Lysholm score below the preoperative value, requirement of 
further surgical interventions (except one-year arthroscopy used to assess the repair site) or 
total knee replacement (TKR). An overview of the technique is illustrated in Figure 4.1. 
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Figure 4.1 The 1st stage (as in standard ACI) is shown with the anticlockwise arrows while the steps 
involved in the 2nd stage are shown in the numbered boxes in a clockwise arrangement 
 
 
 
 
 161 
 
4.2.1 Surgical Technique 
The surgical technique had two stages. The first stage comprised an arthroscopy and 
cartilage biopsy to harvest the chondrocytes. The second stage involved insertion of a 
unicortical autologous bone graft in the subchondral bone defect and implantation of the 
autologous chondrocytes in the articular cartilage defect under a secured periosteum (first-
generation ACI) or collagen patch (second generation ACI). The second stage was performed 
approximately three weeks after the first stage (Figure 4.1). 
4.2.1.1 First stage: During the first stage of the procedure, patients underwent a diagnostic 
arthroscopy to evaluate the site and extent of the defect. A cartilage biopsy was undertaken 
at this stage from the lesser weight-bearing area of the knee. The chondrocytes generated 
from the harvested cartilage were expanded in vitro for approximately three weeks in the 
Good Manufacturing Practice (GMP) standard ‘Oscell’ cell production facility in our centre 
(Harrison, 2000). 
4.2.1.2 Second stage: An arthrotomy was performed to access the cartilage and subchondral 
defect. The defect was debrided to healthy articular cartilage laterally and down to the 
healthy bone. The size of the defect was measured with Vernier callipers, and the exact 
location was recorded using the validated Oswestry Knee Map (Talkhani and Richardson, 
1999). A cylindrical cortico-cancellous bone plug was then harvested from the non-articular 
part of the femoral condyle with a dowel drill. A site above the origin of the collateral 
ligament of either condyle was chosen and an osteoperiosteal flap raised. Care was taken to 
leave a 1cm margin from all weight-bearing joint surfaces. A fine osteotome was inserted to 
facilitate the release of the donor plug. This bone plug with the cortex side facing up was 
subsequently impacted into the defect to restore the subchondral bone plate and 
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underlying cancellous bone defect. A slight over-sized graft was used to ensure tight fit 
although the excess bone was trimmed with a high-speed burr. This was subsequently 
impacted into the defect with the cortex-side facing up to restore the subchondral plate and 
the underlying cancellous bone defect (Figure 3.2). The remaining chondral defect was then 
covered with a periosteal patch from the proximal tibia (5 cases) or a collagen membrane 
(Chondro-Gide®; Geistlich Sons Ltd, Manchester, UK) (12 cases), which was sutured with 6-0 
Vicryl (Ethicon, Livingston, UK) to the adjacent cartilage. The edges were subsequently 
sealed using fibrin glue (TISSEEL; Baxter, Newbury, UK). Saline was injected under the patch 
to test for water tightness (‘leak-test’) and subsequently aspirated. Cultured autologous 
chondrocytes suspended in autologous serum were implanted beneath the patch through a 
20 gauge Yale Spinal Needle (Becton Dickinson, Oxford, UK). This novel method of 
concurrent monocortical cylinder graft with first or second generation ACI was termed the 
Osplug technique. This technique of concurrent bone graft with ACI was undertaken to 
simultaneously restore the subchondral bone plate and repair the overlying cartilage.  The 
principle of dealing with these types of osteoarticular defects was first described by 
Peterson et al, (2003) in treating ICRS Grade 4 defects extending to 10mm of the 
subchondral bone using first-generation ACI (described as ‘sandwich technique’). 
Subsequently, a modification of the technique with MACI and cancellous bone graft was also 
undertaken (Bartlett et al., 2005, Vijayan et al., 2012). Use of multiple small bone cylinder 
grafts to address subchondral bone defects is also described in conjunction with MACI (Ochs 
et al., 2011).  However, using second generation ACI and a tailored monocortical autologous 
bone graft is described in the current work. The technique conceives use of precisely 
measured bone cylinder graft to achieve a stable per-operative reconstruction of the 
subchondral bone plate and minimised the donor site morbidity from harvesting multiple 
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small bone cylinder grafts. Following bone graft, a standard second-generation ACI is 
undertaken with a periosteal or collagen patch. 
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Figure 4.2 (a) Insertion of ‘Osplug’ in the osteochondral defect of the medial femoral condyle. (b) 
Second generation ACI on the restored subchondral bone. 
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4.2.2 Rehabilitation  
A standardised rehabilitation protocol was followed for all patients undergoing surgery 
(Bailey et al., 2003). This includes initial immobilisation of the knee for 6 hours allowing 
early cell adherence during the postoperative period (Minas and Peterson, 1999). 
Subsequently, continuous passive movement from full extension of the knee to 45 degrees 
of flexion for the first 48 hours after surgery was instituted to restore passive movement, 
particularly full extension of the knee to prevent adhesion and stiffness and achieve 
superior clinical outcome (Alfredson and Lorentzon, 1999). Patients were subsequently 
allowed to partially weight-bear with a hinged knee brace for 6-8 weeks to allow 
proprioception of the joint in addition to the concentric and eccentric loading of the joint. 
The eccentric loading  improved the shock absorbing capacity of quadriceps during walking 
and converted the potential energy to forceful concentric contraction (this forms the basis 
of plyometric-type-work) (Bailey et al., 2003). Patients returned to full activity under the 
supervision of physiotherapist after 6-8 weeks although they refrained from sporting 
activities. Cycling was encouraged initially to allow dynamic strengthening of the muscles 
with the progressive proprioceptive conditioning of the joint, then swimming and running 
by six months. The total period of rehabilitation was tailored according to individual 
progress at this stage and can extend up to 12 months. 
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4.2.3 Outcome assessment 
 4.2.3.1 Primary clinical outcome: Functional outcome in this study was assessed 
using the patient reported modified Lysholm scale for the assessment of cartilage 
defects (Smith et al., 2009) preoperatively, one year and five years after the surgery. 
All three scores were collected prospectively by the Oswestry Outcome Centre. 
 4.2.3.2 Arthroscopic assessment:  Patients had an arthroscopic assessment of the 
repair site documented in the knee map using the validated Oswestry Arthroscopy 
Score (OAS; (Smith et al., 2005)) approximately one year after the second stage of 
the procedure. Five parameters were assessed: the level of the treated articular 
surface compared to the surrounding cartilage (0-2), integration with the 
surrounding cartilage (0-2), the appearance of the surface (0-2), the colour of the 
graft (0-2), and stiffness of the graft on probing (0-2). The total score ranges from 0-
10, with higher values indicating a better quality of repair tissue.  
 4.2.3.3 Histological assessment: Biopsies of the repair tissue at the treated site were 
obtained during follow-up arthroscopic assessment of the knee. This was not routine 
and only performed if patients consented to the additional procedure. The Oswestry 
Knee Map, which recorded the site of the defect during the second stage, was used 
to ascertain the location of the graft. A core biopsy was taken with a Jamshidi needle 
close to the centre of the treated defect and included both the chondral and the 
underlying subchondral bone repair tissue. Biopsies were snap-frozen in liquid 
nitrogen-cooled hexane, embedded in OCT compound (Tissue-Tek, Zoeterwoude, 
Netherlands) and cryosectioned to produce 7 mm thick sections which were 
collected onto poly-L-lysine coated slides.  These were then stained with either 
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haematoxylin and eosin (H&E) or toluidine blue for histological assessment of the 
general morphology of the repair tissue and glycosaminoglycan content, 
respectively, as per standard protocols (Roberts and Menage, 2004). The biopsy was 
assessed with bright light and polarised light microscopy for the morphology and 
collagen organisation. Sections were scored semi-quantitatively using the 
International Cartilage Repair Score II (ICRS II; (Mainil-Varlet et al., 2010)), assessing 
the quality of the repair tissue. This has 14 parameters, each with a range of 0-10 
with higher values indicating better quality. One parameter, the ‘overall score’, 
assesses the full biopsy. 
 4.2.3.4 MRI Scans: MRI scans were also used to determine the quality of repair 
following the surgery. All MRIs were scored by a single musculoskeletal radiologist, 
with expertise in cartilage imaging, in conjunction with an orthopaedic surgeon 
inclined towards cartilage repair surgery. 
The MRI acquisition was composed of coronal and sagittal spin echo T1, and gradient 
echo T2 weighted sequences; axial dual echo (proton density and T2 weighting), and 
3D fat-suppressed FLASH and 3D DESS sequences were also acquired. A 1.5 Tesla 
unit with 25mT/m gradient strength (Siemens Vision, Erlangen, Germany) and a 
standard Siemens viewing station and software (VB33A) were used. The parameters 
for the five sequences were: 
1) SE T1: Flip angle 90°, TR 722, TE 20, FOV 200, matrix 336x512. 
2) GRE T2: Flip angle 30°, TR 608, TE 18, FOV 200, matrix 224x512 matrix. 
3) Axial dual echo images: Turbo spin echo flip angle 180°, echo train length 5, 
spectral fat saturation, TR 3500, TE 16/98, FOV 175x200, matrix 210x256.4) 3D 
FLASH: Spectral fat saturation. Flip angle 30°, TR 50 ms, TE 11 ms, TA 9:38 min, FOV 
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180x180 mm, matrix 192x256, slab=90mm displayed as 60 continuous sagittal 
images of 1.5mm thickness.  
5) 3D DESS: Spectral fat saturation and magnetisation transfer. Flip angle 40°, TR 
58.6 ms, TE 9 ms, TA 12:01 min, FOV 180x180 mm, matrix 192x256, slab=96mm 
displayed as 64 continuous sagittal images of 1.5mm thickness. 
The cartilage repair site was semi-quantitatively assessed with magnetic resonance 
observation of cartilage repair tissue (MOCART) parameters (Marlovits et al., 2006, 
Marlovits et al., 2004, Welsch et al., 2010). Also, particular attention was paid to 
determine if a subchondral lamina had reformed post-treatment (referred to as a 
‘neo-lamina’) and also to the underlying autologous bone graft. The presence of a 
‘neo-lamina’, indicating remodelling, was assessed along the whole dimension of the 
bony defect. This was categorised as described by Ochs et al., i.e., Grade-1 (0-25% of 
defect diameter), Grade-2 (26-50% defect diameter), Grade-3 (51-75% defect) and 
Grade-4 (>76% defect diameter) (Ochs et al., 2011).  
Lateral integration of the cylindrical bone graft was assessed in both the coronal and 
sagittal planes at the graft and the host bone junction on the MRI scans. The 
presence of continuous trabeculae along this whole interface indicated 100% 
integration while the persistence of trabecular discontinuity indicated a lack of 
integration. The lateral integration was semi-quantitatively classified into four 
categories: Grade-1 (<25%), Grade-2 (26-50%), Grade-3 (51-75%) and Grade-4 (76-
100%). The morphology of the central subchondral grafted bone was assessed 
according to the type of trabecular architecture and presence of cysts within the 
graft and was graded from completely remodelled graft to disorganised bone graft 
or bone graft with the presence of a cyst(s).  Scans performed at least 12 months 
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after the second stage of the surgery were evaluated to appraise the longer-term 
quality of the repair, presence of the neo-lamina and the integration of the 
monocortical bone cylinder graft. 
4.2.4 Statistics 
A Shapiro-Wilk test was used to ascertain the normality of the data. The paired 
Wilcoxon Signed Rank test was used to demonstrate the difference between 
Lysholm scores at different time points. Rank-biserial and bivariate rank (Spearman) 
correlation analysis were used to investigate the relation between the Lysholm score 
and various categorical or continuous predictors and outcomes. IBM SPSS Statistics 
vs. 22 (IBM UK Ltd, Portsmouth, UK) was used for the analysis of the data. 
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4.3 Results 
4.3.1 Patient characteristics 
A total of 12 cases of OD (ICRS grade 3 and 4) and 5 cases of isolated OCD (ICRS grade 4) 
were included in this study. Their mean age at the time of surgery was 27 years ±7SD (range 
17-40). Fifteen patients had the defect on the medial femoral condyle and two on the lateral 
femoral condyle. Ten patients had a lesion in the right knee and seven in the left knee. The 
mean defect size was 4.5 cm² ±2.6SD (range 1-9). The mean defect depth was 11.3 mm ±5SD 
(range 5-18). Twelve patients had a collagen patch (Chondro-Gide®; Geistlich Sons Ltd, 
Manchester, UK) and five patients had a periosteal patch from the proximal tibia to cover 
the defect. Each patient had received at least one previous surgery with a mean of 1.6 
operations (range 1-4) to treat the defect; not including the 1st stage of the ACI. There was 
no association between the number of previous surgeries and one-year Lysholm scores 
(p=0.47, Spearman’s rho -0.214) or 5 years Lysholm scores (p=0.96, Spearman’s rho -0.16). 
One patient was lost to follow-up at one year, and a further two patients were lost to 
follow-up at 5 years. 
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Pt. No. Previous surgeries 
1 Arthroscopy + removal of loose body + drilling 
2 Arthroscopy + removal of loose body; Arthroscopy + debridement +drilling; Arthroscopy 
+microfracture 
3 Arthroscopy + Smiles's pin fixation; Arthroscopy +debridement +drilling 
4 Arthroscopy+ removal of loose bodies +debridement + drilling 
5 Arthroscopy+ removal of loose bodies +debridement 
6 Arthroscopy+ removal of loose bodies+ debridement 
7 Arthroscopy+ removal of loose bodies+ debridement 
8 Arthroscopy+ removal of loose bodies +microfracture 
9 Arthroscopy+ removal of loose bodies; Arthroscopy +drilling 
10 Arthroscopy+ removal of loose bodies +debridement 
11 Arthroscopy+ removal of loose bodies+ debridement 
12 Arthroscopy+ removal of loose bodies, 3x Arthroscopy + debridement 
13 Arthroscopy+ removal of loose bodies +debridement 
14 Arthroscopy+ removal of loose bodies+ debridement; Arthroscopy + debridement 
15 Arthroscopy+ removal of loose bodies +microfracture 
16 Arthroscopy+ pin fixation; Arthroscopy +removal of loose bodies+ debridement 
17 Arthroscopy+ removal of loose bodies +microfracture; Arthroscopy + debridement 
Table 4.1 Details of previous surgeries in patients treated with ‘Osplug’ technique 
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4.3.2 Clinical outcome 
A Shapiro-Wilk test confirmed that the Lysholm scores did not follow a normal distribution 
(p=0.01). The median preoperative Lysholm score was 45 (IQR 24, range 16-79). The median 
Lysholm score increased to 77 (IQR 28, range 41-100) at 1 year and was 70 (IQR 35, range 
33-91) 5 years after the surgery. A Wilcoxon Signed Rank test showed a statistically 
significant improvement in Lysholm scores at 1 year (p-value 0.001) and 5 years (p-value 
0.009) in comparison to preoperative scores. The difference in Lysholm scores between 1 
and 5 years was not statistically significant (p=0.50).  
No association was found between the type of patch used (periosteum/collagen) and 
Lysholm score at 1 year (p-value = 0.86, point-biserial correlation-0.05) and 5 years (p-value 
= 0.95, point-biserial correlation-0.02). The clinical outcome was not related to the size (at 
one year, p=0.8 and five years, p=0.3) or depth (at one year, p=0.7 and five years, p=0.2) of 
the defect. A total of three patients had treatment failure with one requiring TKR and the 
other two required further surgical intervention, but none of these patients had their 
Lysholm score below the preoperative level.  
The patient requiring TKR had a Lysholm score of 33 before failure at 5 years after the 
Osplug procedure; this score improved from 16 preoperatively to 41 at one year. Two 
patients required further surgical intervention, one at 2 years and one at 4 years because of 
persistent symptoms. Both had a Lysholm score of 45 prior to subsequent surgery, but in 
both cases, this was higher than their score before the Osplug procedure. 
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4.3.3 Arthroscopic assessment 
Eleven patients had an arthroscopic assessment of the repair site at a mean of 1.3 years 
(range 0.7-2) postoperatively. The mean OAS was 6.2 (range 0-9). A statistically significant 
correlation was noted between OAS and Lysholm score at both 1 year (p=0.008, Spearman’s 
rho 0.78) and 5 years (p-value=0.046, Spearman’s rho 0.64). Furthermore, a significant 
association between the OAS and failure of the Osplug technique was observed (p-value = 
0.001, point-biserial correlation-0.865). 
4.3.4 Histological assessment 
The mean value of the ICRS II ‘overall score’ for the repair tissue biopsies analysed was 
5.2±1.6SD (range 2.3-7.4; Table 4.2).  Of the 10 biopsies obtained (from 8 patients), 9 were 
found to be fibrocartilage, and one was a mixture of fibrocartilage and hyaline 
cartilage.  Matrix metachromasia was very variable between different biopsies, with scores 
ranging from 2.7 to 8.9, being nearly normal (with a maximum of 10) for 2 biopsies.  The 
surface architecture was generally good to excellent.  Integration of the repair cartilage to 
the underlying subchondral bone was also good, with the tidemark being visible in more 
than half of the biopsies (Figure 4.3).  Cell morphology was variable throughout the biopsies, 
with some being fibroblastic in shape, while others were more rounded and of chondrocyte 
morphology; clustering of cells was rare.  Three biopsies contained evidence of ectopic 
calcification. One of these was a second biopsy from patient 1 taken 13 months after the 
first biopsy when no evidence of calcification was observed. One biopsy (from patient 9) 
showed quite an extensive calcification. There was no evidence of either vascularisation or 
inflammation in any of the biopsies examined. One patient (Patient 3) with sequential 
biopsies taken at 13 and 37 months after the Osplug procedure demonstrated an interesting 
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histological feature. Under polarised light, the 13 month biopsy showed collagen fibres 
running predominantly parallel between the cartilage and subchondral bone along the 
cartilage/bone graft interface; at 37 months, the orientation of the fibres in the bone had 
changed from being parallel to much more oblique, integrating the cartilage into the bone 
(Figure 4.4).  In addition, the latest biopsy demonstrated an improvement in the individual 
ICRS II parameters for tissue morphology, cell morphology, subchondral bone, as well as the 
overall score, compared to the earlier biopsy. 
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Pt. 
No. 
     Months 
post 
ACI 
Tissue 
Morphology Staining 
 
Cell 
Morphology 
Clusters Surface Integration Tidemark 
 
SCB 
 
Inflammation Calcification Vasc. 
 
Superficial 
zone 
 
Mid/deep 
zone 
Overall 
1 11 5.45 2.7 0.45 10 6.75 7.85 7.8 6.35 10 10 10 3.9 3.7 3.8 
1 24 5.35 3.55 0.7 10 7.75 9.5 0.05 9.9 10 8.7 10 4.3 4.75 4.35 
2 24 1.9 4.8 8.9 6.7 9.9 9.9 8.9 9 10 10 10 7.7 6.1 7.4 
3 13 3.9 5.8 7.8 10 8.4 9.8 8.2 4.5 10 10 10 6.4 5.4 5.5 
3 37 6.5 5.7 9.5 10 8.4 10 8.5 8 10 10 10 7.6 7.6 7.2 
4 12 5.55 8.9 5.5 9.95 9.55 9.95 1.1 8 10 10 10 7.2 6.65 6.75 
7 13 5.4 2.25 2.55 9.95 8.6 n/a n/a 2.95 10 10 10 5.8 3.65 4.7 
9 22 4.1 2.7 5.1 10 n/a n/a n/a n/a 10 1.4 10 2.7 n/a 2.3 
12 18 5.15 6.55 9.1 10 9.45 9.2 0.55 2.2 10 2.75 10 5.75 4.15 5.2 
14 16 4.8 8.85 1.4 10 n/a n/a n/a n/a 10 10 10 n/a 4.95 4.65 
 
Table 4.2 Individual scores for the 14 parameters assessed with the ICRS II Histology Score (Mainil-Varlet et al., 2010) for each biopsy 
(SCB-subchondral bone, Vasc-vascularisation
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Figure 4.3 Representative image of a tidemark (arrow) in one of the repair tissue biopsies analysed 
(Scale bar represents 100μm)  
 
Figure 4.4 Sequential biopsy specimens at 13 months (A, B) and 37 months (C, D) after autologous 
chondrocyte implantation from patient 3. Under polarised light (images B and D are polarised light 
images of the hematoxylin and eosin–stained sections in A and C, respectively), collagen fibres in 
the 13-month biopsy specimen can be seen running parallel in the bone to the cartilage-bone 
interface. By 37 months, these fibres within the bone can be seen to be more oblique and 
integrate between the cartilage and bone. Scale bars = 500 mm. b, bone; c, cartilage. 
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4.3.5 MRI assessment 
MRI scans were available for eleven patients, at a mean of 2.6 years ±1.8SD (range 1-6) after 
surgery. The overall MOCART score was 61±22SD (range 20-85) out of a total score of 100 
with higher score implying better quality of cartilage repair (Table4.3). The degree of defect 
fill with the repair tissue was noted to be complete in 4 patients. Two patients had exposed 
subchondral bone. In one patient (patient 2) the repair cartilage was hypertrophic for more 
than 50% of the defect diameter and showed incomplete fill (to a level of >50% of the 
thickness of the adjacent cartilage) in the rest of the defect. Complete integration of the 
repair cartilage with adjacent healthy cartilage, represented by the isointense signal 
intensity of the repair tissue compared to the adjacent cartilage, was noted in 8 patients 
(73%). The neo-lamina was observed to be intact in only 3 patients; however, it was seen to 
be partially formed in the rest indicating a continuous process of remodelling in the 
subchondral lamina. The subchondral bone was not intact in 10 patients, with cysts in 5 
patients (Figure 4.5) and disorganised bone graft with inhomogeneous signals in comparison 
to the adjacent bone in another 5 patients (Figure 4.6).  
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Figure 4.5 Sagittal image with proton density turbo spin echo spectral fat saturation MRI sequence 
of the knee demonstrating cyst within the bone graft. 
 
 
Figure 4.6 Sagittal image with proton density turbo spin echo spectral fat saturation MRI sequence 
of the knee demonstrating inhomogenous signal within the bone graft In comparison to  the 
adjacent subchondral bone 
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Marginal integration of the ‘Osplug’ was classified as Grade 4 (76-100%) in the orthogonal 
plane of the bone graft in 8 out of 11 patients (73%; Figure 4.7). Interestingly, the three 
patients who failed had poor integration of the bone graft suggesting this to be a significant 
predictor of failure of the Osplug technique (Spearman’s rho 0.8, p=0.003). Lateral 
integration seen on the MRI scans had a significant positive correlation with a good clinical 
outcome at 1 year (p-value=0.007, Spearman’s rho 0.75) although it failed to reach 
statistical significance at 5 years (p-value=0.08, Spearman’s rho 0.55). The grade of neo-
lamina evident in MRI scans had a significant positive correlation to time of the scan since 
surgery (p-value=0.001, Spearman’s rho 0.86). However, grade of neo-lamina had no 
significant correlation with the lateral integration of the bone graft (p=0.15), MOCART 
scores (p=0.8), one-year Lysholm scores (p=0.43) or five years Lysholm scores (p=0.5) 
(Table4.4). 
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Figure 4.7 Representative image of lateral integration of the ‘Osplug’ in T2 weighted MRI sequence 
with continuous trabecular pattern representing Grade 4 (76-100%) marginal integration of the 
subchondral bone 
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Pt. 
No. 
Time 
of MRI 
(years) 
post- 
ACI 
 
 
Degree of 
repair + 
filling of 
defect 
 
 
Integration of 
border of repair 
& native 
cartilage? 
 
 
Surface of 
the repair 
cartilage 
 
 
Structure 
of the 
repair 
 
 
Signal intensity of 
repair cartilage? 
(DT2FSE/3D-GE-
FS) 
 
 
Subchondral 
lamina 
 
 
Subchondral 
bone 
 
 
Adhesion 
 
 
Effusion 
 
 
Total 
MOCART 
Score 
  
 
Neo-lamina 
(Grade-1=0-
25%, Gr 2=26-
50%, Gr 3=51-
75%, Gr 4=76-
100%) 
 
 
‘Osplug’ lateral 
integration ( Gr 1=0-
25%, Gr2=26-50%, Gr 
3=51-75%,Gr4=76-
100%) 
2 2 10 15 5 0 30  5 0 5 0 75  4.00 4.00 
3 6 10 15 5 5 30 5 5 5 5 85  4.00 4.00 
5 3 5 15 0 5 30 0 0 5 0 60  3.00 4.00 
9 1 20 10 5 5 30 0 0 5 0 75  1.00 3.00 
10 4 0 0 0 0 15 5 0 5 0 25  4.00 4.00 
11 1 20 15 5 5 30 0 0 5 0 80  1.00 4.00 
12 3 20 15 5 0 15 0 0 5 0 60  3.00 3.00 
14 2 20 15 5 0 30 0 0 5 0 75  3.00 4.00 
15 3 5 0 0 0 30 0 0 5 0 40  3.00 4.00 
16 1 15 15 5 0 30 0 0 5 0 70  1.00 4.00 
17 1 0 0 0 0 15 0 0 5 0 20  1.00 2.00 
Table 4.3 MRI characteristics of the cartilage in the repair site according to the MOCART scale. Two other bone properties were also assessed: the 
remodelling of the neo-lamina and the lateral integration of the monocortical cylinder graft  
Scores ascertained to MOCART parameters are represented below (Welsch et al., 2010)- 
a. The degree of defect fill and repair-Complete-20, Hypertrophy-15, Incomplete (>50% of adjacent cartilage)-10, Incomplete (<50% of adjacent cartilage)-5, Subchondral bone exposed-0. 
b. Integration of the border-Complete-15, Incomplete(split like border visible)-10, Defect visible <50% of length-5, Defect visible >50% of length-0 
c. Surface of the repair tissue-Surface intact-10, Surface damaged <50%  of depth-5, Surface damaged >50%  of depth-0 
d. Structure of the repair-Homogenous-5, Inhomogenous-0 
e. Signal intensity of the repair tissue-Normal(identical to the adjacent cartilage)-30, Nearly normal-15, Abnormal-0 
f. Subchondral lamina-Intact-5, Not intact-0 
g. Subchondral bone-Intact-5, Not intact-0 
h. Adhesion-No-5, Yes-0 
i. Effusion-No-5, Yes 
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j.  
Variables p-value Correlation coefficient 
1 year Lysholm 
score 
Lateral integration of bone graft 0.007* 0.75 
OAS 0.008* 0.78 
Neo-lamina 0.43 0.27 
5 year Lysholm 
score 
Lateral integration of bone graft 0.08 0.55 
OAS 0.046* 0.64 
Neo-lamina 0.54 0.23 
Failure 
Lateral integration of bone graft 0.003* 0.8 
OAS 0.001* 0.86 
Neo-lamina 0.54 0.20 
Time of MRI 
from surgery 
Neo-lamina 0.004* 0.8 
Lateral integration 0.27 0.36 
(p-value <0.05 (2-tailed) considered significant (marked with *), point-biserial and Spearman’s correlation analysis 
was used to investigate the relation between the Lysholm score and various categorical or continuous 
predictors and outcome)  
 
 
Table 4.4 Correlation matrix between variables 
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4.4 Discussion 
This current work demonstrates that significant clinical and functional improvement can 
result for up to 5 years from the novel Osplug technique if patients have more severe OCD 
(ICRS 4) or OD (ICRS 3 and 4). The mean age of patients included in this study is 27 years 
with a mean defect size of 4.5 cm² (range 1-9) and an average depth of 11.3 mm (range 5-
18). These parameters are comparable to previous reports of treatment with simultaneous 
ACI and bone graft (Peterson et al., 2003, Steinhagen et al., 2010, Vijayan et al., 2012, Ochs 
et al., 2011). Moreover, all patients in the current study had, at least, one previous surgical 
procedure (mean-1.6, range 1-4) which is comparable to an earlier study (Vijayan et al., 
2012). However, such techniques have been described as a primary procedure in a 
proportion of their patients in two other series describing MACI with bone graft (Steinhagen 
et al., 2010, Ochs et al., 2011).  Interestingly, these two studies of MACI and bone graft 
described a significant clinical and functional improvement at 12 months, which was 
maintained subsequently with no further significant rise or fall for a total follow-up of 36-39 
months (Steinhagen et al., 2010, Ochs et al., 2011, Peterson et al., 2003). The present study 
noted a similar finding of a significant rise in Lysholm score at 1 year which was retained for 
at least 5 years of follow-up, with no further significant change in functional outcome in a 
patient group in which this technique was used as a salvage procedure after at least one 
failed procedure. 
The validated arthroscopy score (Smith et al., 2005) for the repair site at 1.3 years was seen 
to have a significant positive correlation with the one and five-year clinical outcome. This is 
the first report demonstrating an association of the functional outcome with the 
macroscopic quality of the repair site after simultaneous ACI and bone graft technique, 
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where a poor arthroscopy score, indicative of suboptimal graft, was linked with a higher rate 
of treatment failure. A further unique finding was the low grade of bone plug integration 
seen in MRI scans which had a significant correlation with poor clinical outcome in one year 
and failure of the procedure, requiring reintervention or TKR. These findings indicate the 
contribution of the richly innervated subchondral bone as a potential source of pain and 
functional limitation, especially if it occurs in association with loss of overlying cartilage (Suri 
and Walsh, 2012). The current evidence suggests that in such cases the definition between 
articular cartilage and the subchondral bone is lost leading to the invasion of the articular 
cartilage by sensory nerves and blood vessels forming the basis of pain and progression of 
OA (Yuan et al., 2014). These promotes ‘cross-talk’ between the cartilage and subchondral 
bone which is primarily regulated by β-NGF (Nerve Growth Factor) and VEGF, specific 
antagonists to these growth factors also lead to clinical and functional improvement in 
patients reinstating their in role symptomatic and functional deterioration (Nagai et al., 
2010, Spierings et al., 2013). 
There are several reports in the literature of subchondral bone graft techniques in 
conjunction with cell therapy for cartilage repair. Impaction of loose cancellous bone was 
described by the proponents of the original ‘sandwich’ technique (Peterson et al., 2003) and 
kept unchanged in BCMT (Bartlett et al., 2005, Vijayan et al., 2012). Two studies described 
using a diamond core drill to harvest a monocortical graft (Ochs et al., 2011, Steinhagen et 
al., 2010), although the cortical layer was removed in one study, actually rendering those 
grafts to be cancellous bone cylinders (Steinhagen et al., 2010). A press-fit was attempted in 
these two studies by using more than one graft, with one study using fibrin glue between 
the grafts to ensure an adequate seal (Ochs et al., 2011) whilst the other one used an under-
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sized core drill on the host bone to provide a tight fit (Steinhagen et al., 2010). Both of these 
studies had uniform patient characteristics (OD of ICRS grade 3 and 4 ) and used a single 
layer of MACI with the cylindrical bone graft. Both studies reported a significant clinical 
improvement at a mean follow-up of approximately 3 years  (Steinhagen et al., 2010, Ochs 
et al., 2011). However, a poor clinical outcome was reported in defects larger than 6cm² 
with the use of cancellous bone cylinder grafts (Steinhagen et al., 2010, Ochs et al., 2011). 
The Osplug technique was developed to address large osteoarticular lesions in the knee as 
multiple bone plugs were found to be unstable in our experience. Moreover, large numbers 
of bone plugs may also lead to donor site morbidity. The Osplug technique advocates using 
a single monocortical bone graft which is tailored to the dimension of the defect. In the 
present study, it has been  demonstrated that a similar functional outcome can be achieved 
using this technique at a longer follow-up of 5 years. The outcome does not depend on 
defect area or depth or whether a first or second generation ACI was used. The present 
study also demonstrates Grade 4 (76-100%) lateral integration of the monocortical graft in 8 
of 11 patients using the novel technique, which had a significant positive correlation with 
the functional outcome at 1 year. 
The only published study of patients with OD, which were treated with bone graft and ACI 
reported MOCART scores of consecutive MRI scans from 26 patients treated with cortico-
cancellous bone graft and single layer MACI (Ochs et al., 2011). This study found a mean 
value of 62±19SD, comparable to the mean results of 61±22SD at 2.6 years from the present 
work (Ochs et al., 2011). A larger presence of a neo-lamina in this study was positively 
correlated with the duration between the surgery and the scan reinstating the previously 
hypothesised time-dependent process of remodelling in the subchondral lamina (Ochs et al., 
 186 
 
2011). There was no relationship between the grade of neo-lamina seen in MRI scans to the 
clinical outcome, overall MOCART score or lateral integration of the bone graft. This lack of 
correlation can be related to the small sample size in the current work, causing type-2 
errors. Nevertheless, the findings in earlier work (Ochs et al., 2011) and the present work 
consistently demonstrate the presence of the subchondral neo-lamina at the interface of 
repair cartilage and bone graft following the concurrent use of cortico-cancellous cylinder 
grafts with ACI. 
This is the first report of the histological assessment of the repair tissue following 
simultaneous bone graft and ACI using the ICRS II score (Mainil-Varlet et al., 2010). The most 
striking and structurally relevant microscopic finding in these samples was the consistent 
integration of the repair cartilage and the underlying subchondral bone, implying interfacial 
bonding between the grafted bone and overlying repair cartilage. Interestingly, two patients 
had a biopsy taken at two time-points, both demonstrating an increase over time in scores 
for tissue morphology, cell morphology, subchondral bone and overall score. This suggests a 
slow remodelling and maturation of the repair cartilage, as had previously been shown 
(McCarthy and Roberts, 2013, Roberts et al., 2009), in addition to a similar process occurring 
within the transplanted bone.  
However, the present study has a small sample size of seventeen patients. To detect a large 
effect of the intervention (correlation coefficient of 0.5) we should ideally have 26 patients 
for the point-biserial correlation coefficient and 29 patients for Spearman’s rank coefficient. 
This highlights the relative rarity of the condition from a single centre which is also evident 
from other published series (Bartlett et al., 2005, Maus et al., 2008, Vijayan et al., 2012). 
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In summary, the Osplug technique, combining a tailored monocortical autologous bone plug 
with ACI, shows promising early and mid-term functional outcomes with first or second 
generation ACI, irrespective of the size of the defect. A low arthroscopic score and poor 
integration of the monocortical bone graft assessed with MRI is associated with a poor 
clinical outcome and subsequent failure of the intervention. Establishing proper integration 
between the implanted cells and bone core appears critical to the long-term success of the 
procedure. Once this is established, there appears to be improvement and maturation with 
time, both in the quality of the cartilage repair histologically and also the remodelling of the 
subchondral neo-lamina of the bone, particularly in those patients who go on to benefit 
clinically. 
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Chapter 5: Combining osteotomy with autologous chondrocyte implantation to treat early 
osteoarthritis of the knee 
 
 
 
 
 
 
 
 
 
 189 
 
5.1 Introduction 
In the last decade, the rate of primary total knee replacements (TKRs) has doubled annually 
in the United States with a decrease in the average age of patients due to a growing 
incidence of knee injuries and an expanding indication for the surgery (Losina et al., 2012). 
Such a remarkable increase in primary TKR among a younger population with increased life 
expectancy implies that a higher proportion of the community will live with TKRs for longer 
(Weinstein et al., 2013). Despite the success in improving symptoms with knee arthroplasty, 
several studies have demonstrated functional limitations. Approximately 17 percent of 
patients with primary TKRs and 41 percent patients with revision TKRs remain dissatisfied 
with the outcome of the surgery (Dunbar et al., 2013). Given the rate of the sub-optimal 
outcome, it is not surprising to propose that TKRs should be reserved as a final option after 
first having tried alternatives (Dieppe et al., 2011).  
Commonly used alternative procedures for cartilage repair are ACI (Bhosale et al., 2009), 
microfracture (Steadman et al., 2003) and Osteochondral Autologous Transplantations 
(OATS) (Hangody et al., 2004). The treatment of symptomatic articular cartilage defects is, 
however, more challenging if it co-exists with malalignment of the mechanical axis in the 
lower limb. Alternative techniques for biological restoration of the joint in such cases must 
include realignment osteotomy around the knee joint to correct the mechanical axis, 
alongside methods to repair the articular cartilage (Franceschi et al., 2008, Bauer et al., 
2012, Sterett et al., 2010). A 10-year follow-up of a randomised controlled trial comparing 
ACI with OATS has shown better graft survival and significant clinical improvements after 
ACI (Bentley et al., 2012). Moreover, ACI was also shown to produce a better quality of 
repair tissue at 1 year in comparison to mosaicplasty during arthroscopic and histological 
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assessment (Bentley et al., 2003). Furthermore, the microscopic quality of repair tissue was 
also demonstrated to be superior in comparison to microfracture at 1 year (Saris et al., 
2008). Furthermore, ACI has been demonstrated to be superior to other cartilage repair 
techniques for cartilage defects greater than 4 cm²(Gomoll and Minas, 2012).  
According to the Finnish Registry, High Tibial Osteotomy (HTO) for medial compartment 
osteoarthritis has an 89% survival at 5 years and 73% survival at 10 years, with failure 
defined as conversion to TKR (Niinimäki et al., 2012). Similarly, opening Distal Femoral Varus 
Osteotomy (DFVO) for lateral compartment OA has an estimated 79% survival at 5 years 
(Saithna et al., 2014). 
Significant clinical improvement has been reported by combining HTO with ACI for repairing 
chondral defects in the medial compartment of the knee joint with varus malalignment at a 
mean follow-up of 28 months (Franceschi et al., 2008) and 5 years (Bauer et al., 2012). A 
non-randomised retrospective case-series confirmed that combining ACI with HTO imparts 
clinically significant improvement in outcomes in comparison to ACI in isolation. The same 
study also demonstrated a decreased rate of reintervention at 6 years follow-up in patients 
with ACI and HTO compared to ACI alone in patients with less than 5⁰ of varus malalignment 
(Bode et al., 2013). A retrospective study showed significantly better clinical outcome at 11 
years after HTO or HTO with ACI compared to HTO with microfracture (Ferruzzi et al., 2014). 
An evaluation of ACI highlighted that corrective osteotomy around the knee (for both varus 
and valgus malalignment) significantly improved survivorship of the cartilage repair for up to 
15 years (Minas et al., 2014). 
In this study, we prospectively evaluated the effectiveness of augmenting osteotomy with 
simultaneous ACI in knee joints with idiopathic varus or valgus malalignment and 
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symptomatic chondral defects in the medial or lateral compartments respectively. The 
primary outcome assessed was the change in Lysholm scores at final follow-up in 
comparison to the preoperative scores. The secondary outcomes were an objective 
assessment of chondral repair in the knee with arthroscopies and histological evaluation of 
the quality of the repair in patients where biopsies were available. Accurate assessment of 
the degree of correction achieved after realignment osteotomies were evaluated with 
standard weight-bearing knee radiographs. 
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5.2 Methods 
The present study was approved by the hospital’s audit and quality assurance board for 
review of outcome. Data was collected prospectively by the Oswestry Outcome Centre, an 
independent body within the hospital. All patients were operated by the senior author (JBR) 
between 1999 and 2010. 
Patient inclusion criteria for combined treatment of osteotomy and ACI were: 
1. Symptomatic cartilage defect(s) confirmed by knee arthroscopy in the lateral or 
medial compartment of the knee joint. 
2. Established idiopathic malalignment of the lower limb identified on a standard 
weight-bearing radiograph. 
3. Simultaneous ACI and osteotomy are done during the second stage of the 
procedure. 
Patient exclusion criteria were: 
1. Skeletally immature patients with open physis in the distal femur or proximal tibia. 
2. Fixed flexion deformity of the knee. 
3. Inflammatory arthritis. 
The degree of preoperative malalignment was determined from standard weight-bearing 
knee radiographs (Colebatch et al., 2009).  Functional outcomes were assessed by modified 
Lysholm scores validated for evaluation of the knee joint with underlying cartilage defects 
(Smith et al., 2009). ‘Failure’ was defined as conversion to TKR before the end of follow-up 
in this study. In these cases, the Lysholm score immediately before the TKR was considered 
as the final score. 
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5.2.1 Surgical Technique 
The technique had two stages; the first stage comprised of a diagnostic knee arthroscopy 
and cartilage biopsy and the second stage involved corrective osteotomy of the knee and 
ACI. The second stage was performed three weeks after the first stage. 
First stage:  This includes diagnostic arthroscopy to evaluate the site and extent of the 
chondral defect. Cartilage biopsy was taken at this stage from an unaffected, less-weight-
bearing area of the knee. The chondrocytes generated from the harvested cartilage were 
expanded in vitro for 3 weeks in the Good Manufacturing Practice (GMP) standard cell 
production facility in our centre. The number of chondrocytes from each patient was 
recorded in the laboratory before cell implantation at the second stage. 
Second stage: The corrective osteotomy was combined with ACI at this stage. The deformity 
and planned degree of correction were determined preoperatively using weight-bearing 
knee radiographs. This was verified during the operation with an image intensifier and 
confirmed postoperatively. Varus alignment was defined as ≥2° towards varus, and valgus 
alignment was defined as ≥2° towards valgus from the neutral alignment of 180 ± 2° (Issa et 
al., 2007). Restoration of the neutral alignment (180 ± 2°) at the knee was considered to be 
the gold standard for correction which was ascertained with weight-bearing knee 
radiographs (Colebatch et al., 2009, Issa et al., 2007).  DFVO was undertaken for correction 
of the mechanical axis in valgus knees and HTO for varus knees. One patient with a chondral 
defect in the lateral tibial plateau was treated with a lateral closing wedge high tibial 
osteotomy for the valgus knee. 
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a.  Lateral Opening Wedge Distal Femoral Varus Osteotomy  
Patients were positioned supine with their knee flexed to approximately 30⁰ using sand 
bags. An image intensifier was used to confirm the site of the osteotomy. A skin incision was 
made laterally, starting distal to the lateral epicondyle and extending proximally up to 15-18 
cm. A guidewire was inserted to ascertain the direction and level of the osteotomy. The 
osteotomy was performed 5cm proximal to the knee joint line with a Tuke saw aiming 
towards the medial epicondyle but maintaining a medial hinge on the cortex. The 
osteotomy site was gently opened to achieve the desired correction and the position 
secured with two conical absorbable composite screws (BonejackTM; Biocomposites Ltd., 
Keele, UK) or with cancellous bone grafts (Precision Bone Grafting System, Kaltec, 
Edwardstown, SA, Australia). A titanium plate was used to fix the osteotomy site (TomoFix®; 
Synthes Ltd, Welwyn Garden City, UK). 
b. Medial Opening Wedge High Tibial Osteotomy  
Patients were placed in supine position with their knees flexed to 90 ⁰ to allow full extension 
permitting an intra-operative check of the alignment. An anteromedial approach to the 
proximal tibia was used for HTO extending approximately 7-8 cm from the joint line. 
Insertion of the patellar tendon and its medial edge were exposed. The point of insertion of 
the patellar tendon was marked relative to the proximal tibia. The plane underneath the 
tendon was developed, followed by gentle placement of retractors for the osteotomy. The 
osteotomy level was 5cm distal to the joint line directed towards the proximal tibiofibular 
joint ensuring sufficient cortical contact laterally to form an effective hinge. A guidewire was 
placed with the extended knee directed towards the planned hinge point under an image-
intensifier. The osteotomy was performed with a Tuke saw, and the continuity of the lateral 
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cortex was maintained. The osteotomy was then opened with the sequential use of 
increasing sizes of an osteotome to achieve the desired correction. Cancellous bone or two 
absorbable osteoconductive conical composite screws were used at the osteotomy site. A 
further vertical cut was made behind the patellar tendon insertion exiting through the 
anterior tibial cortex approximately 3 cm distal to the level of the osteotomy. The patellar-
tendon-bone block was subsequently secured with a screw at the level of the patellar 
tendon marked initially before the osteotomy. This prevented the alteration of the height of 
patella following an opening wedge osteotomy (LaPrade et al., 2010). A titanium plate was 
used to stabilise the osteotomy site. 
c. Autologous Chondrocyte Implantation  
An arthrotomy was performed to access the articular cartilage defect and debride it to 
healthy adjacent articular cartilage and down to the subchondral bone plate, but without 
penetrating it. The size of the articular cartilage defect was recorded at this stage. Next, the 
defect was covered by a periosteal patch, harvested from the proximal medial tibia or by a 
collagen membrane (Chondro-Gide®; Geistlich Sons Ltd, Manchester, UK). The patch was 
sutured with 6-0 Vicryl (Ethicon, Livingston, United Kingdom) to the adjacent cartilage and 
the edges were sealed using fibrin glue (Tisseal; Baxter, Newbury, UK). A ‘water-leak’ test 
was performed to identify and seal any leak that might result in chondrocytes escaping from 
the enclosed space. The autologous chondrocyte suspension was subsequently injected into 
the defect before closing the patch. The outline of the defect was finally recorded on a knee 
map (Talkhani and Richardson, 1999). 
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5.2.2 Rehabilitation protocol 
Patients received continuous passive movement from full extension to 30° flexion for the 
first 24-48 hours. They were subsequently mobilised allowing weight bearing as tolerated by 
the patient. A hinged knee brace was used to support the knee from full extension to 
flexion. The range of movement exercises was started on the first postoperative day. 
Mobilisation and weight bearing was restricted from 4-8 weeks to enable low strain 
consolidation of bone healing at the osteotomy site (Jagodzinski and Krettek, 2007). 
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5.2.3 Outcome assessment 
5.2.3.1 Clinical follow-up 
Patients were followed up at 2 and 6 months with a radiograph to ensure that the 
osteotomy had healed and also to check the final alignment. Subsequently, all patients were 
followed up annually to assess their clinical progress. The Lysholm scores were collected 
during each clinic visit by an independent member of the Oswestry Outcome Centre.  
5.2.3.2 Arthroscopy 
Patients had an arthroscopy of the knee at 1 year after the second stage of the procedure to 
assess the repair site. The repair site was evaluated with the validated OAS, in all cases by 
the senior author (Smith et al., 2005). The six scoring parameters were: graft level with 
surrounding cartilage (0-2), integration with surrounding cartilage (0-2), the appearance of 
the surface (0-2), the colour of the graft (0-2), and stiffness of the graft on probing (0-2). A 
higher score implied better quality of the cartilage repair tissue at the treated site.  
5.2.3.3 Histology 
Biopsies of the repair tissue at the treated site were obtained during follow-up arthroscopic 
assessment of the knee. This was not routine and subject to patients consenting to the 
additional procedure. A Jamshidi needle was used to take core-biopsies close to the centre 
of the treated defect and included both the repair tissue and the underlying subchondral 
bone (where possible).  The cartilage repair site was ascertained from the knee-map used 
during the second stage of the procedure. The biopsy was snap-frozen in liquid nitrogen-
cooled hexane before cryosectioning at 7um thickness onto poly-L-lysine coated slides.  The 
sections were stained with haematoxylin and eosin to assess the general morphology of the 
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repair tissue and with toluidine blue to determine the metachromasia and proteoglycan 
content.  Sections were scored for histological analysis using the International Cartilage 
Repair Score II (Mainil-Varlet et al., 2010) and the OsScore scoring systems (Roberts et al., 
2003) for objective assessment of the quality of the repair tissue. 
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5.2.4 Statistics 
A Shapiro-Wilks test and Q-Q plot were used to ascertain the distribution of the Lysohm 
scores. The data was not found to be normally distributed, and hence, non-parametric tests 
were used for the analysis. A paired Wilcoxon signed-rank test was used to evaluate the 
difference between pre- and postoperative Lysholm scores. A Mann-Whitney U test was 
used to determine the influence of gender, varus or valgus osteotomies, femoral or tibial 
osteotomies or type of patch used (periosteum or collagen), on the change of Lysholm 
scores. A univariable linear regression analysis was used to find if age, BMI, defect size or 
number of implanted chondrocytes of the studied cohort influenced the change in Lysholm 
scores. Additionally, a logistic regression analysis was used to ascertain the influence of the 
OAS on the failure of the procedure. A linear regression model was used to analyse the 
impact of corrected mechanical alignment on the change in the functional scores. A Kaplan-
Meier cumulative survival analysis was done to estimate the time to failure. A Log-Rank test 
was used to determine the difference in estimated survival probability for varus and valgus 
osteotomies done for correction of mechanical alignment. All analyses were done using 
SPSS software (Version 22.0.0.0, IBM United Kingdom Ltd, Portsmouth, UK). For all analyses, 
a two-tailed p-value of 0.05 or below was assumed to denote significance. 
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5.3 Results 
5.3.1 Patient Demographics 
Fifteen patients with idiopathic malalignment and underlying chondral defects were treated 
with concurrent osteotomy and ACI (Table 5.1). The mean age at the time of surgery was 
41.5 ± 11.2(SD) years (range 25.4-65.6), and the mean BMI was 28.8 ±4.3 (range 23.1-40.8). 
Five patients had a femoral osteotomy, and 10 patients had a tibial osteotomy; 4 patients 
had a periosteal patch and 11 patients a collagen membrane patch to cover the chondral 
defect. The average duration of follow-up was 5.7 years (range 1.7-10.3). No patients were 
lost to follow-up. A total of 4 patients had a ‘failure’ and required conversion to TKR. The 
average follow-up for these patients was 3.2 years (range 1.3-5). 
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Patient 
No. 
Gend
er 
 
Age 
(years) 
Chondral 
Defect Size 
(cm²) 
Cells 
(x10⁶/cm²) 
Osteotomy  
Site 
Osteotomy 
Type 
Follow-
up 
( years) 
Failures
1 F 50.3 13.75 0.655 Femur Varus 1.7 Yes 
2 M 45.1 7.71 0.519 Femur Varus 9.6 No 
3 M 29.7 6.6 1.030 Femur Varus 5 Yes 
4 M 25.4 6.6 0.803 Femur Varus 5.6 No 
5 M 38.5 5.5 1.441 Femur Varus 4.6 Yes 
6 F 36.3 1 6.875 Tibia Varus 9.9 No 
7 F 46.1 13.75 0.291 Tibia Valgus 10 No 
8 M 53.1 13.75 0.296 Tibia Valgus 10.3 No 
9 F 43.4 17.5 0.457 Tibia Valgus 9 No 
10 F 65.6 9.4 0.532 Tibia Valgus 1.3 Yes 
11 M 52.9 13.2 0.152 Tibia Valgus 4.1 No 
12 M 40.2 3.32 1.596 Tibia Valgus 4 No 
13 M 28.6 13.25 0.090 Tibia Valgus 2.8 No 
14 M 33.0 4 1.5 Tibia Valgus 5.7 No 
15 M 34.3 8 1.188 Tibia Valgus 2.3 No 
         
Table 5.1 Patient characteristics receiving osteotomy with ACI in addition to follow-up and failures  
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5.3.2 Functional outcome 
The median Lysholm score before treatment was 42 (IQR of 25-54) and was 65 (IQR 36-84) 
at latest follow-up. The median change in Lysholm score was 29 (IQR of-6 to 37). This 
change was statistically significant (Wilcoxon signed-rank test, p=0.03). The median change 
in Lysholm scores was 36 points larger in patients receiving valgus osteotomies than those 
receiving varus osteotomies (Mann-Whitney U test, p=0.03; Table 2). The median change 
was 35 points greater in patients with tibial than in patients with femoral osteotomies 
(Mann-Whitney U test, p=0.02; Table 4.2). None of the other categorical parameters 
(gender or patch type) significantly influenced the change in outcome (Table 2). No 
significant influence was found in the continuous variables (age, BMI, size of the chondral 
defects and the cell number) on the change in Lysholm scores. 
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Patient grouping 
variables 
Median change in Lysholm Scores  
(95% CI) 
Mann-Whitney U test 
 (p-value) 
                
              Gender 
Male: 27 ( -4.6 to 55.4) 
0.6 Female: 27 (-3.9 t0 32.1) 
Type of osteotomy 
Varus: -4 (-22.5 to 24.8) 
0.03* Valgus: 32 (13.6-44.3) 
Site of osteotomy 
Femur: -6  (-29.9 to 21.9) 
0.02* Tibia: 29 (15.3-42.2) 
Patch type 
Collagen: 29 (1.7to 35.3) 
0.85 Periosteum: 16.4 (-27.1 to 59.1) 
Table 5.2 Change in the Lysholm scores between pre-and post-treatment for different patient 
grouping variables  
(*significance considered at p<0.05) 
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5.3.3 Final alignment of the knee 
The mean preoperative alignment from neutral was 7.5° for the 6 valgus knees and 6.8° for 
the 9 varus knees (Table 4.3). There was a significant change in the corrected postoperative 
alignment in comparison to the preoperative alignment following the osteotomy (Table 4.3). 
A linear regression analysis showed that the final alignment in this cohort did not influence 
the change in Lysholm scores (p-value 0.31, adjusted R²-0.03). 
 
     Alignment Preoperative (Mean±SD) 
Postoperative 
(Mean±SD) p-value 
Valgus(n=6) 7.5 ̊± 3.8 ̊ (range 4-13) 2.25 ̊±1.5 ̊(range 0-5) 0.046 
Varus(n=9) 6.8 ̊±1.6 ̊(range 5-10) 1.75 ̊±1.5 ̊(range 0-4) 0.0001 
Table 5.3 Pre and Postoperative alignment of the knee (measured from neutral 180 ̊) 
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5.3.4 Arthroscopic Assessment 
Twelve patients had an arthroscopic assessment of the repair site at an average interval of 
13.2 months (range 5.2-31) from the second stage of the intervention. The mean OAS in 
these patients was 4.3 (range 0-10). In 4 out of 12 patients, the score was 0. The procedure 
failed in these four patients, and they eventually required TKR. Three patients scored 9 and 
above on the scale of 10, implying the excellent macroscopic quality of the graft. Logistic 
regression analysis demonstrated that OAS significantly predicted failure (p-value-0.004 and 
Nagelkerke’s R²= 1). Three patients did not have an arthroscopic intervention, and their 
mean Lysholm score was 61 (range 25-87) at 14 months follow-up.  
5.3.5 Histology 
Eight biopsies from 8 patients were obtained at a mean interval of 11.5 months ±2.7 SD 
(range 8-16). Histological assessments revealed 2 biopsies to be predominantly hyaline 
cartilage; 1 was a mixture of hyaline cartilage and fibrocartilage, and 5 were predominantly 
fibrocartilage. All 6 of the 8 biopsies that included the underlying subchondral bone had 
good or very good integration between the repair tissue and the underlying bone. There 
was only one case of ectopic vascularisation within the repair tissue. The tissue 
metachromasia indicating proteoglycan content was found to be good or very good in 7 
repair biopsies and poor in 1 biopsy. Cellular morphology was found to be very good across 
all but 2 samples, where the cells had a less rounded chondrocyte-like appearance. A 
representative histological section from the repair site is illustrated in Figure 5.1 to show the 
tissue morphology and hyaline type cartilage at 13 months from surgery. The relationship 
between arthroscopic and histological scores with the outcome is shown in Table 5.4. 
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Patient 
No. 
OAS ICRS II OS score Change 
in 
Lysholm 
Outcome 
1 0 2.9 6.3 -6 Failed 
3 0 NA NA -22 Failed 
5 0 7.2 8.4 -2 Failed 
6 9 7.25 7.5 27 Not failed 
7 5 8.9 9.5 34 Not failed 
8 4 5.2 6.5 29 Not failed 
9 4 6.9 7.5 59 Not failed 
10 0 NA NA -12 Failed 
12 10 1.5 6.25 25 Not failed 
13 5 3.65 6.75 37 Not failed 
14 5 NA NA 12 Not failed 
15 10 NA NA 32 Not failed 
Table 5.4 Relationship between histological scores (ICRS II & OsScore), arthroscopic scores and 
outcome (NA-Not Available) 
 
 
 
 
Figure 5.1 Histology of the repair tissue after 13 months of surgery from the same patient: (a) 
Haematoxylin & Eosin staining showing tissue morphology (b) Toluidine blue staining showing 
proteoglycan content (c) Polarised light microscopy showing hyaline type repair cartilage 
(Scale bar represents  500 um) 
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5.3.6 Survival analysis 
A Kaplan-Meier survival analysis of the 15 patients showed that the estimated cumulative 
survival probability was 87% (±9 SE) at 5 years and 67% (±14 SE) at 10 years. The estimated 
survivorship after high tibial valgus osteotomy for correction of the varus deformity of the 
knee was 89% (±11 SE) at 5 years and 10 years. Survival after lateral opening wedge DFVO 
done for correction of the valgus deformity of the knees was 67% (±19 SE) at 5 years and 
50% (±20 SE) at 10 years. A Log Rank test (Mantel-Cox) showed no significant difference in 
survival probability in the two groups (p-value 0.26,). A group of six patients receiving distal 
femoral varus osteotomy for valgus deformity in addition to five patients treated with high 
tibial osteotomy for varus deformity of the knee by the same surgeon was identified outside 
the study to ascertain the survival probability in patients receiving osteotomy in isolation. 
These patients did not receive ACI during their realignment surgery because no underlying 
chondral defect was identified on pre-operative imaging. However, a comparison of the 
population-based cumulative survival probability of the four groups (HTO with and without 
ACI & DFO with and without ACI) by a log-rank test revealed no significant difference 
amongst the group (p-value 0.27).  An interesting observation, when compared with 
patients receiving osteotomy in isolation, is a complete absence of failure in HTO group 
when not complemented with ACI(i.e. no underlying chondral damage) and similarly, only 
one patient in the DFO group without ACI failed to highlight the propensity of failures in 
these patients when presenting with underlying chondral damage. The Kaplan-Meier graph 
demonstrating the cumulative survival in these four groups is illustrated in Fig 5.2. 
 
 
 208 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Kaplan-Meier survival curves comparing the cumulative survival probability of patients 
receiving High Tibial Osteotomy (HTO) or Distal Femoral Osteotomy (DFO) with/without ACI 
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5.4 Discussion 
This is the first study that reports augmenting osteotomy with ACI for both medial and 
lateral compartment chondral defects with idiopathic varus and valgus malalignment of the 
knee respectively. The present work shows significant clinical improvement in median 
Lysholm scores after an average follow-up of 5.7 years, with no patients lost to follow-up. At 
the end of the latest follow-up, 11 patients had a well-functioning native knee, and 4 
patients had failures which required TKR.  
The median change in Lysholm score of 29 in this study is comparable to the mean 
improvement of 29 points following ACI with concurrent HTO used to treat chondral defects 
with varus malalignments of the knee (Franceschi et al., 2008). The present study showed 
significantly better clinical outcomes in cases treated with opening wedge valgus osteotomy 
in the proximal tibia (valgus HTO) for varus knee compared to opening wedge varus 
osteotomy in the distal femur (DFVO) for the valgus knee. This result is comparable to an 
earlier series of 12 patients, which reported the poor clinical outcome in 5 patients 
evaluated by Lysholm score at 74 months following opening wedge DFVO (Das et al., 2008). 
The present study also confirms the absence of any significant influence of age, BMI, defect 
size or number of implanted chondrocytes on the final clinical outcome, which is in 
agreement with larger studies of patients undergoing only ACI (Jungmann et al., 2012, 
Gooding et al., 2006). 
The current study shows an estimated probability of retaining the native knee with 
improved functional outcome after combined osteotomy with ACI of 87% at 5 years and 
73% at 10 years. The survivorship of knees receiving high tibial valgus osteotomy with ACI in 
the present series was 89%  at 5 years and can be compared to recent reports of HTO that 
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also suggest an estimated survival of 89% at 5 years (Niinimäki et al., 2012, Saithna et al., 
2014). Moreover, the 10 year survival probability was the same as the 5-year probability. 
This maintenance of short-term results over longer time periods is in line with results from 
ACI alone, where clinical outcomes are maintained over periods up to 9.3 years (Bhosale et 
al., 2009). This would be in contrast to HTO alone, for which the Finnish registry reports a 
survival probability of 73 % (Niinimäki et al., 2012).  
The opening wedge lateral DFVO in the present study had survivorship of 67% at 5 years, 
less than previously reported series suggesting estimated survival probabilities of 79% at 5 
years (Saithna et al., 2014) and 82% at 7 years (Dewilde et al., 2013). However, it is 
important to note that one of these previous studies, in which the same implant was used 
for opening wedge DFVO as in the current study, does acknowledge a lack of statistically 
significant clinical improvement in Lysholm score at 4.5 years follow-up (Saithna et al., 
2014). A recent report has also described complications associated with friction and 
irritation of the iliotibial band following opening wedge DFVO using an identical fixation 
device (Jacobi et al., 2011) which is reflected by the poor functional outcome at follow-up 
(Das et al., 2008). Moreover, the lateral opening wedge DFVO tightens the iliotibial band 
and can increase the lateral compartment load. The tightening may also contribute to the 
reported high incidence of friction and irritation between the plate and the iliotibial band, in 
a similar way that a taut band can cause iliotibial band friction (Richards et al., 2003). The 
tautness leading to friction and irritation of the iliotibial band and an increased lateral load 
could explain the poorer clinical outcome in patients who had a combined varus osteotomy 
with ACI for valgus knee and lateral compartment chondral defects. It is also noteworthy 
that patients from the same centre with no underlying chondral damage and hence 
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necessitating no concurrent ACI treatments had lower rate of failures for both distal femoral 
varus osteotomies and high tibial valgus osteotomies in comparison to patients with 
underlying chondral damage requiring ACI, however no statistically significant difference in 
cumulative survival probability was noted in these groups. The postoperative alignments 
measured on standard knee radiographs were significantly improved in comparison to the 
preoperative alignment for both varus and valgus knees. The corrected alignment did not 
significantly correlate with the change in final Lysholm scores at follow-up.  
The OAS was used to evaluate the quality of the repair site for 12 patients at an average 
interval of 13.2 months was a significant predictor of failure at final follow-up in the present 
work (Smith et al., 2005). Moreover, this is the first report of the histological outcome at the 
graft site following concurrent realignment and ACI. The ICRS II and the OsScores for 
histological evaluation of the repair site did not significantly relate to the functional 
outcome, but this can be due to the small sample size in this study (Roberts et al., 2003, 
Mainil-Varlet et al., 2010). The presence of good to very good subchondral integration, high 
proteoglycan content in addition to a cellular morphology consistent with chondrocytes in 
the majority of the biopsies demonstrates a promising structural outcome of the underlying 
surgical principle. 
The clinical result of the current study supports the principle of combining osteotomy with 
ACI to treat chondral defects associated with idiopathic malalignment of the knee. In 
particular, the combination of opening wedge medial HTO and ACI is promising in 
addressing medial compartment cartilage defects in varus knees. However, the combination 
of opening wedge DFO to treat lateral compartment cartilage defects in valgus knees seems 
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disappointing. The OAS can be used to assess the quality of the graft, which can predict 
early failures.  
However, there are limitations to the current work, and future studies are required. The 
number of patients in the study is small making it liable to Type-II errors. A control group 
was lacking in the present study to compare the outcome of osteotomy with ACI to that of 
osteotomy in isolation. Histology and OAS were not available for all patients. Furthermore, 
there was no uniform protocol in ascertaining the extent of correction of the varus and 
valgus deformity with standardised weight-bearing long leg alignment radiographs. 
However, the encouraging results of our study and earlier studies (Bode et al., 2013, Bauer 
et al., 2012, Franceschi et al., 2008) suggest that a randomised controlled trial to compare 
this treatment with other available options is justified. Such studies should be adequately 
powered to identify the differences between groups and ideally conducted in multiple units 
to improve the external validity. It should not only focus on OAS and histology of repair site 
in patients with clinically successful treatment but also have a detailed cellular and 
histological analysis of the treated knees which have failed and required joint replacement 
surgery. 
To conclude, this study suggests that the combination of ACI and osteotomy can be used 
successfully in selected cases of large symptomatic cartilage defects, especially in cases of 
idiopathic varus malalignment of the knee.  In contrast, a lateral opening wedge distal 
femoral osteotomy to treat lateral compartment cartilage lesions in a valgus knee showed 
relatively high failure rates in this series. The structural outcome of the repair site assessed 
by the OAS and histology reinforces the benefits of the underlying principles of the 
technique. 
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Chapter 6: Conclusion 
This thesis covers subjects from bench to bedside. Work spans from an in vitro technique for 
cell therapy to the assessment of clinical effectiveness following applications of cell therapy 
in orthopaedics for bone and cartilage repair.  
The in vitro research in the present thesis explores the potential of the umbilical cord as an 
alternate allogeneic source of cells to engineer cartilage and/or bone defects in 
orthopaedics. The novel technique of dissecting the four discrete regions of UC with 
subsequent explant culture of the four separate tissues to isolate cells is described in the 
work. All four cell preparations derived from the four regions of UC (PA, PV, CL, and WJ) 
express the surface markers prescriptive of MSC (Dominici et al., 2006). These cells showed 
tri-lineage differentiation capability to varying degrees; particularly the WJ-derived cells 
appeared to have weaker osteogenicity in comparison to cells from the other three 
locations. Cells from each of the four regions also expressed pluripotency markers, further 
indicating their differentiation potential and self-renewing capacity. Additionally, these four 
types of cell preparations were demonstrated to be non-immunogenic and expressed MHC 
Class I molecule (HLA-ABC) in the absence of HLA-DR or co-stimulatory molecules CD40, 
CD80 and CD86. These features observed in the cell populations obtained from four UC 
locations are suggestive of their potential for allogeneic transplantation in regenerative 
medicine. 
The in vivo research focussed on assessing the potential of cultured autologous BMSC in 
new bone formation at nonunion fracture sites. This was ascertained by a randomised self-
control trial designed with BMSC being inserted at one side of the non-united fracture (‘test’ 
side) with ‘control’ being on the opposite side of the nonunion, which precluded the 
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confounding variables exclusive to each patient’s biology.  The results of this study 
highlighted the lack of statistically significant rise in new bone formation at the side of BMSC 
insertion in comparison to their respective controls. However, a novel observation in the 
study was the direct correlation of shorter cell doubling time during in vitro culture with 
successful fracture union in these patients.  Patient-related factors such as diabetes, 
multiple previous surgeries, and higher age group were observed to be negatively 
influencing bony union. A  probabilistic model is used for the first time to ascertain the 
primary radiological outcome of increased bone formation at the nonunion site following 
BMSC insertion. This technique takes into account the difficulty of image analysis and 
experience of the independent assessors to achieve more sensitive outcome data in 
comparison to the conventional majority vote system (Whitehill et al., 2009b).  
Clinical outcome of the novel  ‘Osplug’ technique for treating ICRS Grade-4 cartilage defects 
or ICRS Grade 3 or 4 osteochondritis dissecans has been described in the current work. This 
method is shown to produce significant clinical improvement in patients for up to 5 years. A 
scoring parameter to assess the subchondral bone graft integration with the remodelling of 
the lamina (termed ‘neo-lamina’) as seen on MRI scans was devised and used for the first 
time in conjunction with conventional MOCART scoring criteria (Marlovits et al., 2006), to 
evaluate the osteoarticular repair. A low arthroscopic score (assessed with OAS) and poor 
integration of the monocortical bone graft (evaluated with the improvised criteria) at one 
year has been associated with a poor clinical outcome and subsequent failure of the surgical 
technique. Such observations highlight the importance of establishing proper integration 
between the implanted cells and bone core to be critical for long-term success of the 
procedure. The present work also reports the outcome of combining osteotomy with ACI to 
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treat chondral defects associated with malalignment of the knee. The results of the case-
series treated with this method demonstrated favourable clinical outcome in cases with 
large chondral defects in varus knees. The structural outcome of the graft site evaluated 
arthroscopically with OAS and microscopically with ICRS II scoring parameters showed the 
benefits of the surgical technique. A cumulative probability estimate demonstrated 87% 
chance of retaining the native knee for five years; the macroscopic features of the graft 
assessed with OAS at one year was observed to be predictive of long-term failure. However, 
valgus knees requiring distal femoral opening wedge osteotomy had relatively poor results, 
with early failure. No studies on the outcome of treating valgus knees with combined 
osteotomy and ACI have previously been reported.  
Future work: 
UC-derived cells: Further work is required to demonstrate the immunological profile of UC-
derived cells in vitro to investigate the allogeneic transplantation potential of these cells. 
Additionally, differentiation potential of these cells after being primed with pro-
inflammatory cytokines needs to be undertaken, and the efficacy of different tissues (PA, 
PV, WJ, and CL) compared to develop insights of the best cell source if any. The safety 
profile of the UC-derived cells must be evaluated before animal and human clinical 
translation. Extensive animal studies to assess the in vivo efficacy should follow but pre-date 
the human application of these cells in orthopaedics regenerative medicine.  
BMSC for fracture non-union: Future RCTs to determine the in vivo efficacy of autologous 
BMSCs for long bone nonunions are required, with separately matched control and a test 
group of patients. This will avoid the carry across effects of cells inserted in the ‘test’ side to 
the ‘control’ side, which can potentially influence the outcome of a self-controlled trial. Use 
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of a single carrier type is also recommended for a future trial to allow comparison of 
outcome between patients and avoid bias on the outcome due to the influence of the 
carriers themselves. Autologous BMSCs in these patients with non-union  need to be 
characterised, especially with respect to their in vitro osteogenic performance and paracrine 
effects that can affect in vivo new bone formation in nonunions.  
Clinical studies of ACI in special cases: Further follow-up with ten-year reports of the 
‘Osplug’ technique mainly focussing on the clinical outcome and structural repair needs to 
be assessed with additional MRI scans to identify the long-term efficacy of this technique. 
Repair site biopsies at subsequent follow-up will improve our understanding of the 
interaction of the implanted chondrocytes in the cartilage repair tissue with the grafted 
bone in these cases. The potential use of biphasic scaffolds in such situations will need to 
transcend for human applications following successful use in larger animal models. 
Encouraging preliminary results by implementing concurrent realignment osteotomy with 
ACI needs to be evaluated with further robust clinical studies and larger sample size. 
Patients in this study need to be randomised to treatment with ACI and osteotomy versus 
osteotomy in isolation. Further information on the repair site ought to be assessed with 
serial MRI scans, diagnostic arthroscopy, and biopsy. 
To summarise, the thesis sheds light on the promising results of using cells derived from the 
umbilical cord to be a potential universal donor source that can be used ‘off-the-shelf’ for 
cell therapies in orthopaedics. Such findings form the basis for further in vitro 
characterisation of these cells particularly with respect to its immunogenicity in different 
inflammatory settings followed by large animal model studies to identify its in vivo 
efficacies. The present work also highlights the critical importance of in vitro doubling time 
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of autologous BMSC in predicting fracture union in patients with recalcitrant nonunions. 
This observation indicates towards the importance of in vitro characterisation of autologous 
BMSCs in patients with nonunions to identify potential correlations with clinical outcome 
and the in vivo performance of these cells in patients with nonunion. The outcome of the 
‘Osplug’ technique described in the present work focusses the integral role of bone plug 
integration in treating osteoarticular defects when complemented with ACI. It also features 
successful preliminary results of combining ACI with osteotomy around maligned varus 
knees. Such positive clinical outcomes will complement the future use of biphasic scaffolds 
in treating osteoarticular defects in addition to the use of MSCs in the setting of cartilage 
regeneration in the knee. 
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Appendices 
A. Literature search strategy for UC derived cells in orthopaedics 
A review of the literature was undertaken using Pubmed, Embase and Ovid Medline in 
addition to hand searching of bibliographies of relevant articles to identify pertinent 
literature in this area. 
Search strategy: The following search terms were used-cord lining, Wharton's jelly, umbilical 
cord artery, umbilical cord vein, umbilical cord stroma, sub-amnion, umbilical cord lining, 
peri-vascular, stem cell, MSC, umbilical cord, umbilical cord matrix and orthopaedic 
regeneration. The search terms were combined with ‘AND’/‘OR’ Boolean operators to refine 
the results. Studies describing UC-derived stem cells tested for non-orthopaedic 
regeneration or UC from non-human sources were excluded. Only articles published in the 
English language were considered for the literature review. 
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B. Literature search strategy for the potential of BMSC in new bone formation in human 
fractures and nonunion 
A review of medical literature from the electronic databases of Ovid MEDLINE, EMBASE and 
PubMed, was supplemented by hand searching of bibliographies of relevant articles.  
Search strategy: The following search terms were used-nonunion, bone defects, bone 
marrow stromal cells, bone marrow derived cells, stem cells and MSC. The search terms 
were combined with ‘AND’/‘OR’ Boolean operators to refine the results. Studies describing 
the treatment of human long bone nonunions or bone defects with autologous bone 
marrow derived cultured cells were included for the purpose of this review. Articles 
published in the English language only were included for review. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 238 
 
C. Literature search strategy for the use of ACI with concurrent bonegraft for treating 
osteoartcular defects:  
Hand searching of bibliographies supplemented a review of medical literature from the 
electronic databases of Ovid MEDLINE, EMBASE and PubMed of the relevant articles.  
Search strategy: The following search terms were used: osteochondral defects, 
osteoarticular defects, Autologous Chondrocyte Implantation, bone graft, Osteochondritis 
dissecans and knee joint. The search terms were combined with ‘AND’/‘OR’ Boolean 
operators to refine the results. All types of ACI ( first generation to the third generation) 
with autologous bone grafts in human knees were included. Studies describing other forms 
of treatment and treatment of other joints were excluded.  
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D. Literature search strategy  for treating chondral defect with malaligned knee with ACI and 
osteotomy 
Hand-searching of bibliographies supplemented a review of medical literature from the 
electronic databases of Ovid MEDLINE, EMBASE and PubMed.  
Search strategy: The following search terms were used-Autologous Chondrocyte 
Implantation, High Tibial Osteotomy (HTO), Femoral osteotomy, Valgus osteotomy, Varus 
osteotomy and knee. The search terms were combined with ‘AND’/‘OR’ Boolean operators 
to refine the results. Studies describing the treatment of cartilage defects of knee joint were 
only included for the review. A comparative study evaluating the outcome of ACI + 
osteotomy, ACI in isolation and microfracture with/without realignment were included for 
the purpose of this review. Only articles published in the English language were considered. 
 
 
 
